U.S. patent application number 16/151232 was filed with the patent office on 2019-01-24 for therapeutic drug for malignant tumors.
The applicant listed for this patent is National University Corporation Kochi University. Invention is credited to Minoru Fujimoto, Tetsuji Naka, Satoshi Serada, Yuji Shoya, Masayoshi Toyoura.
Application Number | 20190023781 16/151232 |
Document ID | / |
Family ID | 53478009 |
Filed Date | 2019-01-24 |
![](/patent/app/20190023781/US20190023781A1-20190124-D00001.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00002.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00003.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00004.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00005.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00006.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00007.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00008.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00009.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00010.png)
![](/patent/app/20190023781/US20190023781A1-20190124-D00011.png)
View All Diagrams
United States Patent
Application |
20190023781 |
Kind Code |
A1 |
Naka; Tetsuji ; et
al. |
January 24, 2019 |
THERAPEUTIC DRUG FOR MALIGNANT TUMORS
Abstract
According to the present disclosure there are provided
compositions and methods for treating malignant tumors, including
an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody
that comprises the presently disclosed antibody heavy and light
chain complementarity determining region (CDR) sequences, or an
antigen-binding fragment thereof, or a functional equivalent
thereof. Further provided for treating an LSR-positive malignancy
is an LSR antagonist or an LSR inhibitor such as a nucleic acid.
Therapeutic administration of the anti-LSR antibody to a subject
having an LSR-positive malignant tumor is also described.
Inventors: |
Naka; Tetsuji; (Osaka,
JP) ; Serada; Satoshi; (Osaka, JP) ; Fujimoto;
Minoru; (Osaka, JP) ; Toyoura; Masayoshi;
(Kyoto, JP) ; Shoya; Yuji; (Kyoto, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
National University Corporation Kochi University |
Kochi-shi |
|
JP |
|
|
Family ID: |
53478009 |
Appl. No.: |
16/151232 |
Filed: |
October 3, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15108242 |
Jun 24, 2016 |
|
|
|
PCT/JP2014/006456 |
Dec 25, 2014 |
|
|
|
16151232 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 16/28 20130101;
C07K 2317/33 20130101; C07K 2317/622 20130101; C12N 2310/14
20130101; A61K 31/713 20130101; A61K 2039/505 20130101; C07K
16/3046 20130101; C07K 2317/92 20130101; A61P 15/00 20180101; C07K
2317/34 20130101; G01N 2333/705 20130101; A61P 43/00 20180101; G01N
33/57492 20130101; A61P 15/08 20180101; C07K 2317/565 20130101;
C12N 15/1138 20130101; G01N 33/92 20130101; C07K 16/3023 20130101;
G01N 33/57449 20130101; A61P 35/04 20180101; C07K 16/303 20130101;
C07K 16/3069 20130101; A61P 35/00 20180101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; G01N 33/574 20060101 G01N033/574; C07K 16/30 20060101
C07K016/30; A61K 31/713 20060101 A61K031/713; C12N 15/113 20100101
C12N015/113; G01N 33/92 20060101 G01N033/92 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 27, 2013 |
JP |
2013-272084 |
Claims
1. A method of treating or preventing a malignant tumor in a
subject in need thereof, comprising administering an effective
amount of a suppressant of an lipolysis stimulated lipoprotein
receptor (LSR) to the subject, wherein the suppressant comprises an
anti-LSR antibody or an antigen binding fragment or a functional
equivalent thereof, wherein the anti-LSR antibody has positions
116-134 and/or 216-230 of SEQ ID NO: 7 as an epitope.
2. The method of claim 1, wherein the malignant tumor is an LSR
positive malignant tumor.
3. The method of claim 1, comprising administering the suppressant
to the subject wherein the subject is a patient determined to have
an episode of LSR positive malignant tumor.
4. The method of claim 1, comprising administering the suppressant
to the subject wherein the subject is a patient among malignant
tumor patients whose malignant tumor has been determined to be LSR
positive malignant tumor.
5. The method of claim 1, wherein the anti-LSR antibody is an
antibody having an ability to inhibit exacerbation due to a
VLDL.
6. The method of claim 1, wherein the anti-LSR antibody is an
antibody selected from a monoclonal antibody, polyclonal antibody,
chimeric antibody, humanized antibody, human antibody,
multifunctional antibody, bispecific or oligospecific antibody,
single chain antibody, scFV, diabody, sc(Fv).sub.2 (single chain
(Fv).sub.2), and scFv-Fc.
7. The method of claim 1, wherein the malignant tumor comprises
ovarian cancer or metastasized ovarian cancer.
8. The method of claim 7, wherein the ovarian cancer is recurrent
ovarian cancer or early-stage ovarian cancer.
9. The method of claim 1, wherein the malignant tumor comprises
ovarian cancer, pancreatic cancer, lung cancer, gastric cancer, or
colon cancer.
10. The method of claim 7, wherein the ovarian cancer is ovarian
serous adenocarcinoma or ovarian clear cell adenocarcinoma.
11. The method of claim 1, further comprising administering a
cell-killing agent.
12. The method of claim 1, wherein the anti-LSR antibody is one or
more antibodies selected from the group consisting of: (a) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-230 of SEQ ID NO: 1,
respectively; (b) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-103, 152-165, 182-188 and
221-230 of SEQ ID NO: 2, respectively; (c) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 3, respectively; (d) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 4,
respectively; (e) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 5, respectively; (f) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 6, respectively; and (g)
a mutant of the antibody according to any one or more of (a)-(f),
which is free of a mutation in the CDRs but comprises one or
several substitutions, additions, or deletions in a framework of
the antibody in the mutant.
Description
STATEMENT REGARDING SEQUENCE LISTING
[0001] The Sequence Listing associated with this application is
provided in text format in lieu of a paper copy, and is hereby
incorporated by reference into the specification. The name of the
text file containing the Sequence Listing is
690188_402D1_SEQUENCE_LISTING.txt. The text file is 32.9 KB, was
created on Oct. 2, 2018, and is being submitted electronically via
EFS-Web.
TECHNICAL FIELD
[0002] The present invention relates to a therapeutic drug,
diagnostic drug or the like for malignant tumor.
BACKGROUND ART
[0003] LSR (lipolysis stimulated lipoprotein receptor) is known as
a molecule associated with metabolism of low-density lipoprotein
(LDL). Several LSR related research results have been reported. For
example, Non Patent Literature 1 describes that LSR expression is
reduced in a liver of obese and type 2 diabetes mouse models.
Further, Non Patent Literature 2 describes that LSRs are expressed
in bladder cancer. Non Patent Literature 3 describes that LSRs are
expressed in colon cancer cells. Non Patent Literature 4 describes
that LSRs are expressed in breast cancer cells. Patent Literature 1
describes that LSRs are expressed in ovarian cancer cells or the
like.
CITATION LIST
Patent Literature
[0004] [PTL 1] WO 2012/140627
Non Patent Literature
[0004] [0005] [NPL 1] "Liver-specific loss of lipolysis-stimulated
lipoprotein receptor triggers systemic hyperlipidemia in mice."
Narvekar et al., Diabetes. 2009 May; 58(5): 1040-9 [0006] [NPL 2]
"Increased cell motility and invasion upon knockdown of lipolysis
stimulated lipoprotein receptor (LSR) in SW780 bladder cancer
cells." Herbsleb et al., BMC Med Genomics. 2008 Jul. 22; 1:31.
[0007] [NPL 3] "Prognostic value of LISCH7 mRNA in plasma and tumor
of colon cancer patients." Garcia et al., Clin Cancer Res. 2007
Nov. 1; 13(21): 6351-8. [0008] [NPL 4] "Functional heterogeneity
within the CD44 high human breast cancer stem cell-like compartment
reveals a gene signature predictive of distant metastasis."
Leth-Larsen et al., Mol Med. 2012 Sep. 25; 18: 1109-21.
SUMMARY OF INVENTION
Solution to Problem
[0009] The disease mechanism of malignant tumor is complex, with
many parts unclear. Thus, many medical needs remain unfulfilled in
the field. The inventors have discovered that growth of malignant
tumor cells is suppressed when the malignant tumor cells are
contacted with an anti-LSR antibody as a number of researches are
conducted on malignant tumor. Furthermore, when an LSR siRNA was
transfected into malignant tumor cells, growth of malignant tumor
cells was also suppressed in this case. In addition, when an
anti-LSR antibody was actually administered to a malignant tumor
model mouse, a notable decrease in tumor volume was observed. In
view of the above, it was elucidated that an LSR suppressant such
as an anti-LSR antibody is effective in treating malignant tumor.
In this regard, the present invention provides a novel therapeutic
agent for malignant tumor targeting LSRs and the like.
[0010] Further, the inventors elucidated, as described in the
Examples disclosed below, the presence of many LSR negative
patients while there are LSR positive patients among malignant
tumor patients. In view of the above, it was elucidated that
diagnosis of the presence or absence of LSR positive state in a
malignant tumor patient prior to therapy is important in the
treatment of malignant tumor targeting LSRs.
[0011] The Examples of the above-described Patent Literature 1
suggest that an LSR mRNA was detected in a few types of cancer. The
claims have an actual recitation of an anti-LSR antibody inducing
apoptosis of cancer cells. However, Patent Literature 1 does not
have any pharmacological data from an actual successful cancer
therapy. In addition, Patent Literature 1 does not describe that
the presence or absence of an LSR positive condition in a malignant
tumor patient is diagnosed prior to therapy. For this reason, an
anti-LSR antibody could not be considered effective for treating
malignant tumor only from the results of Patent Literature 1.
[0012] In one aspect, the present invention provides a therapeutic
or prophylactic drug for malignant tumor, comprising a suppressant
of an LSR (lipolysis stimulated lipoprotein receptor).
[0013] In one embodiment, the suppressant in the present invention
can comprise an anti-LSR (lipolysis stimulated lipoprotein
receptor) antibody, an antigen binding fragment or a functional
equivalent thereof, or a nucleic acid.
[0014] In another embodiment, the suppressant in the present
invention can comprise an anti-LSR (lipolysis stimulated
lipoprotein receptor) antibody or an antigen binding fragment or a
functional equivalent thereof.
[0015] In still another embodiment, the suppressant in the present
invention can be an RNAi molecule directed to an LSR or a
polynucleotide encoding the RNAi molecule.
[0016] In still another embodiment, the malignant tumor in the
present invention can be LSR positive malignant tumor.
[0017] In still another embodiment, the present invention can be
for administration to a patient determined to have an episode of
LSR positive malignant tumor.
[0018] In still another embodiment, the present invention can be
for administration to a patient among malignant tumor patients
whose malignant tumor has been determined to be LSR positive
malignant tumor.
[0019] In still another embodiment, the anti-LSR antibody in the
present invention can be an anti-LSR antibody that specifically
binds to an epitope of an LSR. More specifically, the antibody may
have positions 116-134 and/or 216-230 of SEQ ID NO: 7 as the
epitope.
[0020] In still another embodiment, the anti-LSR antibody in the
present invention can be an antibody having an ability to inhibit
exacerbation due to a VLDL.
[0021] In still another embodiment, the anti-LSR antibody in the
present invention may be one or more antibodies selected from the
group consisting of: (a) an antibody with heavy chain CDRs 1, 2,
and 3 and light chain CDRs 1, 2, and 3 comprising amino acid
sequences set forth in positions 31-35, 50-66, 99-104, 153-165,
182-188 and 221-230 of SEQ ID NO: 1, respectively; (b) an antibody
with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3
comprising amino acid sequences set forth in positions 31-35,
50-66, 99-103, 152-165, 182-188 and 221-230 of SEQ ID NO: 2,
respectively; (c) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 3, respectively; (d) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 4, respectively; (e) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 5,
respectively; and (f) an antibody with heavy chain CDRs 1, 2, and 3
and light chain CDRs 1, 2, and 3 comprising amino acid sequences
set forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 6, respectively, or a mutant of the antibody,
which is free of a mutation in the CDRs but comprises one or
several substitutions, additions, or deletions in a framework of
the antibody in the mutant.
[0022] In still another embodiment, the anti-LSR antibody in the
present invention can be a monoclonal antibody.
[0023] In still another embodiment, an antibody class of the
anti-LSR antibody in the present invention may be IgG.
[0024] In still another embodiment, the anti-LSR antibody in the
present invention may be an antigen binding fragment.
[0025] In another aspect, the present invention provides an agent
for suppressing cell division of a malignant tumor cell, comprising
an anti-LSR antibody.
[0026] In another aspect, the present invention provides a
companion diagnostic drug for malignant tumor therapy targeting an
LSR, comprising an LSR detection agent.
[0027] In one embodiment, the LSR detection agent in the present
invention can comprise an anti-LSR antibody. In another aspect, the
present invention provides a companion diagnostic method for
malignant tumor therapy targeting an LSR, comprising inspecting
whether a malignant tumor sample of a malignant tumor patient is
LSR positive. In another aspect, the present invention provides an
antibody or antibodies selected from the group consisting of: (a)
an antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs
1, 2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-230 of SEQ ID NO: 1,
respectively; (b) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-103, 152-165, 182-188 and
221-230 of SEQ ID NO: 2, respectively; (c) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 3, respectively; (d) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 4,
respectively; (e) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 5, respectively; and (f) an antibody with
heavy chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3
comprising amino acid sequences set forth in positions 31-35,
50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 6,
respectively, or a mutant of the antibody, which is free of a
mutation in the CDRs but comprises one or several substitutions,
additions, or deletions in a framework of the antibody in the
mutant. These antibodies may be an antibody selected from a
monoclonal antibody, polyclonal antibody, chimeric antibody,
humanized antibody, human antibody, multifunctional antibody,
bispecific or oligospecific antibody, single chain antibody, scFV,
diabody, sc(Fv).sub.2 (single chain (Fv).sub.2), and scFv-Fc.
[0028] In another aspect, the present invention provides a
composition for preventing or treating malignant tumor, comprising
an LSR binding agent. In one embodiment, the malignant tumor in the
present invention can be LSR positive malignant tumor.
[0029] In another embodiment, the present invention can further
comprise a cell-killing agent.
[0030] In another embodiment, the LSR binding agent in the present
invention may be an antibody, a fragment or a functional equivalent
thereof, or a nucleic acid. In a specific embodiment, the LSR
binding agent in the present invention may be an antibody or a
fragment or a functional equivalent thereof, further bound to a
cell killing agent. In a specific embodiment, the malignant tumor
in the present invention may comprise ovarian cancer. The ovarian
cancer in the present invention may be recurrent ovarian cancer.
Alternatively, the malignant tumor may be metastasized ovarian
cancer. The malignant tumor can comprise ovarian cancer, pancreatic
cancer, lung cancer, gastric cancer, or colon cancer.
Alternatively, the malignant tumor may be early-stage ovarian
cancer. In another embodiment, ovarian cancer can be ovarian serous
adenocarcinoma or ovarian clear cell adenocarcinoma. In a specific
embodiment, the LSR binding agent in the present invention may be
characterized by having an antibody or a fragment or a functional
equivalent thereof, the antibody being one or more antibodies
selected from the group consisting of: (a) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-230 of SEQ ID NO: 1, respectively; (b) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-103, 152-165, 182-188 and 221-230 of SEQ ID NO: 2,
respectively; (c) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 3, respectively; (d) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 4, respectively; (e) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 5,
respectively; and (f) an antibody with heavy chain CDRs 1, 2, and 3
and light chain CDRs 1, 2, and 3 comprising amino acid sequences
set forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 6, respectively, or a mutant of the antibody,
which is free of a mutation in the CDRs but comprises one or
several substitutions, additions, or deletions in a framework of
the antibody in the mutant.
[0031] In still another embodiment, the anti-LSR antibody is an
antibody selected from a monoclonal antibody, polyclonal antibody,
chimeric antibody, humanized antibody, human antibody,
multifunctional antibody, bispecific or oligospecific antibody,
single chain antibody, scFV, diabody, sc(Fv).sub.2 (single chain
(Fv).sub.2), and scFv-Fc.
[0032] That is, according to another aspect of the present
invention, a therapeutic drug for malignant tumor comprising an
anti-LSR antibody is provided.
[0033] Further, according to another aspect of the present
invention, a therapeutic drug for malignant tumor, comprising an
LSR antagonist is provided.
[0034] Further, according to another aspect of the present
invention, an agent for suppressing cell division of a malignant
tumor cell, comprising an anti-LSR antibody is provided.
[0035] Further, according to another aspect of the present
invention, a companion diagnostic drug for malignant tumor therapy
targeting an LSR, comprising an anti-LSR antibody is provided. One
embodiment is characterized in that the malignant tumor is
determined to be LSR positive by the companion diagnostic method of
present invention, and the LSR binding agent is administered
thereafter.
[0036] Further, according to another aspect of the present
invention, a companion diagnostic method for malignant tumor
therapy targeting an LSR, comprising inspecting whether a malignant
tumor sample of a malignant tumor patient is LSR positive, is
provided.
[0037] In a specific embodiment, the malignant tumor may be LSR
positive malignant tumor. Further, in one embodiment of the present
invention, the above-described therapeutic drug may be a
therapeutic drug for administration to a patient determined to have
an episode of LSR positive malignant tumor. Further, in one
embodiment of the present invention, the above-described
therapeutic drug may be a therapeutic drug for administration to a
patient among tumor patients whose malignant tumor has been
determined to be LSR positive malignant tumor. Further, in one
embodiment of the present invention, the anti-LSR antibody may be
an anti-LSR antibody that specifically binds to an epitope of an
LSR. Further, in one embodiment of the present invention, the
anti-LSR antibody may be one or more antibodies selected from the
group consisting of: (a) an antibody with heavy chain CDRs 1, 2,
and 3 and light chain CDRs 1, 2, and 3 comprising amino acid
sequences set forth in positions 31-35, 50-66, 99-104, 153-165,
182-188 and 221-230 of SEQ ID NO: 1, respectively; (b) an antibody
with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3
comprising amino acid sequences set forth in positions 31-35,
50-66, 99-103, 152-165, 182-188 and 221-230 of SEQ ID NO: 2,
respectively; (c) an antibody with heavy chain CDRs 1, 2, and 3 and
light chain CDRs 1, 2, and 3 comprising amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 3, respectively; (d) an antibody with heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 comprising
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 4, respectively; (e) an
antibody with heavy chain CDRs 1, 2, and 3 and light chain CDRs 1,
2, and 3 comprising amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 5,
respectively; and (f) an antibody with heavy chain CDRs 1, 2, and 3
and light chain CDRs 1, 2, and 3 comprising amino acid sequences
set forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 6, respectively, or a mutant of the antibody,
which is free of a mutation in the CDRs but comprises one or
several substitutions, additions, or deletions in a framework of
the antibody in the mutant. These antibodies may be an antibody
selected from a monoclonal antibody, polyclonal antibody, chimeric
antibody, humanized antibody, human antibody, multifunctional
antibody, bispecific or oligospecific antibody, single chain
antibody, scFV, diabody, sc(Fv).sub.2 (single chain (Fv).sub.2),
and scFv-Fc. The antibodies used are not limited, but an antibody
having positions 116-134 and/or 216-230 of SEQ ID NO: 7 as an
epitope can be advantageously used. This is because an advantageous
effect as well as safety and stability thereof are demonstrated
herein.
[0038] Further, in a specific embodiment of the present invention,
the above-described anti-LSR antibody may be a monoclonal antibody.
Further, in one embodiment of the present invention, an antibody
class of the above-described anti-LSR antibody may be IgG. Further,
in one embodiment of the present invention, the above-described
anti-LSR antibody may be the antigen binding fragment. Further, in
one embodiment of the present invention, the above-described LSR
antagonist may be an RNAi molecule directed to an LSR or a
polynucleotide encoding the RNAi molecule.
[0039] In another aspect of the present invention, the present
invention provides a poor prognosis marker for malignant tumor
therapy, comprising an LSR (lipolysis stimulated lipoprotein
receptor) binding agent. It is understood that a binding agent in
any form of the present invention explained herein can be used as
the binding agent used in this aspect. For example, the binding
agent may be an antibody, a fragment or a functional equivalent
thereof, or a nucleic acid, which may be labeled.
[0040] In another aspect of the present invention, the present
invention provides a method of using an expression level of an LSR
(lipolysis stimulated lipoprotein receptor) as an indicator for
poor prognosis of malignant tumor therapy. It is understood that a
binding agent in any form of the present invention explained herein
can be used as the binding agent used in this aspect. For example,
the binding agent may be an antibody, a fragment or a functional
equivalent thereof, or a nucleic acid, which may be labeled.
[0041] In another aspect of the present invention, the present
invention provides a diagnostic agent for poor prognosis of
malignant tumor therapy, comprising an LSR (lipolysis stimulated
lipoprotein receptor) binding agent. It is understood that a
binding agent in any form of the present invention explained herein
can be used as the binding agent used in this aspect. For example,
the binding agent may be an antibody, a fragment or a functional
equivalent thereof, or a nucleic acid, which may be labeled.
[0042] In still another aspect, the present invention provides a
therapeutic method, prophylactic method, use and the like using a
pharmaceutical composition, therapeutic agent or prophylactic agent
of the present invention.
[0043] It is understood that one or more of the aforementioned
features can be further combined for use.
[0044] Those skilled in the art who have read and understood the
following Detailed Description as needed would recognize further
embodiments and advantages of the present invention.
Advantageous Effects of Invention
[0045] According to the present invention, a novel therapeutic
drug, diagnostic drug or the like for malignant tumor is
obtained.
BRIEF DESCRIPTION OF DRAWINGS
[0046] FIG. 1 is a diagram showing results of RT-PCR performed on
nucleic acids obtained from ovarian serous adenocarcinoma cell
strains. One on the left show normal cells (HOSE2 on the left
side). Three on the right show cancer cells (from the left: OVCAR3,
OVSAHO, and JHOS4). The top row shows LSRs and the bottom row shows
the background .beta. actin.
[0047] FIG. 2 is a diagram showing results of RT-PCR performed on
nucleic acids obtained from ovarian clear cell adenocarcinoma cell
strains. One on the left show normal cells (HOSE2C on the left
side). Four on the right show cancer cells (from the left: OVTOKO,
OVMANA, OVISE, and RMG-1). The top row shows LSRs and the bottom
row shows the background .beta. actin.
[0048] FIG. 3 is a diagram showing results of RT-PCR performed on
nucleic acids obtained from endometrial cancer cell strains. The
left end shows normal cells (E6/E7/TERT), and the others are cancer
cells (from the left: HEC1, HEC1A, HEC6, HEC88nu, HEC108, HEC116,
HEC251, and SNG-M). The top row shows LSRs and the bottom row shows
the background .beta. actin.
[0049] FIG. 4 is a diagram showing results of Western blot
performed on proteins obtained from ovarian serous adenocarcinoma
cell strains. One on the left show normal cells (HOSE2C on the left
side). Three on the right show cancer cells (from the left: OVCAR3,
OVSAHO, and JHOS4).
[0050] FIG. 5 is a diagram showing results of Western blot
performed on proteins obtained from ovarian clear cell
adenocarcinoma cell strains. One on the left show normal cells
(HOSE2C on the left side). Four on the right show cancer cells
(from the left: OVTOKO, OVMANA, OVISE, and RMG-1).
[0051] FIG. 6 is a diagram showing results of Western blot
performed on proteins obtained from endometrial cancer cell
strains. The top left end shows normal cells (E6/E7/TERT), and
others are cancer cells. The top row shows, from the left, HEC1,
HEC1A, HEC6, and HEC88nu. The bottom row shows from the left,
HEC108, HEC116, HEC251, and SNG-M. All of them represent LSRs.
[0052] FIG. 7 is a diagram showing results of Western blot
performed on proteins obtained from tissue on which surgery has
been performed for ovarian serous adenocarcinoma and tissue on
which surgery has been performed for ovarian clear cell
adenocarcinoma. The Figure shows, from the left, two samples from
normal (healthy individual's) ovaries (No. 1 and No. 2=represented
by (1) and (2)), two samples from clear cell adenocarcinoma
patients (No. 1 and No. 2=represented by (3) and (4)), and two
samples from serous adenocarcinoma patients (No. 1 and No.
2=represented by (5) and (6)).
[0053] FIG. 8 is a diagram showing results of Western Blot
performed on proteins obtained from tissue on which surgery has
been performed for endometrial cancer. The Figure shows, from the
left, two samples from normal (healthy individual's) ovaries (No. 1
and No. 2=represented by (1) and (2)), and two samples from
endometrial cancer patients (No. 1 and No. 2=represented by (3) and
(4)).
[0054] FIG. 9 is a diagram showing the amino acid sequence of the
anti-LSR antibody described in the Examples.
[0055] FIG. 10 is a diagram showing results of assessing reactivity
of #9-7 antibody to, from the left, OVSAHO, JHSO4, RMG-I, and
OVISE. The vertical axis indicates intensity and the horizontal
axis indicates cell frequency.
[0056] FIG. 11 is a diagram showing results of assessing reactivity
of #16-6 antibody to, from the left, OVSAHO, JHSO4, RMG-I, and
OVISE. The vertical axis indicates intensity and the horizontal
axis indicates cell frequency.
[0057] FIG. 12 is a diagram showing results of assessing reactivity
of #26-2 antibody to, from the left, OVSAHO, JHSO4, RMG-I, and
OVISE. The vertical axis indicates intensity and the horizontal
axis indicates cell frequency.
[0058] FIG. 13 is a diagram showing results of assessing reactivity
of #27-6 antibody to, from the left, OVSAHO, JHSO4, RMG-I, and
OVISE. The vertical axis indicates intensity and the horizontal
axis indicates cell frequency.
[0059] FIG. 14 is a diagram showing results of assessing reactivity
of #1-25 antibody to, from the left, OVSAHO, JHSO4, RMG-I, and
OVISE. The vertical axis indicates intensity and the horizontal
axis indicates cell frequency.
[0060] FIG. 15 is a diagram showing a result of analyzing ovarian
serous adenocarcinoma tissue for expression of LSRs by an
immunohistochemical staining method using monoclonal the antibody
#1-25. The top row shows serous G2 of ovary, serous G3 of tube,
serous G3 of ovary and serous G3 of ovary. All pictures in the
bottom row show a clear cell of ovary.
[0061] FIG. 16 is a diagram showing a result of analyzing ovarian
serous adenocarcinoma tissue for expression of LSRs by an
immunohistochemical staining method using monoclonal antibodies
#1-25. The top row shows stage IIIc of serous G2 of ovary, stage Ic
of serous G3 of tube, stage IIb of serous G3 of ovary, and stage
IIIb of serous G3 of ovary. The bottom row shows, from the left,
stage IIIc of clear cell of ovary, stage IIc of clear cell of
ovary, and stage IV of clear cell of ovary.
[0062] FIG. 17 is a diagram showing a result of analyzing
endometrial cancer tissue for expression of LSRs by an
immunohistochemical staining method using monoclonal antibodies
#9-7 (4.5 .mu.g/ml). The left side is endometrial cancer #1 applied
with Toyobo Can get signal immunostain solution A as the primary
antibody diluent, and the right is endometrial cancer #1 applied
with Toyobo Can get signal immunostain solution B as the primary
antibody diluent.
[0063] FIG. 18 is a diagram showing results of assessing #9-7
antibody for the effect of suppressing growth of RMG-I. The
vertical axis indicates relative growth compared with no treatment.
The horizontal axis is the dosage of IgG.
[0064] FIG. 19 is a diagram showing results of assessing #1-25
antibody for the effect of suppressing growth of RMG-I. The
vertical axis indicates relative growth compared with no treatment.
The horizontal axis is the dosage of IgG.
[0065] FIG. 20 is a diagram showing results of assessing #1-25
antibody (the left three; from the left, 1 .mu.g/ml, 10 .mu.g/ml,
and 100 .mu.g/ml, respectively) and #26-2 antibody (middle three;
from the left, 1 .mu.g/ml, 10 .mu.g/ml, and 100 .mu.g/ml,
respectively) for the effect of suppressing growth of A2780. The
control IgG is shown on the right (right three; from the left, 1
.mu.g/ml, 10 fag/ml, and 100 .mu.g/ml, respectively). Each antibody
has an effect, but #1-25 exhibited a stronger effect than
#26-2.
[0066] FIG. 21 is a diagram showing results of assessing the LSR
siRNA described in the Examples for the effect of suppressing
growth of OVSAHO. From the left, day 1, day 2, day 3, day 4, and
day 5 are shown. 4 bars for each day indicate, from the left, mean
amount with no treatment, mean value of control, mean value of LSR
siRNA 1, and mean value of LSR siRNA2.
[0067] FIG. 22 is a diagram of a result showing that lipid
(cholesterol) incorporation is elevated in the cells stably
expressing LSRs described in the Examples. The left shows the
effects on total cholesterol, the middle graph shows the effects on
triglyceride, and the right shows the effects on phospholipid. The
vertical axis indicates each incorporation (mg/ml). The horizontal
axis indicates each of EMP1 low density, EMP1 high density, L45 low
density, and L45 high density. EMP indicates empty vector
introduced cells and L indicates cells forced to express LSRs.
[0068] FIG. 23 is a diagram of a result showing that lipid
(cholesterol) incorporation is elevated in high density culture in
the cells stably expressing LSRs described in the Examples. The
vertical axis indicates total cholesterol incorporation (mg/ml).
EMP1 indicates empty vector introduced cells and L45 indicates
cells forced to express LSRs.
[0069] FIG. 24 is a diagram of a result showing that LSR expression
described in the Examples elevates VLDL metabolism, but elevation
in metabolism due to VLDL is inhibited by LSR antibody
administration. Significant inhibition of elevation in metabolism
due to VLDL is exhibited for #9-7. Slight inhibition is also
observed for the #1-25 antibody. In each graph, the vertical axis
is OCR (pMoles/min) % and the horizontal axis indicates the elapsed
time (minutes). Squares indicate PBS (background control),
triangles indicate the control IgG, and rhombuses indicate anti-LSR
antibodies. The top panel is for empty vector (E1) and the bottom
is for cells forced to express LSRs (L45).
[0070] FIG. 25 is a diagram showing the condition when the anti-LSR
antibody described in the Examples was administered to a malignant
tumor model mouse.
[0071] FIG. 26 is a diagram showing results of assessing the
anti-LSR antibody described in the Examples for the antitumor
effect after administration of #9-7 or #1-25 to a malignant tumor
model mouse. The vertical axis indicates tumor volume (mm.sup.3).
The horizontal axis indicates the number of elapsed days. Squares
indicate the control IgG, triangles indicate anti-LSR antibody
(#9-7), and rhombuses indicate anti-LSR antibody (#1-25).
[0072] FIG. 27 is a diagram showing results of assessing the
anti-LSR antibody described in the Examples for the antitumor
effect after administration of #9-7 or #1-25 to a malignant tumor
model mouse. The vertical axis indicates tumor weight (mg). From
the left, control IgG administered group (n=8), anti-LSR antibody
(#9-7) administered group (n=6), and anti-LSR antibody (#1-25)
administered group (n=6) are shown.
[0073] FIG. 28 is a diagram showing results of assessing the
anti-LSR antibody described in the Examples for the antitumor
effect after administration of #9-7 or #1-25 to a malignant tumor
model mouse. From the left, control IgG administered group (n=8),
anti-LSR antibody (#9-7) administered group (n=6), and anti-LSR
antibody (#1-25) administered group (n=6) are shown.
[0074] FIG. 29 shows that recurrent ovarian cancer does not have an
effective therapeutic method. Conventionally, there was no
effective therapeutic method for recurrent ovarian cancer. The
epidemiological characteristic of ovarian cancer is that ovarian
cancer readily infiltrate into the surrounding by the lymph node
and peritoneal metastasis or the like and advances quickly. For
instance, 40% or more of ovarian cancer in Japanese patients is
considered serous, 24% clear cells, 17% endometrioid, and 13%
mucinous adenocarcinoma. As a 1st line of defense, cisplatin or
taxol is used, and Avastin is used for recurrent ovarian cancer.
However, it was considered that improvement in survival rate was
not observed. Since a therapeutic method during the progression
stage or recurrence is non-existent, ovarian cancer was considered
as tumor with poor prognosis. Thus, development of a novel
therapeutic method is considered imperative. The Table on the left
shows antibody medicaments approved as a cancer therapeutic drug
(Carter P J Nat. Rev. Immunol. 006, May 6 (5) 343-357, Review). The
graph on the right side of FIG. 29 shows the 5 year survival rate
(31% in Stage IV) (Japanese Society of Obstetrics and Gynecology,
Fujinka Shuyo Iinkai Hokoku [Gynecology tumor committee report],
2012, Vol. 64, No. 6).
[0075] FIG. 30 is an immunostaining diagram showing that LSRs are
expressed in ovarian cancer tissue. The left shows ovarian serous
adenocarcinoma and the right shows ovarian clear cell
adenocarcinoma. The bottom panel shows Western blot of each cell.
The left three columns show normal ovary, columns 4-5 from the left
show clear cell adenocarcinoma, and column 6 from the left to the
right end show serous adenocarcinoma. LSR indicates the band of
LSRs, and GAPDH indicates the control.
[0076] FIG. 31 is a diagram showing that LSRs are also expressed in
ovarian cancer metastasized sites. The left column shows lymph node
metastasis and the right column shows greater omentum metastasis.
The top panel shows 100 times magnification and the bottom panel
shows 400 times magnification.
[0077] FIG. 32 is a diagram showing that LSRs are also expressed in
ovarian cancer metastasized sites. The left column shows lymph node
metastasis and the right column shows greater omentum metastasis.
The top panel shows 100 times magnification and the bottom panel
shows 400 times magnification.
[0078] FIG. 33 is a diagram showing that LSRs are expressed in
ovary cancer from an early stage. The top left shows hematoxylin
and eosin stain (HE) staining. Top middle shows #1-25A, top right
shows #1-45A, bottom left shows #9-7B, bottom middle shows #1-25B,
and bottom right shows #1-45B. The cells shown are ovarian clear
cells in Stage Ic/IIc.
[0079] FIG. 34 shows that LSRs are also specifically expressed in
gastric cancer. The results of examination by immunostaining are
shown, which are results of immunostaining. The top row shows, from
the left column, 40 and 400 times magnification of ovarian clear
cell cancer and 40 and 400 times magnification of MK2 cells. The
bottom row shows pictures of 40 and 400 times magnificent of MK1
and 40 and 400 times magnification of MK3.
[0080] FIG. 35 is a diagram showing that LSRs are strongly
expressed in gastric cancer (signet ring cell cancer). The top left
panel shows a picture magnified 5 times, top right shows a picture
magnified 10 times, bottom left shows a picture magnified 20 times,
and bottom right shows a picture magnified 40 times.
[0081] FIG. 36 is a diagram showing analysis of LSR expression by
IHC using a normal frozen tissue array. The top row shows, from the
left, adrenal gland, bone marrow, breast, brain (cerebellum), and
brain (cerebral cortex). The middle row shows, from the left, brain
(pituitary gland), colon, endothelium (aorta), endothelium (aorta,
thoracic), and endothelium (artery). The bottom row shows, from the
left, esophagus, fallopian tube, heart (right ventricle), kidney,
and liver.
[0082] FIG. 37A is a diagram showing analysis of LSR expression by
IHC using a normal frozen tissue array. The top row shows, from the
left, lung, lymph node, ovary, pancreas, and placenta. The second
row from the top shows, from the left, prostate, skin, spinal cord,
spleen, and striated muscle. The second row from the bottom shows,
from the left, stomach, testis, thymus, thyroid, and ureter. The
bottom row shows, from the left, endometrium and cervix.
[0083] FIG. 37B shows results of calculating the dissociation
constant (K.sub.D) of anti-LSR antibodies by FACS. RMG-I cells were
stained with antibodies of various concentrations and analyzed by
FACS. As shown, #9-7 had K.sub.D=2.52 nM, #1-25 had K.sub.D=2.03
nM, #16-6 had K.sub.D=2.33 nM, #26-2 had K.sub.D=4.04 nM, #27-6 had
K.sub.D=4.29 nM, and #1-43 had K.sub.D=24.62 nM.
[0084] FIG. 38 shows results of investigating prognosis of ovarian
serous adenocarcinoma patients or ovarian clear cell adenocarcinoma
based on whether the LSR expression is high or low. 21 cases of
patients with strong expression of LSRs and 12 cases of patients
with weak expression were studied for ovarian serous
adenocarcinoma, and 27 cases of patients with strong expression of
LSRs and 24 cases of patients with weak expression were studied for
ovarian clear cell adenocarcinoma. It can be seen that ovarian
serous adenocarcinoma with high level of expression has poorer
prognosis compared to the group with low level of expression.
[0085] FIG. 39 shows a comparison of the epitope region of hLSR
antibody of the antibody of the present invention with the amino
acid sequence of hLSR(SEQ ID NO: 21) and mLSR(SEQ ID NO: 22).
[0086] FIG. 40 shows that an anti-hLSR antibody cross-reacts with
mLSR. The original diagram is shown in red and blue, where red
indicates mIgG2a. Blue indicates the staining pattern in clones of
various anti-LSR antibodies. Blue is marked with an arrow in this
diagram. The reaction of various antibodies to COS7 cells subjected
to transgenesis with pCMV5-mLSR-myc/DDK such that mSR is
transiently expressed was confirmed by FACS. The top row shows
mixture of COS7 and mLSR and the bottom row shows only COS7 cells.
Various antibodies are shown, which are from the left, #9-7, #16-6,
#26-2, #27-2, #1-25, and #1-43.
[0087] FIG. 41 shows that anti-LSR induces cell cycle arrest in
RMG-I cells in the G0/G1 phase. The graph shows the percentage of
cells in the G0/G1 phase, S phase and G2/M phase. For each phase,
results for no treatment, treatment with the control IgG, and
treatment with antibody #1-25 are shown from the left. The
experiment was carried out with a 6 well plate at 15000 cells/well
under the conditions of RPMI 1640 medium+1% FBS+1%
penicillin-streptomycin (100 .mu.g/ml antibody condition, 96
hours). Treatment with antibody #1-25 was statistically significant
(p<0.0001) (one way ANOVA and Dunnett's test).
[0088] FIG. 42 shows that anti-LSR antibodies enhance p27
expression, suppress cyclin D1 expression, suppress Rb and MAPK
activity, and suppress cell growth. Expression was observed by
Western blot. The left panel shows, from the top, p27, cyclin D1,
phosphorylated Rb (retinoblastoma protein; Ser780), phosphorylated
Rb (Ser807/811), Rb only, LSR, and GAPDH as a control. The right
panel shows, from the top, phosphorylated-MEK1/2, MEK1/2,
phosphorylated p44/42 MAPK, p44/42 MAPK, and GAPDH. For each
protein, the results of using, from the left, no treatment, mouse
IgG2a, and anti-LSR mAb #1-25 are shown.
[0089] FIG. 43 shows that an anti-LSR antibody also has an ADCC
non-dependent anti-tumor effect in addition to antitumor effects
mediated by ADCC. This is an experiment modeled after RMG-I
(NOD/SCID). The graph shows days after treatment (horizontal axis)
and tumor volume (mm.sup.3) (vertical axis). The rhombuses indicate
the control IgG (N=6) and the triangles indicate treatment with
anti-LSR Ab (#1-25) (N=6). *, **, and ***indicate statistical
significance (p<0.05, 0.01, and 0.001, Student's t-test),
respectively.
[0090] FIG. 44 is another graph showing that an anti-LSR antibody
also has ADCC non-dependent anti-tumor effects in addition to an
antitumor effect mediated by ADCC. The left side shows the control
IgG administered group and the right side shows the anti-LSR
antibody (#1-25) administered group. Each group was N=6, and the
vertical axis is tumor weight (mg). RMG-I (NOD/SCID) was used as
the model. The results were statistically significant (p<0.001,
Student's t-test).
[0091] FIG. 45 shows that tumor cells in the growth phase were
decreased in vivo by anti-LSR antibodies. Anti-Ki67 antibodies were
used for immunohistochemical staining, and RMG-I (NOD-SCID) was
used. The left column shows the control IgG administered group, and
the right column shows the anti-LSR antibody (#1-25) administered
group. The top row shows 100 times magnification and the bottom row
shows 400 times magnification.
[0092] FIG. 46 shows examination of antitumor effects of anti-LSR
antibodies on ovarian cancer cell strain (SKOV3-E1, SKOV3-L45, and
xenograph model). #1-25 was used as the LSR antibody, and mouse
IgG2a (Sigma M7769) was used as the control. 10 mg/kg was
intraperitoneally administered. SKOV3-E1 was used as an empty
vector introduced strain, and SKOV3-L45 was used as a strain stably
expressing LSRs. The arrows on the top side indicate
intraperitoneal administration (every other day, up to day 14), and
the bottom indicates tumor volume measurement (every 4 days up to
day 16 as well as measurement on day 18). An SCID female 6-week old
mouse was used as a model. The tumor size was about 60 mm.sup.3 on
day 0.
[0093] FIG. 47 shows that an anti-LSR monoclonal antibody exhibits
an antitumor effect on an ovarian cancer cell strain xenograft
model expressing LSRs. The graph on the left shows SKOV3-L45 (SCID)
(strains stably expressing LSRs) and the graph on the right shows
SKOV3-E1 (SCID) (empty vector). For each graph, the horizontal axis
indicates the days after treatment, and the vertical axis indicates
the tumor volume (mm.sup.3). The rhombuses indicate the control IgG
(N=5) and the triangles indicate treatment with anti-LSR Ab (#1-25)
(N=5). *, **, and *** indicate statistical significance (p<0.05,
0.01, and 0.001, Student's t-test), respectively.
[0094] FIG. 48 shows that an anti-LSR monoclonal antibody exhibits
an antitumor effect on an ovarian cancer cell strain xenograft
model expressing LSRs. The graph on the left shows SKOV3-L45 (SCID)
(strains stably expressing LSRs) and the graph on the right shows
SKOV3-E1 (SCID) (empty vector). N=5 for each group, and the
vertical axis is the tumor weight (mg). The rhombuses indicate the
control IgG (N=5) and the triangles indicate treatment with
anti-LSR Ab (#1-25) (N=5). As shown, it was demonstrated that
anti-LSR monoclonal antibodies do not exhibit an antitumor effect
on LSR negative cells, but exhibit an antitumor effect specifically
against LSR expressing positive cells (was statistically
significant (p<0.00076, Student's t-test)).
[0095] FIG. 49 shows that an LSR incorporates VLDL and promotes
lipid metabolism. The left side shows a vector introduced cell, and
the right side shows cells forced to express LSRs.
[0096] FIG. 50 shows results of examining intracellular
incorporation of LSR monoclonal antibodies. The top row shows
results of SKOV3-LSR#45 and the bottom row shows results of
SKOV3-Empty#1 (empty vector). The results are shown, from the left,
for control treatment, Herceptin treatment, antibody #1-25
treatment, and antibody #9-7 treatment. The arrows indicate various
clones of anti-LSR antibodies or Herceptin incorporated into the
cell.
[0097] FIG. 51 shows results of examining intracellular
incorporation of LSR monoclonal antibodies similar to FIG. 50. The
top row shows results for SKOV3-LSR#45 and the bottom row shows
SKOV3-Empty#1 (empty vector). From the left, antibodies #16-6,
#26-2, #27-6 and #1-43 are shown. The arrows show various clones of
anti-LSR antibodies incorporated into the cell.
[0098] FIG. 52 shows the protocol for a safety test on anti-LSR
antibodies using a mouse. 1 mg/body weight of mouse IgG2a (Sigma
M7769) and anti-LSR antibody #1-26 was intraperitoneally
administered to C57BL/6J (8 weeks old) to assess the following
items on day 7. The brain, heart, kidney, liver, lung and spleen
are selected as the extracted organs. The measured items include
while blood cell (WBC), red blood cell (RBC), hemoglobin (Hb),
platelet (Plt), total bilirubin (T-Bil), alanine aminotransferase
(ALT), alkaline phosphatase (ALP), amylase (Amy), blood urea
nitrogen (BUN), chrome (Cr), calcium (Ca), phosphorus (P), total
protein (TP), albumin (Alb), sodium (Na), potassium (K), globulin
(Globn), and glutamine (Glu). VetScan.TM. HMII (Abaxis, Inc.) was
used as an automated blood cell counter, and VetScan' VS2 (Abaxis,
Inc. 0) was used as a veterinary biochemical blood analyzer.
[0099] FIG. 53 shows a comparison of control IgG versus anti-LSR
antibody (male). In the Table, the left column shows the items,
second column from the left shows control IgG (n=3), the third
column shows anti-LSR antibodies (n=3), the second column from the
right shows normal values, and the right end shows the p value
(statistical significance in Student's t-test). In addition to the
abbreviations explain in FIG. 52, Ly indicates lymphocytes and Mo
indicates monocytes. Gr indicates granulocytes and Hct indicates
hematocrit values.
[0100] FIG. 54 shows a comparison of control IgG versus anti-LSR
antibody (female). Each of the values is the same as that in FIGS.
52-53.
[0101] FIG. 55 shows a comparison of control IgG versus anti-LSR
antibody (male). In the Table, the left column shows the items, the
second column from the left shows control IgG (n=3), the third
column shows anti-LSR antibodies (n=3), the second column from the
right shows normal values, and the right end shows the p value
(statistical significance in Student's t-test). The abbreviations
are as explained in FIG. 52.
[0102] FIG. 56 shows a comparison of control IgG versus anti-LSR
antibody (female). Each of the values is the same as that in FIGS.
52-53 and 55.
DESCRIPTION OF EMBODIMENTS
[0103] The embodiments of the present invention are described in
detail hereinafter. It should be noted that descriptions are
omitted when appropriate for the same content in order to avoid
complicating the content by repeating. Throughout the entire
specification, a singular expression should be understood as
encompassing the concept thereof in the plural form, unless
specifically noted otherwise. Thus, singular articles (e.g., "a",
"an", "the" and the like in case of English) should also be
understood as encompassing the concept thereof in the plural form
unless specifically noted otherwise. Further, the terms used herein
should be understood as being used in the meaning that is commonly
used in the art, unless specifically noted otherwise. Thus, unless
defined otherwise, all terminologies and scientific technical terms
that are used herein have the same meaning as the terms commonly
understood by those skilled in the art to which the present
invention pertains. In case of a contradiction, the present
specification (including the definitions) takes precedence.
[0104] First, explanations are provided for the terms and general
techniques used in the present invention.
[0105] As used herein, "LSR (lipolysis stimulated lipoprotein
receptor)" is generally known as a molecule associated with the
metabolism of a low density lipoprotein (LDL). The details of the
amino acid sequence or the like of LSRs can be found on the
websites of the NCBI (National Center for Biotechnology
Information), HGNC (HUGO Gene Nomenclature Committee) or the like.
Examples of accession numbers of LSRs described in NCBI are
NP_991403 (amino acid) and/NM_205834.3 (mRNA). An example of the
amino acid sequence of an LSR is SEQ ID NO: 7. An example of the
base sequence of an LSR mRNA is SEQ ID NO: 8. The amino acid
sequence of an LSR is not limited, as long as the sequence has LSR
activity. Thus, it is understood that not only proteins (or nucleic
acid encoding the same) having an amino acid sequence set forth in
a specific sequence identification number or accession number, but
also a functionally active analog or derivative thereof, a
functionally active fragment thereof or homolog thereof, or a
mutant encoded by a nucleic acid which hybridizes to a nucleic
encoding said protein under a highly stringent condition or lowly
stringent condition can also be used in the present invention, as
long as they align with the specific objective of the present
invention.
[0106] As used herein, "derivative", "analog", or "mutant"
includes, but is not intended to be limited to, molecules
comprising a region substantially homologous to a target protein
(e.g., LSR). Such a molecule, in various embodiments, is at least
30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% identical throughout
the amino acid sequence of the same size or in comparison to a
sequence aligned by a homology computer program known in the art.
Alternatively, a nucleic acid encoding such a molecule can
hybridize to a sequence encoding the constituent protein under a
(highly) stringent condition, moderately stringent condition, or
non-stringent condition. This refers to a product of altering a
naturally-occurring protein by an amino acid substitution, deletion
and addition, respectively, a protein whose derivative exhibits the
biological function of the naturally-occurring protein, although
not necessarily to the same degree. For instance, the biological
function of such a protein can be investigated by a suitable and
available in vitro assay described herein or known in the art. As
used herein, "functionally active" refers to polypeptides, i.e.,
fragments or derivatives, having a structural function, regulatory
function or biochemical function of a protein such as biological
activity in accordance with an embodiment associated with the
polypeptides, i.e., fragments or derivatives, of the present
invention. The discussion regarding LSRs in the present invention
mainly pertains to humans, but it is understood that many animals
other than humans, especially mammals, are within the scope of the
present invention, as they are known to express LSRs. Preferably,
the functional domain of LSRs e.g., transmembrane domain (positions
260-280) or phosphorylation sites (positions 309, 328, 406, 493,
528, 530, 535, 540, 551, 586, 615, and 646), are conserved.
[0107] A fragment of an LSR in the present invention is a
polypeptide comprising any region of the LSR. As long as such a
fragment serves the function of interest (e.g., marker or
therapeutic target) of the present invention, it is not necessary
that the fragment has biological functions of a naturally-occurring
LSR.
[0108] Thus, a representative nucleotide sequence of an LSR may
be:
[0109] (a) a polynucleotide having a base sequence set forth in SEQ
ID NO: 7 or a fragment sequence thereof;
[0110] (b) a polynucleotide encoding a polypeptide consisting of
the amino acid sequence set forth in SEQ ID NO: 8 or a fragment
thereof;
[0111] (c) a polypeptide encoding a variant polypeptide having a
mutation selected from the group consisting of a substitution,
addition, and deletion of one or more amino acids in the amino acid
sequence set forth in SEQ ID NO: 8, the variable polypeptide having
biological activity, or a fragment thereof;
[0112] (d) a polynucleotide, which is a splice mutant or an allelic
mutant of the base sequence set forth in SEQ ID NO: 7, or a
fragment thereof;
[0113] (e) a polynucleotide encoding a species homolog of a
polypeptide consisting of the amino acid sequence set forth in SEQ
ID NO: 8, or a fragment thereof;
[0114] (f) a polynucleotide encoding a polypeptide, which
hybridizes with the polynucleotide of any one of (a)-(e) under
stringent conditions and has biological activity; or
[0115] (g) a polynucleotide encoding a polypeptide consisting of a
base sequence, which is at least 70%, at least 80%, at least 90%,
at least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to the polynucleotide of any one of (a)-(e) or a
complementary sequence thereof and has biological activity.
Biological activity in this regard typically refers to the property
of being distinguishable from other proteins that are present in
the same organism as a marker or activity of an LSR. The amino acid
of an LSR may be
[0116] (a) a polypeptide consisting of the amino acid sequence set
forth in SEQ ID NO: 8 or a fragment thereof;
[0117] (b) a polypeptide, which has a mutation selected from the
group consisting of a substitution, addition, and deletion of one
or more amino acids in the amino acid sequence set forth in SEQ ID
NO: 8 and has biological activity;
[0118] (c) a polypeptide encoded by a splice mutant or an allelic
mutant of the base sequence set forth in SEQ ID NO: 7;
[0119] (d) a polypeptide, which is a species homolog of the amino
acid sequence set forth in SEQ ID NO: 8;
[0120] (e) a polypeptide, which has an amino acid sequence that is
at least 70%, at least 80%, at least 90%, at least 95%, at least
96%, at least 97%, at least 98%, or at least 99% identical to the
polypeptide of any one of (a)-(d) and has biological activity.
Biological activity in this regard typically refers to the property
of being distinguishable from other proteins that are present in
the same organism as a marker or activity of an LSR (for example,
when used as an antigen, a property of comprising a region that can
function as a specific epitope).
[0121] In the context of the present invention, "substance that
binds to an LSR", "LSR binding agent", or "LSR interaction
molecule" is a molecule or substance that binds at least
transiently to an LSR. For detection purposes, it is preferable
that such a molecule or substance is advantageously capable of
indicating that the molecule or substance is bound (i.e., labelled
or in a labelable state). For therapeutic purposes, it is more
advantageous that such a molecule or substance is bound to a
therapeutic agent. Examples of a substance that binds to an LSR
include antibodies, antisense oligonucleotides, siRNAs, low
molecular weight molecules (LMW), binding peptides, aptamers,
ribozymes, peptidomimetics and the like. A substance that binds to
an LSR or LSR interaction molecule may be an LSR inhibitor, and
encompasses, for instance, binding proteins or binding peptides
directed to an LSR, especially those directed to an active site of
an LSR, as well as nucleic acids directed to a gene of an LSR. A
nucleic acid directed to an LSR refers to, for example, a double
stranded or single stranded DNA or RNA inhibiting the expression of
an LSR gene or activity of an LSR or a modified product or
derivative thereof, including, but not limited to, antisense
nucleic acids, aptamers, siRNAs (small interfering RNA) and
ribozymes. As used herein, "binding protein" or "binding peptide",
with respect to an LSR, refers to any protein or peptide that binds
to the LSR, including, but not limited to, antibodies directed to
the LSR (e.g., polyclonal antibodies or monoclonal antibodies),
antibody fragments and functional equivalents.
[0122] As used herein, "protein", "polypeptide", "oligopeptide" and
"peptide" are used herein in the same meaning and refer to an amino
acid polymer of any length. The polymer may be straight, branched
or cyclic. An amino acid may be a naturally-occurring,
non-naturally occurring or altered amino acid. The term may also
encompass those assembled into a complex of multiple polypeptide
chains. The term also encompasses naturally-occurring or
artificially altered amino acid polymers. Examples of such an
alteration include disulfide bond formation, glycosylation,
lipidation, acetylation, phosphorylation, and any other
manipulation or alteration (e.g., conjugation with a labeling
component). The definition also encompasses, for example,
polypeptides comprising one or more analogs of an amino acid (e.g.,
including non-naturally occurring amino acids and the like),
peptide-like compounds (e.g., peptoids) and other alterations in
the art. As used herein, "amino acid" is a general term for organic
compounds with an amino group and a carboxyl group. When the
antibody according to an embodiment of the present invention
comprises a "specific amino acid sequence", any of the amino acids
in the amino acid sequence may be chemically modified. Further, any
of the amino acids in the amino acid sequence may be forming a salt
or a solvate. Further, any of the amino acids in the amino acid
sequence may have an L form or a D form. Even for such cases, the
protein according to an embodiment of the present invention is
considered as comprising the above-described "specific amino acid
sequence". Examples of known chemical modifications applied to an
amino acid comprised in a protein in a living body include
modifications of the N-terminus (e.g., acetylation, myristylation
and the like), modifications of the C-terminus (e.g., amidation,
addition of glycosylphosphatidylinositol and the like)
modifications of a side chain (e.g., phosphorylation, glycosylation
and the like) and the like. The modifications may be
naturally-occurring or non-naturally occurring, as long as the
objective of the present invention is met.
[0123] As used herein, "polynucleotide", "oligonucleotide" and
"nucleic acid" are used herein in the same meaning, and refer to a
polymer of nucleotides with any length. The terms also encompass
"oligonucleotide derivative" and "polynucleotide derivative".
"Oligonucleotide derivative" and "polynucleotide derivative" refer
to an oligonucleotide or polynucleotide that comprises a nucleotide
derivative or has a bond between nucleotides which is different
from normal. The terms are used interchangeably. Specific examples
of such an oligonucleotide include 2'-O-methyl-ribonucleotide,
oligonucleotide derivatives having a phosphodiester bond in an
oligonucleotide converted to a phosphorothioate bond,
oligonucleotide derivatives having a phosphodiester bond in an
oligonucleotide converted to an N3'-P5' phosphoramidate bond,
oligonucleotide derivatives having ribose and phosphodiester bond
in an oligonucleotide converted to a peptide nucleic acid bond,
oligonucleotide derivatives having uracil in an oligonucleotide
replaced with C-5 propinyluracil, oligonucleotide derivatives
having uracil in an oligonucleotide replaced with C-5
thiazoluracil, oligonucleotide derivatives having cytosine in an
oligonucleotide replaced with C-5 propinylcytosine, oligonucleotide
derivatives having cytosine in an oligonucleotide replaced with
phenoxazine-modified cytosine, oligonucleotide derivatives having
ribose in DNA replaced with 2'-O-propylribose, oligonucleotide
derivatives having ribose in an oligonucleotide replaced with
2'-methoxyethoxyribose and the like. Unless noted otherwise,
specific nucleic acid sequences are also intended to encompass
conservatively altered variants (e.g., degenerate codon substitute)
and complement sequences as well as the expressly shown sequences.
Specifically, degenerate codon substitutes can be achieved by
preparing a sequence with the third position of one or more
selected (or all) codons substituted with a mixed base and/or
deoxyinosine residue (Batzer et al., Nucleic Acid Res. 19: 5081
(1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985);
Rossolini et al., Mol. Cell. Probes 8: 91-98 (1994)). As used
herein, "nucleic acid" is used interchangeably with a gene, cDNA,
mRNA, oligonucleotide, and polynucleotide. As used herein,
"nucleotide" may be a naturally-occurring or non-naturally
occurring.
[0124] As used herein, "gene" refers to an agent defining a genetic
trait. "Gene" may refer to "polynucleotide", "oligonucleotide" and
"nucleic acid".
[0125] As used herein, "homology" of genes refers to the level of
identity of two or more genetic sequences with one another. In
general, having "homology" refers to having a high level of
identity or similarity. Thus, two genes with high homology have
higher identity or similarity of sequences. It is possible to
investigate whether two types of genes are homologous by direct
comparison of sequences or, for nucleic acids, by a hybridization
method under a stringent condition. When two genetic sequences are
directly compared, the genes are homologous when DNA sequences are
representatively at least 50% identical, preferably at least 70%
identical, and more preferably at least 80%, 90%, 95%, 96%, 97%,
98%, or 99% identical between the genetic sequences. Thus, as used
herein, "homolog" or "homologous gene product" refers to a protein
in another species, preferably mammal, exerting the same biological
function as a protein constituent of a complex which will be
further described herein. Such a homolog is also called "ortholog
gene product". It is understood that such a homolog, homologous
gene product, ortholog gene product or the like can also be used,
as long as they are in alignment with the objective of the present
invention.
[0126] Amino acids may be mentioned herein by either their commonly
known three letter symbols or their one character symbols
recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
Similarly, nucleotides may be mentioned by their commonly
recognized one character codes. Comparison of similarity, identity
and homology of an amino acid sequence and abase sequence is
calculated herein by using a default parameter using a sequence
analysis tool, BLAST. For example, identity can be searched by
using BLAST 2.2.28 (published on Apr. 2, 2013) of the NCBI. Herein,
values for identity generally refer to a value obtained by
alignment under the default condition using the above-described
BLAST. However, when a higher value is obtained by changing a
parameter, the highest value is considered the value of identity.
When identity is evaluated in a plurality of regions, the highest
value thereamong is considered the value of identity. Similarity is
a value calculated by taking into consideration a similar amino
acid in addition to identity.
[0127] In one embodiment of the present invention, "several" may
be, for example, 10, 8, 6, 5, 4, 3 or 2, or a value less than any
one of the values. It is known that a polypeptide with one or
several amino acid residue deletions, additions, insertions, or
substitutions by other amino acids maintains its biological
activity (Mark et al., Proc Natl Acad Sci USA. 1984 September;
81(18): 5662-5666., Zoller et al., Nucleic Acids Res. 1982 Oct. 25;
10(20): 6487-6500., Wang et al., Science. 1984 Jun. 29; 224 (4656):
1431-1433.). An antibody with a deletion or the like can be made,
for example, by site-directed mutagenesis, random mutagenesis,
biopanning using an antibody phage library or the like. For
example, KOD-Plus-Mutagenesis Kit (TOYOBO CO., LTD.) can be used
for site-directed mutagenesis. An antibody with the same activity
as the wild-type can be selected from mutant antibodies introduced
with a deletion or the like by performing various characterizations
such as FACS analysis and ELISA.
[0128] In one embodiment of the present invention, "90% or greater"
may be, for example, 90, 95, 96, 97, 98, 99 or 100% or greater or
within the range of any two values described above. For the
above-described "homology", the percentage of the number of
homologous amino acids in two or a plurality of amino acid
sequences may be calculated in accordance with a known method in
the art. Before calculating the percentage, amino acid sequences in
a group of amino acid sequences to be compared are aligned. A space
is introduced in a portion of amino acid sequences when necessary
to maximize the percentage of the same amino acids. An alignment
method, method of calculating the percentage, comparison method,
and computer programs associated therewith have been well known in
the art (e.g., BLAST, GENETYX and the like). As used herein,
"homology" can be represented by a value measured with BLAST of the
NCBI, unless specifically noted otherwise. Blastp can be used in
the default setting for an algorithm for comparing amino acid
sequences with BLAST. Results of measurement are expressed in a
numerical form as Positives or Identities.
[0129] As used herein, "polynucleotide which hybridizes under a
stringent condition" refers to commonly used, well-known conditions
in the art. Such a polynucleotide can be obtained by using a method
such as colony hybridization, plaque hybridization, or southern
blot hybridization while using a polynucleotide selected from among
the polynucleotides of the present inventions as a probe.
Specifically, the above-described polynucleotide refers to a
polynucleotide that can be identified by using a filter with
immobilized DNA from a colony or plaque and performing
hybridization at 65.degree. C. in the presence of 0.7-1.0 M NaCl
and then using an SSC (saline-sodium citrate) solution with 0.1-2
times concentration (composition of an SSC solution with 1 time
concentration is 150 mM sodium chloride and 15 mM sodium citrate)
to wash the filter under the condition of 65.degree. C. For
"stringent condition", the following are examples of conditions
that can be used. (1) low ionic strength and a high temperature are
used for washing (e.g., 0.015 M sodium chloride/0.0015 M sodium
citrate/0.1% sodium dodecyl sulfate at 50.degree. C.), (2) a
denaturing agent such as formamide is used in hybridization (e.g.,
50% (v/v) formamide, 0.1% bovine serum albumin/0.1% ficoll/0.1%
polyvinyl pyrrolidone/50 mM sodium phosphate buffer with a pH of
6.5, 750 mM sodium chloride, and 75 mM sodium citrate at 42.degree.
C.), or (3) a solution comprising 20% formamide, 5.times.SSC, 50 mM
sodium phosphate (pH 7.6), 5.times.Denhardt's solution, 10% dextran
sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, is
incubated overnight at 37.degree. C. and then a filter is washed
with 1.times.SSC at about 37-50.degree. C. The formamide
concentration may be 50% or greater. Washing time may be 5, 15, 30,
60, 120 minutes, or greater. A plurality of elements are considered
to affect stringency in a hybridization reaction such as
temperature, salt concentration and the like. Ausubel et al.,
Current Protocols in Molecular Biology, Wiley Interscience
Publishers, (1995) can be referred for details. "Highly stringent
condition", for example, is 0.0015 M sodium chloride, 0.0015 M
sodium citrate, and 65-68.degree. C. or 0.015 M sodium chloride,
0.0015 M sodium citrate, 50% formamide and 42.degree. C.
Hybridization can be performed in accordance with the method
described in experimental publications such as Molecular Cloning
2.sup.nd ed., Current Protocols in Molecular Biology, Supplement
1-38, DNA Cloning 1: Core Techniques, A Practical Approach, Second
Edition, Oxford University Press (1995). In this regard, a sequence
comprising only an A sequence or only a T sequence is preferably
excluded from a sequence that hybridizes under stringent
conditions. A moderately stringent condition can be readily
determined by those skilled in the art based on, for example, the
length of a DNA and is shown in Sambrook et al., Molecular Cloning:
A Laboratory Manual, Third Ed., Vol. 1, 7.42-7.45 Cold Spring
Harbor Laboratory Press, 2001, including, for a nitrocellulose
filters, use of hybridization conditions of a pre-wash solution of
1.0 mM EDTA (pH 8.0), 5.times.SSC, 0.5% SDS, and about 50%
formamide and 2.times.SSC-6.times.SSC at about 40-50.degree. C. (or
other similar hybridization solutions such as a Stark's solution in
about 50% formamide at about 42.degree. C.) and washing conditions
of 0.5.times.SSC, 0.1% SDS at about 60.degree. C. Thus, the
polypeptides used in the present invention encompass polypeptides
encoded by a nucleic acid molecule that hybridizes under highly or
moderately stringent conditions to a nucleic acid molecule encoding
a polypeptide described in the present invention in particular.
[0130] As used herein, a "purified" substance or biological agent
(e.g., nucleic acid, protein or the like) refers to a substance or
a biological agent from which at least a part of an agent naturally
accompanying the substance or biological agent has been removed.
Thus, the purity of a biological agent in a purified biological
agent is generally higher than the purity in the normal state of
the biological agent (i.e., concentrated). The term "purified" as
used herein refers to the presence of preferably at least 75% by
weight, more preferably at least 85% by weight, still more
preferably at least 95% by weight, and most preferably at least 98%
by weight of a biological agent of the same type. The substance or
biological agent used in the present invention is preferably a
"purified" substance. An "isolated" substance or biological agent
(e.g., nucleic acid, protein, or the like) as used herein refers to
a substance or biological agent having agents that naturally
accompany the substance or biological agent substantially removed.
The term "isolated" as used herein varies depending on the
objective. Thus, the term does not necessarily have to be
represented by purity. However, when necessary, the term refers to
the presence of preferably at least 75% by weight, more preferably
at least 85% by weight, still more preferably at least 95% by
weight, and most preferably at least 98% by weight of a biological
agent of the same type. The substance used in the present invention
is preferably an "isolated" substance or biological agent.
[0131] As used herein, a "corresponding" amino acid, nucleic acid,
or moiety refers to an amino acid or a nucleotide which has or is
expected to have, in a certain polypeptide molecule or
polynucleotide molecule (e.g., LSR), similar action as a
predetermined amino acid, nucleotide or moiety in a benchmark
polypeptide or a polynucleotide for comparison, and, particularly
in the case of enzyme molecules, refers to an amino acid which is
present at a similar position in an active site and makes a similar
contribution to catalytic activity and refers to a corresponding
moiety in a complex molecule (e.g., transmembrane domain or the
like). For example, for an antisense molecule, it can be a similar
moiety in an ortholog corresponding to a specified moiety of the
antisense molecule. A corresponding amino acid can be a specified
amino acid subjected to, for example, cysteination,
glutathionylation, S--S bond formation, oxidation (e.g., oxidation
of methionine side chain), formylation, acetylation,
phosphorylation, glycosylation, myristylation or the like.
Alternatively, a corresponding amino acid can be an amino acid
responsible for dimerization. Such a "corresponding" amino acid or
nucleic acid may be a region or a domain over a certain range.
Thus, it is referred herein as a "corresponding" region or domain
in such a case. Such a corresponding region or domain is useful for
designing a complex molecule in the present invention.
[0132] As used herein, a "corresponding" gene (e.g., polynucleotide
sequence or molecule) refers to a gene (e.g., polynucleotide
sequence or molecule) of a certain species which has or is expected
to have similar action as a predetermined gene in a benchmark
species for comparison. When there is a plurality of genes having
such action, the corresponding gene refers to a gene having the
same evolutionary origin. Hence, a gene corresponding to a certain
gene may be an ortholog of such a gene. Thus, an LSR corresponding
to human LSRs can be found in other animals (especially mammals).
Such a corresponding gene can be identified by using a technique
that is well known in the art. For example, a corresponding gene in
a certain animal (e.g., mouse) can be found by searching a database
comprising sequences of the animal from using the sequence of SEQ
ID NO: 7, 8 or the like as a query sequence, as a benchmark gene of
the corresponding gene (e.g., LSR or the like).
[0133] As used herein, "fragment" refers to a polypeptide or
polynucleotide with a sequence length of 1 to n-1 with respect to
the full length polypeptide or polynucleotide (with length n). The
length of a fragment can be appropriately changed in accordance
with the objective. Examples of the lower limit of such a length
include 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 and more
amino acids for a polypeptide. Lengths represented by an integer
that is not specifically listed herein (e.g., 11 and the like) also
can be suitable as a lower limit. Further, examples of length
include 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, and
more nucleotides for a polynucleotide. Lengths represented by an
integer that is not specifically listed herein (e.g., 11 and the
like) also can be suitable as a lower limit. As used herein, such a
fragment is understood to be within the scope of the present
invention, for example, when a full length version functions as a
marker or a target molecule, as along as the fragment itself also
functions as a marker or a target molecule.
[0134] The term "activity" according to the present invention
refers to a function of a molecule in the broadest sense herein.
Activity, although not intended to be limiting, generally includes
a biological function, biochemical function, physical function, and
chemical function of a molecule. Examples of activity include
enzymatic activity, an ability to interact with another molecule,
an ability to activate, promote, stabilize, inhibit, suppress, or
destabilize a function of another molecule, stability, and an
ability to localize at a specific position in a cell. When
applicable, the term also relates to a function of a protein
complex in the broadest sense.
[0135] As used herein, "biological function", when referring to a
certain gene or a nucleic acid molecule or a polypeptide related
thereto, refers to a specific function that the gene, the nucleic
acid molecule or the polypeptide may have in a living body.
Examples of such a function include, but are not limited to,
production of a specific antibody, enzyme activity, impartation of
resistance and the like. In the present invention, examples of this
function include, but are not limited to, a function of an LSR
involved in inhibition of VLDL incorporation or the like. As used
herein, biological function can be exerted by "biological
activity". As used herein, "biological activity" refers to the
activity a certain agent (e.g., polynucleotide, protein or the
like) may have in a living body. Biological activity encompasses an
activity of exerting a variety of functions (e.g., transcription
promoting activity), and also encompasses, for example, an activity
of activating or inactivating another molecule by an interaction
with a certain molecule. When two agents interact, biological
activity thereof may be a bond between two molecules and a
biological change induced thereby. For example, two molecules are
considered to be bound together if, when one molecule is
precipitated using an antibody, the other molecule co-precipitates.
Observation of such co-precipitation is one example of a
determination approach. For example, when a certain agent is an
enzyme, the biological activity thereof encompasses enzyme activity
thereof. In another example, when a certain agent is a ligand,
binding to a receptor corresponding to the ligand is encompassed.
Such biological activity can be measured by a technique that is
well known in the art. Thus, "activity" refers to various
measurable indicators, which indicate or reveal a bond (either
direct or indirect) or affect a response (i.e., having a measurable
effect in response to some exposures of stimuli). Examples thereof
includes affinity of a compound that directly binds to the
polypeptide or polynucleotide of the present invention, the amount
of proteins upstream or downstream after some stimulations or
events, or the level of other similar functions.
[0136] As used herein, "expression" of a gene, a polynucleotide, a
polypeptide or the like refers to the gene or the like being
subjected to a certain action in vivo to be converted into another
form. Preferably, expression refers a gene, a polynucleotide or the
like being transcribed and translated into a form of a polypeptide.
However, transcription to make an mRNA is also one embodiment of
expression. Thus, "expression product" as used herein encompasses
such a polypeptide or protein, or mRNA. More preferably, such a
polypeptide form can be a form which has undergone post-translation
processing. For example, the LSR expression level can be determined
by any method. Specifically, the LSR expression level can be found
by assessing the amount of mRNA of LSRs, the amount of LSR protein,
and the biological activity of the LSR protein. The amount of mRNA
or protein of LSRs can be determined by the method described in
detail in other parts of the specification or a method known in the
art.
[0137] As used herein, "functional equivalent" refers to any entity
having the same function of interest but a different structure
relative to the original target entity. Thus, it is understood that
a functional equivalent of "LSR" or an antibody thereof encompasses
mutants or variants (e.g., amino acid sequence variant or the like)
of the LSR or antibody thereof, not the LSR or antibody thereof
itself, which have the biological action of the LSR and those that
can change, upon action, into the LSR or the antibody thereof
itself or a mutant or variant of the LSR or the antibody thereof
(e.g., including nucleic acid encoding an LSR or an antibody
thereof itself or a mutant or variant of the LSR or antibody
thereof, and vector, cell and the like comprising such a nucleic
acid). It is understood, even without specific mention, that a
functional equivalent of an LSR or an antibody thereof can be used
similarly to the LSR or antibody thereof. A functional equivalent
can be found by searching a database or the like. As used herein,
"search" refers to utilizing a certain nucleic acid base sequence
electronically, biologically, or by another method to find another
nucleic acid base sequence having a specific function and/or
property. Examples of electronic search include, but are not
limited to, BLAST (Altschul et al., J. Mol. Biol. 215: 403-410
(1990)), FASTA (Pearson & Lipman, Proc. Natl. Acad. Sci., USA
85: 2444-2448 (1988)), Smith and Waterman method (Smith and
Waterman, J. Mol. Biol. 147: 195-197 (1981)), Needleman and Wunsch
method (Needleman and Wunsch, J. Mol. Biol. 48: 443-453 (1970)) and
the like. Examples of biological search include, but are not
limited to, stringent hybridization, a macroarray with a genomic
DNA applied to a nylon membrane or the like or a microarray with a
genomic DNA applied to a glass plate (microarray assay), PCR, in
situ hybridization and the like. Herein, a gene used in the present
invention is intended to include corresponding genes identified by
such electronic search or biological search.
[0138] As a functional equivalent of the present invention, it is
possible to use an amino acid sequence with one or more amino acid
insertions, substitutions or deletions, or addition to one or both
ends. As used herein, "one or more amino acid insertions,
substitutions or deletions, or addition to one or both ends" in an
amino acid sequence refers to an alteration with a substitution of
a plurality of amino acids or the like to the extent that can occur
naturally by a well-known technical method such as site-directed
mutagenesis or natural mutation. An altered amino acid sequence can
have, for example, 1-30, preferably 1-20, more preferably 1-9,
still more preferably 1-5, and especially preferably 1-2 amino acid
insertions, substitutions or deletions or additions to one or both
ends. Preferably, an altered amino acid sequence may be an amino
acid sequence having one or more (preferably 1 or several, or 1, 2,
3 or 4) conservative substitutions in an LSR amino acid sequence.
"Conservative substitution" refers herein to a substitution of one
or more amino acid residues with other chemically similar amino
acid residue so as not to substantially alter a function of a
protein. Examples thereof include cases where a hydrophobic residue
is substituted with another hydrophobic residue, cases where a
polar residue is substituted with another polar residue having the
same charge and the like. Functionally similar amino acids that can
be substituted in this manner are known in the art for each amino
acid. Specific examples include alanine, valine, isoleucine,
leucine, proline, tryptophan, phenylalanine, methionine and the
like for nonpolar (hydrophobic) amino acids, glycine, serine,
threonine, tyrosine, glutamine, asparagine, cysteine and the like
for polar (neutral) amino acids. Examples of positively charged
(basic) amino acid include arginine, histidine, lysine and the
like. Further, examples of a negatively-charged (acidic) amino acid
include aspartic acid, glutamic acid and the like.
[0139] As used herein, "suppressant" refers to a substance or agent
that inhibits biological action of a receptor or a cell against a
target entity (e.g., receptor or cell). An LSR suppressant of the
present invention is an agent that can temporarily or permanently
reduce or eliminate a function of a target LSR, a cell expressing
an LSR or the like. Examples of such a factor include, but are not
limited to, antibodies, antigen binding fragments thereof,
derivatives, functional equivalents, antisenses, RNAi agents such
as siRNAs and other nucleic acid forms.
[0140] As used herein, "agonist" refers to a substance that
expresses or enhances biological action of a receptor against a
target entity (e.g., receptor). Examples thereof include natural
agonists (also referred to as ligands), as well as synthesized
agonists, altered agonists and the like.
[0141] As used herein, "antagonist" refers to a substance that
suppresses or inhibits the expression of biological action of a
receptor against a target entity (e.g., receptor). Examples thereof
include natural antagonists (also referred to as ligands), as well
as synthesized antagonists, altered antagonists and the like.
Antagonists include those that competitively or non-competitively
suppress or inhibit expression against an agonist. An antagonist
can also be obtained by altering an agonist. Since physiological
phenomena are suppressed or inhibited, an antagonist may be
encompassed in the concept of suppressant (inhibitor) or
suppressing agent. Thus, antagonists as used herein are
substantially used synonymously with "suppressant".
[0142] As used herein, an "antibody" includes, in a broad sense,
polyclonal antibodies, monoclonal antibodies, multi-specific
antibodies, chimeric antibodies, anti-idiotype antibodies, and
fragments thereof such as Fv fragments Fab' fragments, F(ab').sub.2
and Fab fragments, as well as other conjugates or functional
equivalents produced by recombination (e.g., chimeric antibodies,
humanized antibodies, multifunctional antibodies, bispecific or
oligospecific antibodies, single chain antibodies, scFV, diabodies,
sc(Fv).sub.2 (single chain (Fv).sub.2), and scFv-Fc). Furthermore,
such an antibody may be fused, by a covalently bond or
recombination, with an enzyme such as alkaline phosphatase,
horseradish peroxidase, or a galactosidase. The anti-LSR antibody
used in the present invention is sufficient if it binds to a
protein of LSRs, regardless of the origin, type, shape or the like
thereof. Specifically, known antibodies such as a non-human animal
antibody (e.g., a mouse antibody, a rat antibody, or a camel
antibody), a human antibody, a chimeric antibody, or a humanized
antibody can be used. In the present invention, a monoclonal or
polyclonal antibody can be utilized as an anti-LSR antibody, but a
monoclonal antibody is preferable. It is preferable that an
antibody binds specifically to an LSR protein. Further, antibodies
encompass modified and non-modified antibodies. Modified antibodies
may be formed by an antibody binding to various molecules such as
polyethylene glycol. A modified antibody can be obtained by
applying a chemical modification to an antibody by using a known
approach.
[0143] "Anti-LSR antibody" in one embodiment of the present
invention encompasses antibodies having binding affinity to LSRs.
The production method of such an anti-LSR antibody is not
particularly limited. For example, the antibody may be produced by
immunizing mammals or birds with an LSR.
[0144] Further, it is understood that examples of a "functional
equivalent" of an "antibody to LSR (anti-LSR antibody) or a
fragment thereof" includes, for antibodies, antibodies themselves
having LSR binding activity and optionally suppressing activity and
fragments thereof themselves, as well as chimeric antibodies,
humanized antibodies, multifunctional antibodies, bispecific or
oligospecific antibodies, single chain antibodies, scFV, diabodies,
sc(Fv).sub.2 (single chain (Fv).sub.2), scFv-Fc and the like.
[0145] The anti-LSR antibody according to one embodiment of the
present invention is preferably an anti-LSR antibody that
specifically binds to a specific epitope of an LSR from the
viewpoint of malignant tumor growth being particularly highly
suppressed.
[0146] The anti-LSR antibody according to one embodiment of the
present invention may be a monoclonal antibody. A monoclonal
antibody can be made to more efficiently act against an LSR
relative to a polyclonal antibody. It is preferred that a chicken
is immunized with an LSR from the viewpoint of efficient production
of anti-LSR monoclonal antibodies.
[0147] The antibody class of the anti-LSR antibody according to one
embodiment of the present invention is not particularly limited.
For example, the class may be IgM, IgD, IgG, IgA, IgE, or IgY.
[0148] The anti-LSR antibody according to one embodiment of the
present invention may be an antibody fragment having antigen
binding activity (hereinafter, also referred to as "antigen binding
fragment"). In such a case, there is an effect of improved
stability, antibody production efficiency or the like.
[0149] The anti-LSR antibody according to one embodiment of the
present invention may be a fusion protein. The fusion protein may
comprise a polypeptide or oligopeptide bound to the N or C-terminus
of an anti-LSR antibody. The oligopeptide in this regard may be an
His-tag. The fusion protein may also be fused to a mouse, human, or
chicken antibody partial sequence. Such fusion proteins are also
encompassed as one form of the anti-LSR antibody according to the
present embodiment.
[0150] The anti-LSR antibody according to one embodiment of the
present invention may be, for example, an antibody obtained via the
step of immunizing an organism with a purified LSR, LSR-expressing
cell, or an LSR containing lipid membrane. It is preferable that an
LSR-expressing cell is used for immunization from the viewpoint of
enhancing a therapeutic effect against LSR positive malignant
tumor.
[0151] The anti-LSR antibody according to one embodiment of the
present invention may be an antibody having a CDR set of an
antibody obtained via the step of immunizing an organism with a
purified LSR, LSR-expressing cell, or an LSR containing lipid
membrane. It is preferable that an LSR-expressing cell is used for
immunization from the viewpoint of enhancing a therapeutic effect
against LSR positive malignant tumor. A CDR set is a set of heavy
chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3.
[0152] "LSR expressing cell" in one embodiment of the present
invention may be obtained, for example, by introducing a
polynucleotide encoding an LSR into a cell and having the LSR
expressed. LSRs in this regard encompass LSR fragments. Further,
"LSR-containing lipid membrane" in one embodiment of the present
invention may be obtained, for example, by mixing an LSR and a
lipid bilayer. LSRs in this regard encompass LSR fragments.
Further, the anti-LSR antibody according to one embodiment of the
present invention is preferably an antibody obtained via the step
of immunizing a chicken with an antigen or an antibody having a CDR
set of such an antibody from the viewpoint of enhancing a
therapeutic effect against LSR positive malignant tumor.
[0153] The anti-LSR antibody according to one embodiment of the
present invention may have any binding strength as long as the
object can be accomplished. Examples thereof include, but are not
limited to, at least 1.0.times.10.sup.6 or greater,
2.0.times.10.sup.6 or greater, 5.0.times.10.sup.6 or greater, and
1.0.times.10.sup.7 or greater. The K.sub.D value (kd/ka) generally
may be 1.0.times.10.sup.-7 (M) or less and can be
1.0.times.10.sup.-9 (M) or 1.0.times.10.sup.-1.degree. or less.
[0154] The anti-LSR antibody according to one embodiment of the
present invention may have ADCC or CDC activity.
[0155] The anti-LSR antibody according to one embodiment of the
present invention may be an antibody that binds to a wild-type or
mutant LSR. Mutant LSRs include mutants due to a difference in the
DNA sequences among individuals. The amino acid sequence of a
wild-type or mutant LSR is preferably 80% or more, more preferably
90% or more, more preferably 95% or more, and especially preferably
98% or more homologous to the amino acid sequence set forth in SEQ
ID NO: 8.
[0156] "Antibody" in one embodiment of the present invention
encompasses molecules capable of specifically binding to a specific
epitope on an antigen and populations thereof. Further, the
antibody may be a polyclonal antibody or monoclonal antibody. The
antibody can be present in various forms. For example, the antibody
may be in one or more types of forms selected from the group
consisting of a full-length antibody (antibody having an Fab region
and an Fc region), Fv antibody, Fab antibody, F(ab').sub.2
antibody, Fab' antibody, diabody, single chain antibody (e.g.,
scFv), dsFv, multi-specific antibody (e.g., bispecific antibody),
peptide or polypeptide having antigen binding affinity, chimeric
antibody (e.g., mouse-human chimeric antibody, chicken-human
chimeric antibody or the like), mouse antibody, chicken antibody,
humanized antibody, human antibody, and similar antibodies (or
equivalents). Further, the antibody encompasses modified or
non-modified antibodies. Modified antibodies may be formed by an
antibody binding to various molecules such as polyethylene glycol.
A modified antibody can be obtained by applying a chemical
modification to an antibody by using a known approach. Furthermore,
such an antibody may be fused by a covalent bond or recombination
with an enzyme such as alkaline phosphatase, horseradish
peroxidase, or a galactosidase. The anti-LSR antibody used in the
present invention is sufficient if it binds to an LSR protein,
regardless of the origin, type, shape or the like thereof.
Specifically, known antibodies such as a non-human animal antibody
(e.g., a mouse antibody, a rat antibody, or a camel antibody), a
human antibody, a chimeric antibody, or a humanized antibody can be
used. In the present invention, a monoclonal or polyclonal antibody
can be utilized as the anti-LSR antibody, but a monoclonal antibody
is preferable. It is preferable that an antibody binds specifically
to an LSR protein. Further, the antibody encompasses modified and
non-modified antibodies. Modified antibodies may be formed by an
antibody binding to various molecules such as polyethylene glycol.
A modified antibody can be obtained by applying a chemical
modification to an antibody by using a known approach.
[0157] "Polyclonal antibody" in one embodiment of the present
invention can be produced, for example, by administering an
immunogen comprising an antigen of interest to mammals (e.g., rat,
mouse, rabbit, cow, monkey or the like), birds or the like in order
to induce production of a polyclonal antibody specific to the
antigen. An immunogen may be administered by one or more immunizing
agents and, when desired, an injection of an adjuvant. An adjuvant
may be used to increase immune responses and may comprise a
Freund's adjuvant (complete or incomplete), mineral gel (aluminum
hydroxide or the like), surfactant (lysolecithin or the like) or
the like. Immunization protocols are known in the art and, in some
cases, may be implemented by any method that induces an immune
response, which matches the selected host organism (Tanpakushitsu
Jikken Handobukku [Protein experiment handbook], Yodosha (2003):
86-91).
[0158] "Monoclonal antibody" in one embodiment of the present
invention encompasses individual antibodies constituting a
population being antibodies corresponding to substantially a single
epitope except for antibodies having a mutation that can occur
naturally in small amounts. Further individual antibodies
constituting a population may be antibodies that are substantially
the same except for antibodies having a mutation that can occur
naturally in small amounts. Monoclonal antibodies are highly
specific, which are different from common polyclonal antibodies
that typically include different antibodies corresponding to
different epitopes. In addition to their specificity, monoclonal
antibodies are useful in that they can be synthesized from
hybridoma culture which is not contaminated with other
immunoglobulins. The description "monoclonal" may indicate a
characteristic of being obtained from a substantially homogeneous
antibody population. However, such a description does not mean that
antibodies must be produced by a specific method. For example,
monoclonal antibodies may be made by a method similar to a
hybridoma method as described in "Kohler G, Milstein C., Nature.
1975 Aug. 7; 256 (5517): 495-497". Alternatively, monoclonal
antibodies may be made by a method similar to a recombinant method
as described in U.S. Pat. No. 4,816,567. Further, monoclonal
antibodies may be isolated from a phage antibody library using a
method similar to the technique that is described in, "Clackson et
al., Nature. 1991 Aug. 15; 352 (6336): 624-628." or "Marks et al.,
J Mol Biol. 1991 Dec. 5; 222 (3): 581-597". Further, monoclonal
antibodies may be made by the method described in "Tanpakushitsu
Jikken Handobukku [Protein experiment handbook], Yodosha (2003):
92-96".
[0159] Antibodies can be mass-produced by using any approach that
is known in the art. Examples of construction of mass production
system for a representative antibody and antibody manufacture
include the following. Specifically, an H chain antibody expression
vector and L chain antibody expression vector are transfected into
a CHO cell. The cells are cultured by using a selection reagent
G418 and Zeocin and cloned by limiting dilution. After cloning,
clones stably expressing antibodies are selected by ELISA. The
culture is expanded with selected CHO cells, and the culture
supernatant comprising antibodies are collected. Antibodies can be
purified from the collected culture supernatant by Protein A or
Protein G purification.
[0160] "Fv antibody" in one embodiment of the present invention is
an antibody comprising an antigen recognition site. This region
comprises a dimer of one heavy chain variable domain non-covalently
bound to one light chain variable domain. In this configuration,
three CDRs of each variable domain can interact with one another to
form an antigen binding site on the surface of a VH-VL dimer.
[0161] "Fab antibody" in one embodiment of the present invention
is, for example, a fragment obtained by treating an antibody
comprising an Fab region and an Fc region with proteinase papain,
which is an antibody in which about half of the N-terminus side of
the H chain is bound to the entire L chain via some disulfide
bonds. Fabs can be obtained, for example, by treating the anti-LSR
antibody according to the embodiments of the present invention
comprising an Fab region and an Fc region with proteinase
papain.
[0162] "F(ab').sub.2 antibody" in one embodiment of the present
invention is a fragment obtained by treating an antibody comprising
an Fab region and an Fc region with proteinase pepsin, which is an
antibody comprising two sites corresponding to Fabs. F(ab').sub.2
can be obtained, for example, by treating the anti-LSR antibody
according to the embodiments of the present invention comprising an
Fab region and an Fc region with proteinase pepsin. For example,
the following Fab' can be made by thioether bond or a disulfide
bond.
[0163] "Fab' antibody" in one embodiment of the present invention
is an antibody obtained, for example, by cleaving a disulfide bond
of a hinge region of F(ab').sub.2. For example, F(ab').sub.2 can be
obtained through treatment with a reducing agent
dithiothreitol.
[0164] "ScFv antibody" in one embodiment of the present invention
is an antibody comprising VH and VL linked with a suitable peptide
linker. ScFv antibodies can be produced, for example, by obtaining
a cDNA encoding VH and VL of the anti-LSR antibody according to the
embodiment of the present invention, constructing a polynucleotide
encoding VH-peptide linker-VL, incorporating the polynucleotide
into a vector, and using a cell for expression.
[0165] "Diabody" in one embodiment of the present invention is an
antibody having divalent antigen binding activity. Divalent antigen
binding activity can be configured to be identical or configured
such that one of them has a different antigen binding activity. A
diabody can be produced, for example, by constructing a
polynucleotide encoding scFv such that the length of the amino acid
sequence of a peptide linker is 8 residues or less, incorporating
the resulting polynucleotide into a vector and using a cell for
expression.
[0166] "dsFv" in one embodiment of the present invention is an
antibody in which a polypeptide introduced with cysteine residues
in VH and VL is bound via a disulfide bond between the
above-described cysteine residues. The position to which cysteine
residues are introduced can be selected based on steric structure
prediction of an antibody in accordance with the method
demonstrated by Reiter et al (Reiter et al., Protein Eng. 1994 May;
7(5): 697-704).
[0167] "Peptide or polypeptide with antigen binding affinity" in
one embodiment of the present invention is an antibody comprised of
antibody VH, VL or CD1, 2 or 3 thereof. A peptide comprising a
plurality of CDRs can be bound directly or via a suitable peptide
linker.
[0168] The production method of the above-described Fv antibody,
Fab antibody, F(ab').sub.2 antibody, Fab' antibody, scFv antibody,
diabody, dsFv antibody, and peptide or polypeptide having antigen
binding affinity (hereinafter, also referred to as "Fv antibodies")
is not particularly limited. Fv antibodies can be produced, for
example, by incorporating a DNA encoding a region of the Fv
antibodies in the anti-LSR antibody according to the embodiment of
the present invention into an expression vector and using an
expression cell. Further, Fv antibodies may be produced by a
chemical synthesis method such as the Fmoc
(fluorenylmethyloxycarbonyl) or tBOC (t-butyloxycarbonyl) method.
It should be noted that the antigen binding fragment according to
one embodiment of the present invention may be one or more types of
the above-described Fv antibodies.
[0169] "Chimeric antibody" in one embodiment of the present
invention is, for example, a variable region of an antibody linked
to a constant region of an antibody between xenogenic organisms and
can be constructed by a genetic engineering technique. A
mouse-human chimeric antibody can be made by, for example, the
method described in "Roguska et al., Proc Natl Acad Sci USA. 1994
Feb. 1; 91 (3): 969-973." For example, the basic method of making a
mouse-human chimeric antibody links a mouse leader sequence and a
variable region sequence in a cloned cDNA with a sequence encoding
a human antibody constant region already present in an expression
vector of a mammalian cell. Further, after linking the mouse leader
sequence and variable region sequence in a cloned cDNA with the
sequence encoding a human antibody constant region, the resultant
sequence may be linked with a mammalian cell expression vector. A
fragment of a human antibody constant region can be from any human
antibody H chain constant region and human antibody L chain
constant region. Examples of human H chain fragment include
C.gamma.1, C.gamma.2, C.gamma.3, and C.gamma.4, and examples of L
chain fragment include C.lamda. and C.kappa..
[0170] "Humanized antibody" in one embodiment of the present
invention is, for example, an antibody, which has one or more CDRs
from non-human species, a framework region (FR) from a human
immunoglobulin, and a constant region from human immunoglobulin and
binds to a desired antigen. Antibodies can be humanized by using
various approaches known in the art (Almagro et al., Front Biosci.
2008 Jan. 1; 13: 1619-1633). Examples thereof include CDR grafting
(Ozaki et al., Blood. 1999 Jun. 1; 93 (11): 3922-3930.),
Re-surfacing (Roguska et al., Proc Natl Acad Sci USA. 1994 Feb. 1;
91 (3): 969-973.), FR shuffle (Damschroder et al., Mol Immunol.
2007 April; 44(11): 3049-3060. Epub 2007 Jan. 22.) and the like. An
amino acid residue of a human FR region may be substituted with a
corresponding residue from a CDR donor antibody in order to alter
(preferably in order to improve) the antigen bond. The FR
substitution can be implemented by a method well known in the art
(Riechmann et al., Nature. 1988 Mar. 24; 332 (6162):323-327.) For
example, an FR residue that is important for antigen binding may be
identified by modeling an interaction between a CDR and an FR
residue. Further, an abnormal FR residue at a specific position may
be identified by sequence comparison.
[0171] "Human antibody" in one embodiment of the present invention
is, for example, an antibody in which a region comprising a
variable region and constant region of a heavy chain and variable
region and constant region of a light chain constituting the
antibody is derived from a gene encoding a human immunoglobulin.
Main production methods include a method using a transgenic mouse
for making human antibodies, phage display and the like. A method
using a transgenic mouse for making human antibodies produces human
antibodies with diverse antigen binding capabilities instead of
mouse antibodies when a functional human Ig gene is introduced into
an endogenous Ig knockout mouse. Furthermore, this mouse can be
immunized to obtain human monoclonal antibodies by a conventional
hybridoma method. Such antibodies can be made, for example, by the
method described in "Lonberg et al., Int Rev Immunol. 1995; 13(1):
65-93." Phase display is a system that typically expresses an
exogenous gene as a fusion protein such that phage infectivity is
not lost on the N-terminus side of a coat protein (g3p, g10p, or
the like) of fibrous phage such as M13 or T7 which is an E. coli
virus. Antibodies can be made, for example, by the method described
in "Vaughan et al., Nat Biotechnol. 1996 March; 14(3):
309-314".
[0172] Further, antibodies may be prepared by grafting a heavy
chain CDR or light chain CDR of the anti-LSR antibody according to
the embodiment of the present invention onto any antibody by
CDR-grafting (Ozaki et al., Blood. 1999 Jun. 1; 93(11): 3922-3930).
Further, antibodies can be obtained by linking a DNA encoding a
heavy chain CDR or light chain CDR of the anti-LSR antibody
according to the embodiment of the present invention and a DNA
encoding a region excluding a heavy chain CDR or light chain CDR of
a known antibody derived from a human or a non-human organism to a
vector in accordance with a known method in the art and using a
known cell for expression. When obtaining antibodies in this
manner, a known method in the art (e.g., method of allowing amino
acid residues of an antibody to randomly mutate and screening for
antibodies with high reactivity, phage display, or the like) may be
used to optimize the region excluding a heavy chain CDR or light
chain CDR in order to enhance the efficiency of anti-LSR antibody
acting upon a target antigen. Further, an FR region may be
optimized by using, for example, FR shuffle (Damschroder et al.,
Mol Immunol. 2007 April; 44 (11): 3049-3060. Epub 2007 Jan. 22.) or
a method of replacing a vernier zone amino acid residue or
packaging residue (Japanese Laid-Open Publication No. 2006-241026
or Foote et al., J Mol Biol. 1992 Mar. 20; 224(2): 487-499).
[0173] "Heavy chain" in one embodiment of the present invention is
typically the main constituent element of a full-length antibody. A
heavy chain is generally bound to a light chain by a disulfide bond
and non-covalent bond. A region called a variable region (VH) which
has an amino acid sequence that is not constant even among
antibodies in the same class of the same species, is present in a
domain on the N-terminus side of a heavy chain. VH is generally
known to greatly contribute to the specificity and affinity to an
antigen. For example, "Reiter et al., J Mol Biol. 1999 Jul. 16; 290
(3): 685-98." describes that a molecule with only a VH, when made,
bound to an antigen with specificity and high level of affinity.
Furthermore, "Wolfson W, Chem Biol. 2006 December; 13 (12):
1243-1244." describes that there are antibodies having only a heavy
chain without a light chain among camel antibodies.
[0174] "CDR (complementarity determining region)" in one embodiment
of the present invention is a region that is in actual contact with
an antigen to form a binding site in an antibody. CDRs are
generally located on an Fv (variable region: including heavy chain
variable region (VH) and light chain variable region (VL)) of an
antibody. Further, CDRs generally have CDR1, CDR2, and CDR3
consisting of about 5-30 amino acid residues. In addition, CDRs of
a heavy chain are particularly known for their contribution to
binding of an antibody to an antigen. Among the CDRs, CDR3 is known
to contribute the most in binding of an antibody to an antigen. For
example, "Willy et al., Biochemical and Biophysical Research
Communications Volume 356, Issue 1, 27 Apr. 2007, Pages 124-128"
describes that a heavy chain CDR3 was altered to elevate the
binding capability of an antibody. An Fv region other than the CDRs
is called a framework region (FR), consisting of FR1, FR2, FR3, and
FR4, which are conserved relatively well among antibodies (Kabat et
al., "Sequence of Proteins of Immunological Interest" US Dept.
Health and Human Services, 1983.) Specifically, a factor
characterizing the reactivity of an antibody is considered to be in
CDRs, especially heavy chain CDRs.
[0175] A plurality of methods for defining CDRs and determining the
positions thereof have been reported. For example, the Kabat
definition (Sequences of Proteins of Immunological Interest, 5th
ed., Public Health Service, National Institutes of Health,
Bethesda, Md. (1991)) or the Chothia definition (Chothia et al., J.
Mol. Biol., 1987; 196: 901-917) may be used. One embodiment of the
present invention uses the Kabat definition as an optimal example,
but the definition is not necessarily limited thereto. Further, the
definitions may be determined in some cases after considering both
the Kabat definition and the Chonthia definition. For example, an
overlapping portion of CDR according to each of the definitions, or
a portion comprising both CDRs according to each of the definitions
can be deemed the CDR. A specific example of such a method is the
method of Martin et al using Oxford Molecular's AbM antibody
modeling software, which is a proposal combining the Kabat
definition and the Chonthia definition (Proc. Natl. Acad. Sci. USA,
1989; 86: 9268-9272). Such CDR information can be used to produce a
mutant that can be used in the present invention. Such an antibody
mutant comprises one or several (e.g., 2, 3, 4, 5, 6, 7, 8, 9, and
10) substitutions, additions, or deletions in the framework of the
original antibody. However, a mutant can be produced such that the
CDR does not comprise a mutation.
[0176] As used herein, "antigen" refers to any substrate that can
be specifically bound by an antibody molecule. As used herein,
"immunogen" refers to an antigen that can initiate lymphocyte
activation which leads to an antigen specific immune response. As
used herein, "epitope" or "antigen determinant" refers to a site in
an antigen molecule to which an antibody or a lymphocyte receptor
binds. A method of determining an epitope is well known in the art.
Such an epitope can be determined by those skilled in the art by
using a well-known and conventional technique when a primary
sequence of an amino acid or a nucleic acid is provided. It is
understood that the antibody of the present invention can be
similarly used even for antibodies having other sequences, as long
as the epitope is the same.
[0177] It is understood that antibodies with any specificity may be
used as the antibody used herein, as long as false positive
reactions are reduced. Thus, the antibodies used in the present
invention may be a polyclonal antibody or a monoclonal
antibody.
[0178] As used herein, "means" refers to anything that can be a
tool for accomplishing an objective (e.g., detection, diagnosis,
therapy). As used herein, "selective recognizing means" in
particular refers to means capable of recognizing a certain subject
differently from others.
[0179] As used herein, "marker (substance, protein or gene)" refers
to a substance that can be an indicator for tracking whether a
target is in or at risk of being in a certain condition (e.g.,
diseased state, disorder state, level of or presence of malignant
state or the like). Examples of such a marker include genes, gene
products, metabolites, enzymes and the like. In the present
invention, detection, diagnosis, prognosis, poor prognosis,
diagnosis of poor prognosis, diagnosis of prognostic state,
preliminary detection, prediction, or prediagnosis of a certain
state (e.g., state of a disease such as cancer) can be materialized
by using an agent or means specific to a marker associated with
such a state, or a composition, kit or system comprising the same
or the like. As used herein, "expression product" (also referred to
as a gene product) refers to a protein or mRNA encoded by a gene.
It is found in the present specification that a gene product (LSR),
which does not exhibit association with malignant tumor, especially
to therapy thereof, can be used as an indicator for ovarian
cancer.
[0180] "Malignant tumor" as used herein includes, for example,
tumor that develops from a mutation of normal cells. Malignant
tumor can develop from any organ or tissue of the entire body. Such
malignant tumor comprises one or more type selected from the group
consisting of lung cancer, esophageal cancer, gastric cancer, liver
cancer, pancreatic cancer, renal cancer, adrenal cancer, bile duct
cancer, breast cancer, colon cancer, small intestine cancer,
ovarian cancer, uterine cancer, bladder cancer, prostate cancer,
ureteral cancer, renal pelvis cancer, ureteral cancer, penile
cancer, testicular cancer, cerebral tumor, cancer of the central
nervous system, cancer of the peripheral nervous system, head and
neck cancer, glioma, glioblastoma multiform, skin cancer, melanoma,
thyroid cancer, salivary gland cancer, malignant lymphoma,
carcinoma, sarcoma, and hematologic malignancy. Ovarian cancer in
this regard includes, for example, ovarian serous adenocarcinoma
and ovarian clear cell adenocarcinoma. Uterine cancer includes, for
example, endometrial cancer and cervical cancer. Head and neck
cancer includes, for example, oral cavity cancer, pharyngeal
cancer, nasal cavity cancer, paranasal cancer, salivary gland
cancer, and thyroid cancer. Lung cancer includes, for example,
non-small-cell lung cancer and small cell lung cancer. Further,
malignant tumor may be LSR positive.
[0181] Among malignant tumor, serous adenocarcinoma is cancer that
progresses very rapidly. It is difficult to completely eliminate
the cancer even with commercially available anticancer agents.
Furthermore, in recurrences, commercially available anticancer
agents hardly have any effect thereon. Further, hardly any
therapeutic effect can be expected on clear cell adenocarcinoma by
commercially available anticancer agents. Meanwhile, the anti-LSR
antibody according to the embodiment of the present invention can
be a novel therapeutic drug for serous adenocarcinoma and clear
cell adenocarcinoma.
[0182] "LSR positive malignant tumor" in one embodiment of the
present invention includes malignant tumor that significantly
expresses or overexpresses LSRs. Whether malignant tumor is LSR
positive may be assessed, for example, by RT-PCR, Western blot, or
immunohistochemically staining method. Further, when total protein
of malignant tumor cells is subjected to Western blot and a band
corresponding to LSRs (e.g., band near 649aa) can be observed by
visual inspection, the malignant tumor may be determined as LSR
positive. Further, when the amount of LSR expression of malignant
tumor cells from a patient is significantly more than for normal
cells, the malignant tumor may be determined as LSR positive. It is
preferable that an anti-LSR antibody is used to inspect LSR
expression from the viewpoint of materializing a more optimal
dosing by accurately diagnosing malignant tumor as LSR
positive.
[0183] As used herein, "subject (person)" refers to a target
subjected to diagnosis, detection, therapy or the like of the
present invention (e.g., an organism such as a human or a cell,
blood, serum or the like extracted from an organism).
[0184] As used herein, "sample" refers to any substance obtained
from a subject or the like. For example, serum and the like are
encompassed thereby. Those skilled in the art can appropriately
select a preferred sample based on the descriptions herein.
[0185] As used herein, "agent" is used broadly and may be any
substance or other elements (e.g., energy, radiation, heat,
electricity and other forms of energy) as long as the intended
objective can be achieved. Examples of such a substance include,
but are not limited to, protein, polypeptide, oligopeptide,
peptide, polynucleotide, oligonucleotide, nucleotide, nucleic acid
(including, for example, DNAs such as cDNA and genomic DNA and RNAs
such as mRNA), polysaccharide, oligosaccharide, lipid, organic
small molecule (e.g., hormone, ligand, information transmitting
substance, organic small molecule, molecule synthesized by
combinatorial chemistry, small molecule that can be used as
medicine (e.g., small molecule ligand and the like)) and a complex
molecule thereof. Typical examples of an agent specific to a
polynucleotide include, but are not limited to, a polynucleotide
having complementarity with a certain sequence homology (e.g., 70%
or greater sequence identity) to a sequence of the polynucleotide,
polypeptide such as a transcription factor that binds to a promoter
region and the like. Typical examples of an agent specific to a
polypeptide include, but are not limited to, an antibody directed
specifically to the polypeptide or a derivative or analog thereof
(e.g., single stranded antibody), a specific ligand or receptor
when the polypeptide is a receptor or ligand, a substrate when the
polypeptide is an enzyme and the like.
[0186] As used herein, "diagnosis" refers to identifying various
parameters associated with a disease, disorder, condition (e.g.,
malignant tumor) or the like in a subject to determine the current
or future state of such a disease, disorder, or condition. The
condition in the body can be investigated by using the method,
apparatus, or system of the present invention. Such information can
be used to select and determine various parameters of a formulation
or method for the treatment or prevention to be administered,
disease, disorder, or condition in a subject or the like. As used
herein, "diagnosis" when narrowly defined refers to diagnosis of
the current state, but when broadly defined includes "early
diagnosis", "predictive diagnosis", "prediagnosis" and the like.
Since the diagnostic method of the present invention in principle
can utilize what comes out from a body and can be conducted away
from a medical practitioner such as a physician, the present
invention is industrially useful. In order to clarify that the
method can be conducted away from a medical practitioner such as a
physician, the term as used herein may be particularly called
"assisting" "predictive diagnosis, prediagnosis or diagnosis".
[0187] The term "prognosis" as used herein refers to prediction of
the possibility of progression or death due to cancer, such as the
possibility of recurrence, metastasis and diffusion, drug
resistance and the like of a neoplastic disease such as malignant
tumor (e.g., ovarian cancer). Thus, as used herein, "excellent
prognostic state" refers to a state where recurrence of primary
cancer is not observed beyond a certain period of time (e.g., 4
years) after removal of the cancer tissue, and "poor prognostic
state" or "poor prognosis" refers to a state where recurrence of
primary cancer is observed beyond a certain period of time (e.g., 4
years) after removal of the cancer tissue. A prognostic agent is a
variable related to natural course of malignant tumor, which
affects the rate of recurrence of outcome of a patient who has
experienced malignant tumor. Examples of clinical indicator
associated with exacerbation in prognosis include lymph node
metastasis and highly malignant tumor. A prognostic agent is often
used to classify patients into subgroups with different fundamental
risks of recurrence. In this manner, expression of LSRs of the
present invention can be used as a prognostic agent. The term
"prediction" as used herein refers to the possibility of a patient
having a specific clinical outcome, regardless of good or bad,
after extraction of primary tumor. Thus, LSRs of the present
invention can be used as a poor prognosis marker. A therapeutic
method can be determined by clinically using the prediction method
of the present invention to select the optimal therapeutic method
for a specific patient. The prediction method of the present
invention would be a beneficial means for prediction if there is a
possibility that a patient would have a positive reaction to a
therapeutic regimen, e.g., surgical intervention or the like. A
prognostic agent can be included in the prediction.
[0188] As used herein, "detecting drug (agent)" or "inspection drug
(agent)" broadly refers to all agents capable of detecting or
inspecting a target of interest.
[0189] As used herein, "diagnostic drug (agent)" broadly refers to
all agents capable of diagnosing a condition of interest (e.g.,
disease such as malignant tumor or the like).
[0190] As used herein, "therapy" refers to the prevention of
exacerbation, preferably maintaining of the current condition, more
preferably alleviation, and still more preferably disappearance of
a disease or disorder (e.g., malignant tumor) in case of such a
condition, including being capable of exerting a prophylactic
effect or an effect of improving a disease of a patient or one or
more symptoms accompanying the disease. Preliminary diagnosis with
suitable therapy may be referred to as "companion therapy" and a
diagnostic agent therefor may be referred to as "companion
diagnostic agent".
[0191] As used herein, "therapeutic drug (agent)" broadly refers to
all agents capable of treating a condition of interest (e.g.,
diseases such as malignant tumor or the like). In one embodiment of
the present invention, "therapeutic drug" may be a pharmaceutical
composition comprising an effective ingredient and one or more
pharmacologically acceptable carriers. A pharmaceutical composition
can be manufactured, for example, by mixing an effective ingredient
and the above-described carriers by any method known in the
technical field of pharmaceuticals. Further, mode of usage of a
therapeutic drug is not limited, as long as it is used for therapy.
A therapeutic drug may be an effective ingredient alone or a
mixture of an effective ingredient and any ingredient. Further, the
shape of the above-described carriers is not particularly limited.
For example, the carrier may be a solid or liquid (e.g., buffer
solution). It should be noted that a therapeutic drug of malignant
tumor includes a drug (prophylactic drug) for preventing malignant
tumor or a growth suppressant for malignant tumor cells.
[0192] As used herein, "prevention" refers to the action of taking
a measure against a disease or disorder (e.g., malignant tumor)
from being in such a condition prior to being in such a condition.
For example, it is possible to use the agent of the present
invention to perform diagnosis, and optionally use the agent of the
present invention to prevent or take measures to prevent malignant
tumor or the like.
[0193] As used herein, "prophylactic drug (agent)" broadly refers
to all agents capable of preventing a condition of interest (e.g.,
diseases such as malignant tumor or the like).
[0194] As used herein, "interaction" refers, for two substances, to
applying a force (e.g., intermolecular force (Van der Waals force),
hydrogen bond, hydrophobic interaction, or the like) between one
substance and the other substance. Generally, two substances that
have interacted are in a conjugated or bound state. The detection,
inspection, and diagnosis in the present invention can be
materialized by utilizing such interaction.
[0195] As used herein, the term "bond" refers to a physical or
chemical interaction between two substances or between combinations
thereof. A bond includes an ionic bond, non-ionic bond, hydrogen
bond, Van der Waals bond, hydrophobic interaction and the like. A
physical interaction (bond) may be direct or indirect. Indirect
physical interaction (bond) is mediated by or is due to an effect
of another protein or compound. A direct bond refers to an
interaction, which does not occur through or due to an effect of
another protein or compound and does not substantially involve
another intermediate.
[0196] Thus, an "agent" (or detection agent or the like) that
"specifically" interacts (or binds) to a biological agent such as a
polynucleotide or a polypeptide as used herein encompasses agents
with affinity to the biological agent such as a polynucleotide or
polypeptide that is typically similar or higher, preferably
significantly (e.g., statistically significantly) higher, than
affinity to other unrelated polynucleotides or polypeptides
(especially those with less than 30% identity). Such affinity can
be measured, for example, by hybridization assay, binding assay or
the like.
[0197] As used herein, "specific" interaction (or bond) of a first
substance or agent with a second substance or agent refers to the
first substance or agent interacting with (or binding to) the
second substance or agent at a higher level of affinity than to
substances or agents other than the second substance or agent
(especially other substances or agents in a sample comprising the
second substance or agent). Examples of an interaction (or bond)
specific to a substance or agent include, but are not limited to,
hybridization in a nucleic acid, antigen-antibody reaction in a
protein, enzyme-substrate reaction, other nucleic acid protein
reactions, protein-lipid interaction, nucleic acid-lipid
interaction and the like. Thus, when substances or agents are both
nucleic acids, a first substance or agent "specifically
interacting" with a second substance or agent encompasses the first
substance or agent having at least partial complementarity to the
second substance or agent. Further, examples of a first substance
or agent "specifically" interacting with (or binding to) a second
substance or agent when substances or agents are both proteins
include, but are not limited to, interaction by an antigen-antibody
reaction, interaction by a receptor-ligand reaction,
enzyme-substrate interaction and the like. When two types of
substances or agents include a protein and a nucleic acid, a first
substance or agent "specifically" interacting with (or binding to)
a second substance or factor encompasses an interaction (or a bond)
between an antibody and an antigen. Such a specific interactive or
binding reaction can be utilized to detect or quantify a target in
a sample.
[0198] As used herein, "detection" or "quantification" of
polynucleotide or polypeptide expression can be accomplished by
using a suitable method including, for example, an immunological
measuring method and measurement of mRNAs, including a bond or
interaction to a detection agent, inspection agent or diagnostic
agent. Examples of a molecular biological measuring method include
northern blot, dot blot, PCR and the like. Examples of an
immunological measurement method include ELISA using a microtiter
plate, RIA, fluorescent antibody method, luminescence immunoassay
(LIA), immunoprecipitation (IP), single radial immunodiffusion
(SRID), turbidimetric immunoassay (TIA), western blot,
immunohistochemical staining and the like. Further, examples of a
quantification method include ELISA, RIA and the like.
Quantification may also be performed by a gene analysis method
using an array (e.g., DNA array, protein array). DNA arrays are
outlined extensively in (Ed. by Shujunsha, Saibo Kogaku Bessatsu
"DNA Maikuroarei to Saishin PCR ho" [Cellular engineering, Extra
issue, "DNA Microarrays and Latest PCR Methods"]. Protein arrays
are discussed in detail in Nat Genet. 2002 December; 32 Suppl:
526-32. Examples of a method of analyzing gene expression include,
but are not limited to, RT-PCR, RACE, SSCP, immunoprecipitation,
two-hybrid system, in vitro translation and the like, in addition
to the methods discussed above. Such additional analysis methods
are described in, for example, Genomu Kaiseki Jikkenho Nakamura
Yusuke Labo Manyuaru [Genome analysis experimental method Yusuke
Nakamura Lab Manual], Ed. by Yusuke Nakamura, Yodosha (2002) and
the like. The entirety of the descriptions therein is incorporated
herein by reference.
[0199] As used herein, "amount of expression" refers to the amount
of polypeptide, mRNA or the like expressed in a cell, tissue or the
like of interest. Examples of such an amount of expression include
amount of expression of the polypeptide of the present invention at
a protein level assessed by any suitable method including an
immunological measurement method such as ELISA, RIA, fluorescent
antibody method, western blot, and immunohistochemical staining by
using the antibody of the present invention, and the amount of
expression of the polypeptide used in the present invention at an
mRNA level assessed by any suitable method including a molecular
biological measuring method such as northern blot, dot blot, and
PCR. "Change in amount of expression" refers to an increase or
decrease in the amount of expression of the polypeptide used in the
present invention at a protein level or mRNA level assessed by any
suitable method including the above-described immunological
measuring method or molecular biological measuring method. A
variety of detection or diagnosis based on a marker can be
performed by measuring the amount of expression of a certain
marker.
[0200] As used herein, "decrease" or "suppression" of activity or
expression product (e.g., protein, transcript (RNA or the like)) or
synonyms thereof refers to: a decrease in the amount, quality or
effect of a specific activity, transcript or protein; or activity
that decreases the same. Among decrease, "elimination" refers to
activity, expression product or the like being less than the
detection limit and especially referred to as "elimination". As
used herein, "elimination" is encompassed by "decrease" or
"suppression".
[0201] As used herein, "increase" or "activation" of activity or
expression product (e.g., protein, transcript (RNA or the like)) or
synonyms thereof refers to: an increase in the amount, quality or
effect of a specific activity, transcript or protein; or activity
that increases the same.
[0202] As used herein, "(nucleic acid) primer" refers to a
substance required for initiating a reaction of a polymeric
compound to be synthesized in a polymer synthesizing enzyme
reaction. A synthetic reaction of a nucleic acid molecule can use a
nucleic acid molecule (e.g., DNA, RNA or the like) complementary to
a portion of a sequence of a polymeric compound to be synthesized.
A primer can be used herein as a marker detecting means.
[0203] As used herein, "probe" refers to a substance that can be
means for search, which is used in a biological experiment such as
in vitro and/or in vivo screening. Examples thereof include, but
are not limited to, a nucleic acid molecule comprising a specific
base sequence, a peptide comprising a specific amino acid sequence,
a specific antibody, a fragment thereof and the like. As used
herein, a probe is used as means for marker detection, inspection,
or diagnosis.
[0204] As used herein, "label" refers to an entity (e.g.,
substance, energy, electromagnetic wave or the like) for
distinguishing a molecule or substance of interest from others.
Such a method of labeling includes RI (radioisotope) method,
fluorescence method, biotin method, chemiluminescent method and the
like. When a plurality of markers of the present invention or
agents or means for capturing the same are labeled by a
fluorescence method, labeling is performed with fluorescent
substances having different fluorescent emission maximum
wavelengths. It is preferable that the difference in fluorescent
emission maximum wavelengths is 10 nm or greater. When labeling a
ligand, any label that does not affect the function can be used.
However, Alexa.TM. Fluor is desirable as a fluorescent substance.
Alexa.TM. Fluor is a water-soluble fluorescent dye obtained by
modifying coumarin, rhodamine, fluorescein, cyanine or the like.
This is a series compatible with a wide range of fluorescence
wavelengths.
[0205] Relative to other fluorescent dyes for the corresponding
wavelength, Alexa.TM. Fluor is very stable, bright and has a low
level of pH sensitivity. Combinations of fluorescent dyes with
fluorescence maximum wavelength of 10 nm or greater include a
combination of Alexa.TM. 555 and Alexa.TM. 633, combination of
Alexa.TM. 488 and Alexa.TM. 555 and the like. When a nucleic acid
is labeled, any label can be used that can bind to a base portion
thereof. However, it is preferable to use a cyanine dye (e.g., Cy3,
Cy5 or the like of the CyDye.TM. series), rhodamine 6G reagent,
2-acetylaminofluorene (AAF), AAIF (iodine derivative of AAF) or the
like. Examples of a fluorescent substance with a difference in
fluorescent emission maximum wavelengths of 10 nm or greater
include a combination of Cy5 and a rhodamine 6G reagent, a
combination of Cy3 and fluorescein, a combination of a rhodamine 6G
reagent and fluorescein and the like. The present invention can
utilize such a label to alter a subject of interest to be
detectable by the detecting means to be used. Such alteration is
known in the art. Those skilled in the art can appropriately carry
out such a method in accordance with the label and subject of
interest.
[0206] As used herein, "tag" refers to a substance for
distinguishing a molecule by a specific recognition mechanism such
as receptor-ligand, or more specifically, a substance serving the
role of a binding partner for binding a specific substance (e.g.,
having a relationship such as biotin-avidin or
biotin-streptavidin). A tag can be encompassed in the scope of
"label". Accordingly, a specific substance to which a tag is bound
can distinguish the specific substance by a contact with a
substrate, to which a binding partner of a tag sequence is bound.
Such a tag or label is well known in the art. Typical tag sequences
include, but are not limited to, myc tag, His tag, HA, Avi Tag.TM.
(Avidity LLC, Aurora, Colo.) and the like. Such a tag may be bound
to the marker of the present invention or a detection agent,
inspection agent, or diagnostic agent (may be a primer, probe or
the like) of the marker.
[0207] As used herein, "in vivo" refers to inside of a living body.
In specific context, "in a living body" refers to the position
where a substance of interest should be disposed.
[0208] As used herein, "in vitro" refers to a state where a portion
of a living body is extracted or freed "outside of a living body"
(e.g., in a test tube) for various research purposes. This is a
term that is an antonym of in vivo.
[0209] As used herein, when a procedure is performed outside of the
body, but the subject of the procedure is intended to be
subsequently returned in the body, the series of operations is
referred to as "ex vivo". An embodiment that treats a cell in a
living body with an agent of the present invention and returns the
cell in a patient is also anticipated in the present invention.
[0210] As used herein, "kit" refers to a unit generally providing
portions to be provided (e.g., inspection drug, diagnostic drug,
therapeutic drug, antibody, label, manual and the like) into two or
more separate sections. This form of a kit is preferred when a
composition that should not be provided in a mixed state and is
preferably mixed immediately before use for safety or the like is
intended to be provided. Such a kit advantageously comprises an
instruction or manual describing how the provided portions (e.g.,
inspection drug, diagnostic drug, or therapeutic drug) are used or
how a reagent should be handled. When the kit is used herein as a
reagent kit, the kit generally comprises an instruction describing
how to use an inspection drug, diagnostic drug, therapeutic drug,
antibody and the like.
[0211] As used herein, "instruction" is a document with an
explanation of the method of use of the present invention for a
physician or other users. The instruction has a description of the
detection method of the present invention, method of use of a
diagnostic agent, or administration of a medicament or the like.
Further, an instruction may have a description instructing oral
administration or administration to the esophagus (e.g., by
injection or the like) as a site of administration. The instruction
is prepared in accordance with a format defined by the regulatory
agency of the country in which the present invention is practiced
(e.g., the Ministry of Health, Labor and Welfare in Japan, Food and
Drug Administration (FDA) in the U.S. or the like), with an
explicit description showing approval by the regulatory agency. The
instruction is a so-called package insert and is typically provided
in, but not limited to, paper media. The instructions may also be
provided in a form such as electronic media (e.g., web sites
provided on the Internet or emails).
PREFERRED EMBODIMENTS
[0212] Preferred embodiments of the present invention are described
hereinafter. The embodiments are provided hereinafter for better
understanding of the present invention. It is understood that the
scope of the present invention should not be limited to the
following descriptions. Thus, it is apparent that those skilled in
the art can readily make modifications within the scope of the
present invention while referring to the descriptions herein. It is
understood that the following embodiments of the present invention
can be used alone or in combine.
[0213] (Therapy and Prevention of Malignant Tumor)
[0214] In one aspect, the present invention provides a novel
therapeutic or prophylactic drug for malignant tumor. The
therapeutic or prophylactic drug is a therapeutic or prophylactic
drug for malignant tumor, comprising an LSR suppressant (e.g.,
anti-LSR antibody). LSR positive malignant tumor can be treated or
prevented by using such a therapeutic or prophylactic agent. Since
such a therapeutic or prophylactic drug uses antibodies, it is an
excellent drug from the viewpoint of safety.
[0215] There are LSR positive and LSR non-positive patients or
patients who may be in such a group in malignant tumor patients or
patients who may be in such a group. For this reason, it is
preferable that the therapeutic drug of the present invention is
administered to a patient among the malignant tumor patients who is
determined to have malignant tumor that is LSR positive malignant
tumor. In this manner, a drug can be administered more optimally by
diagnosing in advance the presence of LSR positive.
[0216] In one specific embodiment, the composition or medicament
(therapeutic drug, prophylactic drug or the like) of the present
invention is formulated in anticipation of implementation in
administration to a patient determined to have an episode of LSR
positive malignant tumor.
[0217] In one embodiment, the LSR suppressant used in the present
invention is an antibody, a fragment or a functional equivalent
thereof, or a nucleic acid.
[0218] In a specific embodiment, the LSR suppressant used in the
present invention preferably has the ability to inhibit
exacerbation due to VLDL. In a more specific embodiment, the LSR
antibody of the present invention is an antibody having the ability
to inhibit exacerbation due to VLDL. Although not wishing to be
bound by any theory, LSRs affect cancer growth by incorporating
VLDL and enhancing lipid metabolism. That is, it is understood that
suppression of LSR functions in cancer cells expressing LSRs
results in enhanced suppression of cancer cell growth. The
antibodies of the present invention can suppress VLDL incorporation
into LSRs of cancer cells to enhance suppression of cancer cell
growth. Thus, target cancer or cancer cells of the present
invention may be cancer or cells associated with VLDL (e.g., cancer
shown in the Examples or cancer associated with cancer cells,
ovarian cancer or the like). In a specific embodiment, the LSR
suppressant used in the present invention is a nucleic acid, which
is an antisense nucleic acid, siRNA or the like. Specifically, the
siRNA may comprise SEQ ID NO: 9-14 or the like.
[0219] In another embodiment, the LSR suppressant is an antibody or
a fragment or a functional equivalent thereof. The antibody of the
present invention may be a specific sequence described in other
parts of the present specification. The antibody may be an antibody
or antigen binding fragment thereof comprising any sequence
comprising CDRs of the full length sequence, or an antibody or
antigen binding fragment thereof comprising a variable region of
the following sequence, the framework region thereof comprising 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20 or more substitutions,
additions, or deletions. The antibody can be manufactured by using
an embodiment described in other parts of the specification and/or
an approach known in the art. For therapy or prevention of the
present invention, it is preferable that such an antibody or a
fragment or functional equivalent thereof has activity to suppress
LSRs or downstream information transmitting pathway thereof. Such
activity may be confirmed by observing the amount of expression or
activity of LSRs, or by directly using malignant tumor cell strains
such as ovarian clear cell adenocarcinoma to observe inhibition of
cell growth, cytotoxic activity with antibody-dependent
cell-mediated cytotoxicity (ADCC), tumor regression after
transplantation into model animals or the like. Such approaches are
well known in the art, while the approach used herein may also be
used.
[0220] In another aspect, the present invention provides a method
of preventing or treating malignant tumor of a subject, comprising
administering an effective amount of LSR suppressant to the subject
in need thereof. It is understood that any form described in other
parts of the present specification can be used as the LSR
suppressant used in the prophylactic or therapeutic method of the
present invention.
[0221] In another aspect, the present invention also provides a
composition or a medicament (therapeutic drug or prophylactic drug)
for preventing or treating malignant tumor, comprising an LSR
binding agent. In a preferred embodiment, the composition or
medicament (therapeutic drug, prophylactic drug or the like)
further comprises a cell-killing agent. Thus, such a composition or
medicament (therapeutic drug, prophylactic drug or the like) may
include a complex molecule.
[0222] In a specific embodiment, the LSR binding agent is an
antibody, a fragment or a functional equivalent thereof, or a
nucleic acid. In a preferred embodiment, the LSR binding agent is
an antibody or a fragment or a functional equivalent thereof,
further bound to a cell-killing agent.
[0223] As used herein, "cell-killing agent" is an agent that may
dissolve a cell membrane. When the agent is a peptide, the cell
killing agent is called a cytotoxic peptide. Cytotoxic peptide has
various nomenclatures in the art. For example, "soluble peptidic
component" and "cell-killing sequence" are also called "cytolic
peptide (sequence)", "cell dissolving peptide (sequence)" or the
like. However, they are used synonymously in the content of the
present invention. Representative examples of such a cytotoxic
agent include those listed in Gail D. et al., Cancer Res 2008; 68:
9280-9290.; Ian Krop and Eric P. Winer, Clin Cancer Res; 20 (1);
1-6. and K Naito et al., Leukemia (2000) 14, 1436-144, as well as,
but not limited to, maytansinoid, emtansine, N-acetyl-.gamma.
calicheamicin dimethyl hydrazide (NAc-.gamma. calicheamicin, DMH)
comprised in CMA-676 and the like. Representative cell killing
peptide includes, but is not limited to, cell membrane dissolving
peptide, cell membrane potential destabilizing peptide, cell
membrane dissolving/nucleic acid binding peptide, and mitochondrial
membrane disintegrating peptide.
[0224] Such a cell-killing agent may be bound to the binding agent
of the present invention such as an antibody with a spacer as
needed. As used herein, "spacer" refers to a moiety that forms a
chemical bond between molecules of chain-like polymers so as to
bridge the molecules. Such a spacer is also called a linker.
Representative spacers of a peptide include, but are not limited
to, a sequence of 0-5 amino acids consisting of G and P. A spacer
is not essential and may not be present.
[0225] A combination of the binding agent of the present invention
and cell-killing agent can also be considered a complex molecule.
An example is provided to explain such a molecule. Such a molecule
can be explained as a molecule made by combining a cytotoxic
portion corresponding to the explosive charge portion and a portion
responsible for specificity to a cancer cell corresponding to the
warhead portion (e.g., peptide/sequence that specifically binds to
a receptor which is highly expressed in cancer cells, typically an
antibody). When a spacer is used, the molecule would be comprised
of a cancer cell specific binding agent+spacer+cell-killing agent.
Any cancer specific binding agent, any spacer, and any cell-killing
agent can be combined herein in any manner. Examples of a
manufacturing method and usage method thereof are described. Such a
molecule is generally made by a chemical synthesis method, but when
such a molecule is comprised of peptides, a method of forced
expression and purification by genetic engineering or a method
combining such a method can also be used.
[0226] For use of the present invention, LSR expression on the cell
surface and sensitivity to damage of cancer cells to cell-killing
agent are investigated for cancer cells to be subjected to therapy.
Warhead and explosive charge are selected base on the result
thereof to design an optimal molecule for the cancer cell. A
custom-made peptide toxin obtained from chemical synthesis or the
like can be combined as needed with DDS such as atelocollagen and
administered locally or systemically for therapy.
[0227] In one embodiment, an LSR binding agent is an antibody or a
fragment or a functional equivalent thereof. The antibody can be a
sequence specifically listed in other parts of the present
specification.
[0228] It is preferable that an administration pathway of a
therapeutic drug that is effective in therapy is used. For example,
the administration pathway may be intravenous, subcutaneous,
intramuscular, intraperitoneal, oral administration or the like.
The mode of administration may be, for example, injection, capsule,
tablet, granule or the like. When an antibody or polynucleotide is
administered, use thereof as an injection is effective. An aqueous
solution for injection may be stored, for example, in a vial or a
stainless streel container. Further, an aqueous solution for
injection may contain, for example, saline, saccharide (e.g.,
trehalose), NaCl, NaOH or the like. Further, a therapeutic drug may
contain a buffer (e.g., phosphate buffer), stabilizer or the
like.
[0229] The composition, medicament, therapeutic agent, prophylactic
agent and the like of the present invention generally comprise a
therapeutically effective amount of therapeutic agent or effective
ingredient and a pharmaceutically acceptable carrier or excipient.
As used herein, "pharmaceutically acceptable" means that government
regulatory agency-approved or pharmacopoeia or other commonly
recognized pharmacopoeia-listed for use in animals and more
specifically in humans. As used herein "carrier" refers to a
diluent, adjuvant, excipient or vehicle administered in conjunction
with a therapeutic agent. Such a carrier can be an aseptic liquid
such as water or oil, including but not limited to liquids derived
from petroleum, animal, plant or synthesis, as well as peanut oil,
soybean oil, mineral oil, sesame oil and the like. When a
medicament is orally administered, water is a preferred carrier.
For intravenous administration of a pharmaceutical composition,
saline and aqueous dextrose are preferred carriers. Preferably,
aqueous saline solution and aqueous dextrose and glycerol solution
are used as a liquid carrier of an injectable solution. Suitable
excipients include light anhydrous silicic acid, crystalline
cellulose, mannitol, starch, glucose, lactose, sucrose, gelatin,
malt, rice, wheat flour, chalk, silica gel, sodium stearate,
glyceryl monostearate, talc, sodium chloride, powdered skim milk,
glycerol, propylene, glycol, water, ethanol, carmellose calcium,
carmellose sodium, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, polyvinyl acetal diethylamino acetate,
polyvinylpyrrolidone, gelatin, medium-chain fatty acid
triglyceride, polyoxyethylene hydrogenated castor oil 60,
saccharose, carboxymethylcellulose, corn starch, inorganic salt and
the like. When desired, the composition can contain a small amount
of wetting agent or emulsifier or pH buffer. These compositions can
be in a form of solution, suspension, emulsion, tablet, pill,
capsule, powder, sustained release mixture or the like. It is also
possible to use traditional binding agents and carriers, such as
tryglyceride, to prepare a composition as a suppository. Oral
preparation can also comprise a standard carrier such as medicine
grade mannitol, lactose, starch, magnesium stearate, sodium
saccharin, cellulose, or magnesium carbonate. Examples of a
suitable carrier are described in E. W. Martin, Remington's
Pharmaceutical Sciences (Mark Publishing Company, Easton, U. S. A).
Such a composition contains a therapeutically effective amount of
therapy agent and preferably in a purified form, together with a
suitable amount of carrier, such that the composition is provided
in a form suitable for administration to a patient. A preparation
must be suitable for the administration format. In addition, the
composition may comprise, for example, a surfactant, excipient,
coloring agent, flavoring agent, preservative, stabilizer, buffer,
suspension, isotonizing agent, binding agent, disintegrant,
lubricant, fluidity improving agent, corrigent or the like.
[0230] When the present invention is administered as a medicament,
various delivery systems are known, and such systems can be used to
administer a therapeutic agent of the present invention to a
suitable site (e.g., esophagus). Such a system, for example, can
use a recombinant cell that can express encapsulated therapeutic
agent (e.g., polypeptide) in liposomes, microparticles and
microcapsules or use of endocytosis mediated by a receptor;
construction of a therapy nucleic acid as a part of a retrovirus
vector or other vector or the like. The method of introduction
includes, but not limited to, intradermal, intramuscular,
intraperitoneal, intravenous, subcutaneous, intranasal, epidural
and oral pathways. A medicament can be administered by any suitable
pathway, such as by injection, bolus injection, or by absorption
through epithelial or mucocutaneous lining (e.g., oral cavity,
rectum, intestinal mucosa or the like). In addition, an inhaler or
mistifier using an aerosolizing agent can be used as needed.
Moreover, other biological activating agents can also be
administered together. Administration can be systemic or local.
When the present invention is used in an ovarian region, a
medicament may be administered through any suitable pathway such as
direct injection into an affected site of an ovary or the like.
[0231] In a specific embodiment where a therapeutic agent is a
nucleic acid, the nucleic acid can be constructed as a part of a
suitable nucleic acid expression vector and administered in vivo to
be present in a cell to promote expression of an encoded protein.
This can be implemented, for example, by using a retrovirus vector,
direct injection, use of a microparticle gun, coating the nucleic
acid with lipid, cell surface receptor or transfection agent, or
administering a nucleic acid linked to a tag sequence known to
enter the nucleus. Alternatively, a nucleic acid therapeutic agent
can be introduced in a cell such that it is incorporated into a
host cell DNA by homologous recombination for expression.
[0232] In a preferred embodiment, a composition can be prepared as
a pharmaceutical composition adapted to administration to humans in
accordance with a known method. Such a composition can be
administered by an injection. A composition for injection is
typically a solution in an aseptic isotonic aqueous buffer. A
composition can also comprise a local anesthetic such as lidocaine
which alleviates the pain at the site of injection and a
solubilizing agent as needed. Generally, ingredients can be
supplied separately or by mixing the ingredients together in a unit
dosing form and supplied, for example, in a sealed container such
as an ampoule or sachet showing the amount of active agent or as a
lyophilized powder or water-free concentrate. When a composition is
to be administered by injection, the composition can be distributed
by using an injection bottle containing aseptic agent-grade water
or saline. When a composition is to be administered by injection,
an aseptic water or saline ampoule for injection can also be
provided such that the ingredients can be mixed prior to
administration.
[0233] The composition, medicament, therapeutic agent, and
prophylactic agent of the present invention can be prepared as a
neutral or salt form or other prodrugs (e.g., ester or the like).
Pharmaceutically acceptable salts include salts formed with a free
carboxyl group, derived from hydrochloric acid, phosphoric acid,
acetic acid, oxalic acid, tartaric acid or the like, salts formed
with a free amine group, derived from isopropylamine,
trimethylamine, 2-ethylaminoethanol, histidine, procaine or the
like, and salts derived from sodium, potassium, ammonium, calcium,
or ferric hydroxide or the like.
[0234] The amount of therapeutic agent of the present invention
that is effective in therapy of a specific disorder or condition
may vary depending on the properties of the disorder or condition.
However, such an amount can be determined by those skilled in the
art by a standard clinical technique based on the descriptions
herein. Furthermore, an in vitro assay can be used in some cases to
assist the identification of the optimal dosing range. The precise
dose to be used in a preparation may also vary depending on the
administration pathway or the severity of the disease or disorder.
Thus, the dose should be determined in accordance with the judgment
of the attending physician or the condition of each patient. The
dosage is not particularly limited, but may be 0.001, 1, 5, 10, 15,
100 or 1000 mg/kg body weight per dosage or within a range between
any two values described above. The dosing interval is not
particularly limited, but may be, for example, 1 or 2
administration every 1, 7, 14, 21, or 28 days or 1 or 2
administrations in the range of period between any two values
described above. The dosage, dosing interval, and dosing method may
be appropriately selected depending on the age, weight, symptom,
target organ or the like of the patient. Further, it is preferable
that a therapeutic drug contains a therapeutically effective
amount, or an amount effective for exerting a desired effect, of
effective ingredients. When a malignant tumor marker significantly
decreases after administration, the presence of a therapeutic
effect may be acknowledged.
[0235] "Patient" in one embodiment of the present invention
includes humans and mammals excluding humans (e.g., one or more
types of mice, guinea pigs, hamsters, rats, rabbits, pigs, sheep,
goats, cows, horses, cats, dogs, marmosets, monkeys and the like).
Further, the patient may be a patient determined or diagnosed as
having an episode of LSR positive malignant tumor. It is preferable
that determination or diagnosis in this regard is performed by
detecting the LSR protein level.
[0236] The pharmaceutical composition, therapeutic agent or
prophylactic agent of the present invention can be provided as a
kit.
[0237] In a specific embodiment, the present invention provides an
agent pack or kit comprising one or more containers filled with one
or more ingredients of the composition or medicament of the present
invention. Optionally, information indicating approval for
manufacture, use or sale for administration to a human by a
government agency regulating the manufacture, use or sale of
medicaments or biological products in a stipulated form can be
appended to such a container.
[0238] The kit of the present invention can also contain an
expression vector encoding a protein to be used as the composition,
therapeutic agent, prophylactic agent or medicament of the present
invention. Since such a protein, after expression, forms a
biologically active complex, the protein may be reconstituted. Such
a kit preferably contains a required buffer and a reagent.
Optionally, instruction (package insert) for use of the kit and/or
information indicating approval for manufacture, use or sale for
administration to a human by a government agency regulating the
manufacture, use or sale of medicaments or biological products in a
stipulated form can be appended to such a container.
[0239] In a specific embodiment, the pharmaceutical composition
comprising a nucleic acid of the present invention can be
administered via liposomes, microparticles, or microcapsules. In
various embodiments of the present invention, it may be useful to
use such a composition to achieve sustained release of the nucleic
acid.
[0240] One embodiment of the present invention may be an anti-LSR
antibody, which is one or more antibodies selected from the group
consisting of (a) an antibody comprising heavy chain CDRs 1, 2, and
3 and light chain CDRs 1, 2, and 3 with amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-230 of SEQ ID NO: 1, respectively, (b) an antibody comprising
heavy chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 with
amino acid sequences set forth in positions 31-35, 50-66, 99-103,
152-165, 182-188 and 221-230 of SEQ ID NO: 2, respectively, (c) an
antibody comprising heavy chain CDRs 1, 2, and 3 and light chain
CDRs 1, 2, and 3 with amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 3,
respectively, (d) an antibody comprising heavy chain CDRs 1, 2, and
3 and light chain CDRs 1, 2, and 3 with amino acid sequences set
forth in positions 31-35, 50-66, 99-104, 153-165, 182-188 and
221-229 of SEQ ID NO: 4, respectively, (e) an antibody comprising
heavy chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3 with
amino acid sequences set forth in positions 31-35, 50-66, 99-104,
153-165, 182-188 and 221-229 of SEQ ID NO: 5, respectively, and (f)
an antibody comprising heavy chain CDRs 1, 2, and 3 and light chain
CDRs 1, 2, and 3 with amino acid sequences set forth in positions
31-35, 50-66, 99-104, 153-165, 182-188 and 221-229 of SEQ ID NO: 6,
respectively, or a mutant of the antibody, which is free of a
mutation in the CDRs but comprises one or several substitutions,
additions, or deletions in a framework of the antibody in the
mutant. Use of such an anti-LSR antibody can effectively suppress
especially the growth of LSR-positive malignant tumor cells.
Further, LSR-positive malignant tumor can be efficiently diagnosed.
Further, another embodiment of the present invention is an anti-LSR
antibody comprising at least one of the sets of amino acid
sequences of heavy chain CDRs 1, 2, and 3 listed above. These
antibodies may be an antibody selected from a monoclonal antibody,
polyclonal antibody, chimeric antibody, humanized antibody, human
antibody, multifunctional antibody, bispecific or oligospecific
antibody, single chain antibody, scFV, diabody, sc(Fv).sub.2
(single chain (Fv).sub.2), and scFv-Fc.
[0241] The anti-LSR antibody according to one embodiment of the
present invention may comprise a set of amino acid sequences of
heavy chain CDRs 1, 2, and 3 and light chain CDRs 1, 2, and 3, and
at least one, preferably, 2, 3, 4, 5, 6, 7 or all of the heavy
chain FRs 1, 2, 3, and 4 and light chain FRs 1, 2, 3, and 4 are
identical, substantially identical, or identical except for a
conservative substitution with any one of SEQ ID NOs: 1-6. The
anti-LSR antibody may be one or more types of antibodies. Further,
another embodiment of the present invention is an anti-LSR antibody
comprising at least one of the amino acid sequence set of heavy
chain FRs 1, 2, 3, and 4 listed above.
[0242] The anti-LSR antibody according to one embodiment of the
present invention may be in a form of scFv. In such a case, a
linker between a heavy chain and a light chain may have an amino
acid sequence set forth in positions 116-132 of SEQ ID NO: 1,
positions 116-132 of SEQ ID NO: 2, positions 116-132 of SEQ ID NO:
3, positions 116-132 of SEQ ID NO: 4, positions 116-132 of SEQ ID
NO: 5, or positions 116-132 of SEQ ID NO: 6.
[0243] VHs of #9-7, #16-6, No. 26-2, No. 27-6, No. 1-25, and No.
1-43 described in Example 2 described below are positions 1-115 of
SEQ ID NO: 1, positions 1-115 of SEQ ID NO: 2, positions 1-115 of
SEQ ID NO: 3, positions 1-115 of SEQ ID NO: 4, positions 1-115 of
SEQ ID NO: 5, and positions 1-115 of SEQ ID NO: 6, respectively.
Further, VLs of #9-7, #16-6, No. 26-2, No. 27-6, No. 1-25, and No.
1-43 described in Example 2 described below are positions 133-238
of SEQ ID NO: 1, positions 133-239 of SEQ ID NO: 2, positions
133-238 of SEQ ID NO: 3, positions 133-238 of SEQ ID NO: 4,
positions 133-238 of SEQ ID NO: 5, and positions 133-238 of SEQ ID
NO: 6, respectively.
[0244] The amino acid sequences listed above may be one or more
amino acid sequences selected from the group consisting of (i) the
above-described amino acid sequence with one or several base
sequence deletions, substitutions, insertions or additions, (ii) an
amino acid sequence with 90% or greater homology to the
above-described amino acid sequence, and (iii) an amino acid
sequence encoded by a polynucleotide that hybridizes specifically
to a polynucleotide consisting of a base sequence complementary to
a base sequence encoding the above-described amino acid under
stringent conditions, as long as an anti-LSR antibody has a desired
effect.
[0245] A vector or polynucleotide encoding the anti-LSR antibody
according to one embodiment of the present invention can be
introduced into a cell to produce a transformant. Such a
transformant can be used to make the anti-LSR antibody according to
the embodiment of the present invention. The transformant may be a
cell of a human or a mammal excluding humans (e.g., rat, mouse,
guinea pig, rabbit, cow, monkey or the like). Examples of a
mammalian cell include Chinese hamster ovary cells (CHO cells),
monkey cells COS-7 and the like. Further, the tranformant may be
Escherichia bacteria, yeasts or the like.
[0246] For example, an E. coli derived plasmid (e.g., pET-Blue), a
Bacillus subtilis derived plasmid (e.g., pUB110), a yeast derived
plasmid (e.g. pSH19), an animal cell expression plasmid (e.g.,
pA1-11, pdDNA3.1-V5/His-TOPO), bacteriophage such as A phage, a
virus-derived vector or the like can be used as the above-described
vector. Such vectors may comprise a constituent element required
for protein expression such as a promoter, origin of replication,
or antibiotic resistant gene. The vector may be an expression
gene.
[0247] Examples of method of introducing the above-described
polynucleotide or vector into cells that can be used include
calcium phosphate method, lipofection, electroporation, method
using adenovirus, method using a retrovirus, and microinjection
(Revised 4th edition Shin Idenshikogaku Handobukku [New Genetic
Engineering Handbook], Yodosha (2003): 152-179). Examples of a
method of producing an antibody using a cell that can be used
include the methods described in "Tanpakushitsu Jikken Handobukku
[Protein experiment handbook], Yodosha (2003): 128-142".
Purification of antibodies can use, for example, ammonium sulfate,
ethanol precipitation, protein A, protein G, gel filtration
chromatography, anion, cation exchange chromatography,
phosphocellulose chromatography, hydrophobic interaction
chromatography, affinity chromatography, hydroxyapatite
chromatography, lectin chromatography or the like "Tanpakushitsu
Jikken Handobukku [Protein experiment handbook], Yodosha (2003):
27-52".
[0248] To implement the present invention, a nucleic acid can be
selected as the suppressant in a nucleic acid form of the present
invention by using antisense activity as an indicator. In this
regard, "antisense activity" refers to activity that can
specifically suppress or decrease expression of a target gene. More
specifically, antisense activity refers to activity that can
decrease the amount of protein expression, depending on the
nucleotide sequence introduced into cells, by specifically reducing
the amount of mRNA of a gene having a nucleotide sequence region
complementary to such a sequence. The approach thereof is roughly
classified into a method of introducing an RNA molecule
complementary to mRNA made from a target gene directly into cells,
and a method of introducing a construct vector that can express an
RNA complementary to a gene of interest into cells.
[0249] Antisense activity is achieved by a nucleic acid sequence
with a length of at least 8 contiguous nucleotides, which is
complementary to a nucleic acid sequence of a gene of interest.
Such a nucleic acid sequence may be a nucleic acid sequence
preferably with a length of at least 9 contiguous nucleotides, more
preferably with a length of 10 contiguous nucleotides, and still
more preferably with a length of 11 contiguous nucleotides, a
length of 12 contiguous nucleotides, a length of 13 contiguous
nucleotides, a length of 14 contiguous nucleotides, a length of 15
contiguous nucleotides, a length of 16 contiguous nucleotides, a
length of 17 contiguous nucleotides, a length of 18 contiguous
nucleotides, a length of 19 contiguous nucleotides, a length of 20
contiguous nucleotides, a length of 21 contiguous nucleotides, a
length of 22 contiguous nucleotides, a length of 23 contiguous
nucleotides, a length of 24 contiguous nucleotides, a length of 25
contiguous nucleotides, a length of 30 contiguous nucleotides, a
length of 40 contiguous nucleotides, or a length of 50 contiguous
nucleotides. Such a nucleic acid sequence includes nucleic acid
sequences that are at least 70% homologous, more preferably at
least 80% homologous, still more preferably 90% homologous or 95%
homologous to the aforementioned sequences. Such antisense activity
is preferably complementary to a sequence at the 5' terminus of a
nucleic acid sequence of a gene of interest. Such an antisense
nucleic acid sequence includes the aforementioned sequences with
one or several or one or more nucleotide substitutions, additions,
and/or deletions. Thus, antisense activity as used herein includes,
but is not limited to, decrease in the amount of gene
expression.
[0250] Common antisense techniques are described in text books
(Murray, J A H eds., Antisense RNA and DNA, Wiley-Liss Inc, 1992).
Furthermore, the latest research has elucidated a phenomenon called
RNA interference (RNAi), leading to development of antisense
techniques.
[0251] As used herein, "RNAi" is an abbreviation of "RNA
interference" and is commonly known in the art. RNA interference is
a biological process that inhibits or downregulates gene expression
in cells, mediated by an agent inducing RNAi. For example, RNA
interference refers to a phenomenon of specific degradation of
homologous mRNA to suppress the synthesis of gene products by
introducing into a cell an agent inducing RNAi, such as a double
stranded RNA (also called dsRNA), or a technique used therein. As
used herein, "RNAi" may in some cases be used synonymously with
"agent inducing RNAi", "agent causing RNAi", "RNAi agent" or the
like. For RNAi, see, for example, Zamore and Haley, 2005, Science,
309, 1519-1524; Vaughn and Martienssen, 2005, Science 309,
1525-1526; Zamore et al., 2000, Cell, 101, 25-33; Bass, 2001,
Nature, 411, 428-429; Elbashir et al., 2001, Nature, 411, 494-498;
and Kreutzer et al, International Publication No. WO 00/44895;
Zernicka-Goetz et al, International Publication No. WO 01/36646;
Fire, International Publication No. WO 99/32619; Plaetinck, et al.,
International Publication No. WO 00/01846; Mello and Fire,
International Publication No. WO 01/29058; Deschamps-Depaillette,
International Publication No. WO 99/07409 and Li et al.,
International Publication No. WO 00/44914; Allshire, 2002, Science,
297, 1818-1819; Volpe et al., 2002, Science, 297, 1833-1837;
Jenuwein, 2002, Science, 297, 2215-2218; and Hall et al., 2002,
Science, 297, 2232-2237; Hutvagner and Zamore, 2002, Science, 297,
2056-60; McManus et al., 2002, RNA, 8, 842-850; Reinhart et al.,
2002, Gene & Dev., 16, 1616-1626; and Reinhart & Bartel,
2002, Science, 297, 1831. Further, it is understood that the term
RNAi as used herein represents a synonym of other terms used to
describe sequence specific RNA interference such as
post-transcription gene silencing, inhibition of translation,
inhibition of transcription, or epigenetics. As used herein, "agent
causing RNAi" may be any agent as long as "RNAi" is caused.
[0252] Examples of "agent causing RNAi" as used herein include
"small interfering nucleic acid" "siNA", "small interfering RNA",
"siRNA", "small interfering nucleic acid molecule", "small
oligonucleotide molecule", "chemically modified small interfering
nucleic acid molecule" and the like. These terms refer to any
nucleic acid molecule that can inhibit or downregulate gene
expression or virus replication by sequence specifically mediating
RNA interference "RNAi" or gene silencing. These terms may
represent an individual nucleic acid molecule, multiple such
nucleic acid molecules, or a pool of such nucleic acid molecules.
The molecules may be a double stranded nucleic acid molecule
comprising a self-complementary sense region and an antisense
region.
[0253] "SiRNA" that is typically used in the present invention is a
doubled stranded RNA that is short with a length of generally about
20 bases (e.g., typically about 21-23 bases long) or less. Such an
siRNA, when expressed in cells, suppresses gene expression and
suppresses expression of a target pathogenic gene of the siRNA.
Thus, such an siRNA can be used in therapy, prevention, prognosis
or the like of a disease. The siRNA used in the present invention
may be in any form, as long as it is capable of inducing RNAi.
[0254] In the present invention, an antisense region in an agent
causing RNAi such as an siRNA comprises a sense region having a
nucleotide sequence which is complementary to a nucleotide sequence
in a target nucleic acid molecule or a portion thereof and a
nucleotide sequence corresponding to the target nucleic acid
sequence or a portion thereof. These molecules can be assembled
from two separate oligonucleotides, one being a sense strand and
the other being an antisense strand. The antisense strand and sense
strand in this regard are self-complementary (i.e., each strand
comprises a nucleotide sequence that is complementary to the
nucleotide sequence in the other strand, e.g., the antisense strand
and the sense strand form a double strand or double stranded
structure). A double stranded region in this regard can be, for
example, about 15 to about 30 base pairs such as about 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs or
longer. The antisense strand comprises a nucleotide sequence that
is complementary to a nucleotide sequence in a target nucleic acid
molecule or a portion thereof, and the sense strand comprises a
nucleotide sequence corresponding to the target nucleic acid
sequence or a portion thereof (e.g., about 15-25 or more
nucleotides of the molecule are complementary to a target nucleic
acid or a portion thereof). Alternatively, these molecules are
assembled from a single oligonucleotide, and the self-complementary
sense region and antisense region of these molecules are linked by
a nucleic acid linker or a non-nucleic acid linker. These molecules
can be polynucleotides having a double stranded, asymmetrical
double stranded, hairpin, or asymmetrical hairpin secondary
structure comprising a self-complementary sense region and
antisense region. The antisense region in this regard comprises a
separate sense region having a nucleotide sequence which is
complementary to a nucleotide sequence in a target nucleic acid
molecule or a portion thereof and a nucleotide sequence
corresponding to the target nucleic acid sequence or a portion
thereof. These molecules may be a cyclic single stranded
polynucleotide having two or more loop structures and a stem
comprising a self-complementary sense region and antisense region.
The antisense region in this regard comprises a separate sense
region having a nucleotide sequence which is complementary to a
nucleotide sequence in a target nucleic acid molecule or a portion
thereof and a nucleotide sequence corresponding to the target
nucleic acid sequence or a portion thereof. In addition, a cyclic
polynucleotide can be processed in vivo or in vitro to generate an
active molecule that can mediate RNAi. These agents may also
comprise a single stranded polynucleotide having a nucleotide
sequence, which is complementary to a nucleotide sequence in a
target nucleic acid molecule or a portion thereof (for instance,
for these agents, a nucleotide sequence corresponding to the target
nucleic acid molecule or a portion thereof does not need to be
present in these agents). A single stranded polynucleotide may
further comprise a terminal phosphoric acid group such as 5'
phosphoric acid (for example, see Martinez et Al., 2002, Cell.,
110, 563-574 and Schwarz et al., 2002, Molecular Cell, 10, 537-568)
or 5', 3'-diphosphoric acid. In a certain embodiment, the LSR
suppressant of the present invention comprises separate sense and
antisense sequences or regions. The sense region and antisense
region in this regard are covalently attached by a nucleotide or
non-nucleotide linker molecule known in the art, or non-covalently
attached to each other by ionic interaction, hydrogen bond, Van der
Waal's interaction, hydrophobic interaction and/or stacking
interaction. In a certain embodiment, the LSR suppressant of the
present invention comprises a nucleotide sequence that is
complementary to a nucleotide sequence of a target gene. In another
embodiment, the LSR suppressant of the present invention interacts
with a nucleotide sequence of a target gene such that expression of
the target gene is inhibited. The LSR suppressant is not
necessarily limited herein to molecules comprising only an RNA. The
LSR suppressant also encompasses chemically modified nucleotides
and non-nucleotides. In a certain embodiment, when the present
invention is a small interfering nucleic acid molecule, a 2'
hydroxy (2'-OH) containing nucleotide may be lacking. In a certain
embodiment, the present invention can be a small interfering
nucleic acid, which does not require the presence of a nucleotide
having a 2' hydroxyl group for mediating RNAi. Thus, when the
present invention is a small interfering nucleic acid molecule,
ribonucleotide (e.g., nucleotide having a 2'-OH group) does not
need to be included. However, when the presence of a ribonucleotide
in an LSR suppressant is not required for maintaining RNAi, it may
have a bound linker, or another bound or conjugated group, moiety
or strand comprising one or more nucleotides having a 2'-OH group.
Optionally, an agent suppressing LSRs of the present invention may
comprise a ribonucleotide in about 5, 10, 20, 30, 40 or 50% of the
nucleotide positions. Herein, the LSR suppressant may be a nucleic
acid molecule that can mediate sequence specific RNAi, such as
small interfering RNA (siRNA), double stranded RNA (dsRNA),
microRNA (miRNA), short hairpin RNA (shRNA), small interfering
oligonucleotide, small interfering nucleic acid, small interfering
modified oligonucleotide, chemically modified siRNA, or
post-transcriptional gene silencing RNA.
[0255] Examples of agents inducing RNAi herein include, but are not
limited to, RNAs comprising a double stranded moiety with a length
of at least 10 nucleotides, comprising a sequence having at least
about 70% homology or a sequence that hybridizes under stringent
conditions to a portion of a nucleic acid sequence of a target gene
and variants thereof. The agent in this regard can preferably
comprise a 3' overhang, and more preferably the 3' overhang is a
DNA with a length of 2 nucleotides or longer (e.g., DNA with a
length of 2-4 nucleotides).
[0256] Alternatively, examples of RNAi used in the present
invention include, but are not limited to, a pair of short
complementary sequences in the opposite direction (e.g., 15 bp or
longer such as 24 bp or the like).
[0257] Although not wishing to be bound by any theory, as one
conceivable working mechanism of RNAi, when a molecule inducing
RNAi such as dsRNA is introduced into cells for a relatively long
(e.g., 40 base pairs or greater) RNA, an RNase III-like nuclease
called a dicer having a helicase domain cuts out the molecule into
about 20 base pair each from the 3' terminus in the presence of ATP
to produce short dsRNA (also called siRNA). As used herein, "siRNA"
is an abbreviation for short interfering RNA and refers to a short
double stranded RNA with 10 base pairs or more prepared by
artificial chemical synthesis or biochemical synthesis, synthesis
in the body of an organism, or degradation of a double stranded RNA
with about 40 bases or more in vivo. An siRNA generally has a
5'-phosphoric acid or 3'-OH structure, and the 3' terminus
overhangs by about 2 bases. A specific protein binds to the siRNA
to form an RISC (RNA-induced-silencing-complex). Such a complex
recognizes and binds to an mRNA having the same sequence as the
siRNA and cleaves the mRNA in the middle portion of the siRNA by
RNase III-like enzymatic activity. The relationship of the siRNA
sequence and mRNA sequence to be cleaved as a target is preferably
a 100% match. However, for a mutation of a base at a position away
from the middle of the siRNA, cleaving activity due to RNAi would
not be completely lost, but instead partially remains. On the other
hand, a mutation of a base in the middle portion of the siRNA has a
significant effect, such that mRNA cleaving activity due to RNAi is
dramatically reduced. For mRNAs with a mutation, such a property
can be utilized to degrade only mRNAs comprising a specific
mutation by synthesizing an siRNA with the mutation positioned in
the middle and introducing the siRNA into cells. Thus, the present
invention can use an siRNA itself as an agent inducing RNAi or an
agent that would produce an siRNA (e.g., typically a dsRNA with
about 40 or more bases) as such an agent.
[0258] Although not wishing to be bound by any theory, it is
intended for siRNAs that, aside from the above-described pathway,
an antisense strand of the siRNA binds to an mRNA and acts as a
primer of an RNA-dependent RNA polymerase (RdRP), such that a dsRNA
is synthesized and the dsRNA is used again as a substrate of a
dicer to produce a new siRNA and amplify the action. Thus, the
siRNA itself and agents producing an siRNA are also useful in the
present invention. In fact, for example, 35 dsRNA molecules nearly
completely degrade 1000 or more mRNA copies in cells in insects or
the like. Thus, it is understood that the siRNA itself and agents
producing an siRNA are also useful.
[0259] In another embodiment, the agent inducing RNAi of the
present invention can be a short hairpin structure (shRNA; short
hairpin RNA) having an overhang at the 3' terminus. As used herein,
"shRNA" refers to a molecule with about 20 or more base pairs,
which comprises a partially palindrome-like base sequence in a
single stranded RNA to be in a double stranded structure in a
molecule to have a hairpin-like structure. Such an shRNA is
artificially made by chemical synthesis. Alternatively, such an
shRNA can be produced by synthesizing a hairpin structure DNA
comprising DNA sequences of sense and antisense strands linked in
opposite directions in vitro into an RNA with a T7RNA polymerase.
Although not wishing to be bound by any theory, it should be
understood that such an shRNA, after introduction into cells, is
degraded into a length of about 20 bases (typically, for example,
21 bases, 22 bases or 23 bases) in the cells and induces RNAi as in
an siRNA, resulting in a treatment effect of the present invention.
It should be understood that such an effect is exerted in a wide
range of organisms such as insects, plants and animals (including
mammals). Since an shRNA induces RNAi as in siRNAs in this manner,
it can be used as an effective ingredient of the present invention.
Further, an shRNA preferably can have a 3' overhang. The length of
a double stranded moiety is not particularly limited, but the
length can be preferably about 10 nucleotides long or longer and
more preferably about 20 nucleotides long or longer. The 3'
overhang in this regard can be preferably a DNA, more preferably a
DNA with a length of at least two nucleotides or more, and still
more preferably a DNA with a length of 2-4 nucleotides. The agent
inducing RNAi used in the present invention can be artificially
synthesized (e.g., chemically or biochemically) or naturally
occurring. There is no fundamental difference in the effect of the
present invention therebetween. A chemically synthesized agent is
preferably purified by liquid chromatography or the like.
[0260] The agent inducing RNAi used in the present invention can
also be synthesized in vitro. In such a synthesis system, a T7RNA
polymerase and T7 promoter are used to synthesize antisense and
sense RNAs from a template DNA. After annealing is performed
thereon in vitro, RNAi is induced through the aforementioned
mechanism when cells are introduced to achieve the effect of the
present invention. In this regard, such an RNA can be introduced
into cells, for example, by any suitable method such as the calcium
phosphate method. Examples of the agents inducing RNAi of the
present invention include agents such as a single strand that can
hybridize with an mRNA or all similar nucleic acid analogs thereof.
Such agents are also useful in the present invention.
[0261] One embodiment of the present invention is a therapeutic
drug for LSR positive malignant tumor comprising an RNAi molecule
directed to LSRs or a polynucleotide encoding the RNAi molecule.
Growth of LSR positive malignant tumor cells can be suppressed when
such an RNAi molecule or polynucleotide encoding the RNAi molecule
is used. "Polynucleotide" in one embodiment of the present
invention may be a polymeric compound having 10 or more
nucleotides, comprising a nucleotide polymerized in a straight
chain.
[0262] "RNAi molecule" in one embodiment of the present invention
is an RNA strand having RNAi action. Examples thereof include
siRNA, shRNA, miRNA, small RNA having RNAi action and the like.
[0263] "RNAi" in one embodiment of the present invention includes a
phenomenon of suppressing or silencing a function of a target gene,
mRNA or the like by one or more of siRNA, shRNA, miRNA, single or
double stranded RNA with a short or long chain, modified products
thereof and the like.
[0264] For example, siDirect 2.0 (Naito et al., BMC Bioinformatics.
2009 Nov. 30; 10: 392.) or the like can be used to design an RNAi
molecule. Further, designing can be commissioned to a specialist
company (e.g., Takara Bio Inc. or the like). RNAi action can be
verified by quantification of the amount of RNA strand expression
by real-time RT-PCR. RNAi action can also be confirmed by analysis
of the amount of RNA strand expression by Northern blot or a method
of analyzing the amount of protein and observing the phenotype or
the like by Western blot. Further, a plasmid producing siRNAs or
shRNAs for a specific gene can be purchased, for example, from a
specialist company (e.g., Takara Bio Inc. or the like).
[0265] "SiRNA" in one embodiment of the present invention comprises
an RNA strand capable of inducing RNAi. Two strands of an siRNA can
generally be separated into a guide strand and a passenger strand,
where the guide strand in incorporated into an RISC. The guide
strand incorporated into the RISC is used to recognize a target
RNA. Although an artificially created guide strand is mainly used
in RNAi research, those endogenous in a living body are also known.
The above-described guide chain may be composed of an RNA with 15
bases or more. When there are 15 bases or more, the possibility of
being able to precisely bind to a target nucleotide increases.
Further, the guide strand may be composed of an RNA with 40 bases
or less. With 40 bases or less, the risk of a disadvantageous
phenomenon such as interferon response occurring is further
reduced.
[0266] "shRNA" in one embodiment of the present invention comprises
a single strand of RNA strand that can induce RNAi and form a
structure folded into a hairpin shape (hairpin-like structure).
Typically, an shRNA is cleaved by a dicer in a cell to cut out an
siRNA. It is known that a target RNA is cleaved by the siRNA. The
above-described shRNA may be composed of 35 or more nucleotides.
With 35 or more, the possibility of being able to precisely form a
hairpin-like structure unique to shRNAs increases. Further, the
above-described shRNA may be composed of an RNA with 100 bases or
less. With 100 bases or less, the risk of a disadvantageous
phenomenon such as interferon response occurring is reduced.
However, many of the pre-miRNAs that generally have a similar
structure and function as shRNAs have a length of about 100
nucleotides or more. Thus, it is conceivable that they can function
as a shRNA even when the length of the shRNA is not necessarily 100
bases or less.
[0267] It is known that "miRNA" in one embodiment of the present
invention comprises an RNA strand having a function similar to an
siRNA and suppresses translation of, and degrades, a target RNA
strand. The difference in miRNAs and siRNAs is generally in the
production pathway and the detailed mechanism.
[0268] "Small RNA" in one embodiment of the present invention
refers to a relatively small RNA strand. Examples thereof include
siRNAs, shRNAs, miRNAs, antisense RNAs, small RNAs with one or two
strands and the like.
[0269] The RNAi molecules may comprise an overhang consisting of
1-5 bases at the 5' terminus or the 3' terminus. It is understood
that RNAi efficiency is enhanced in such a case. The number of
bases may be, for example, 5, 4, 3, 2, or 1, or within a range of
any two values described above. When the above-described RNAi
molecule is double stranded, a mismatching RNAs may be present
between each RNA strand. The number of mismatching RNAs may be, for
example, 1, 2, 3, 4, 5, or 10 or less, or within the range of any
two values described above. Further, the above-described RNAi
molecule may comprise a hairpin loop. The number of bases of a
hairpin loop may be, for example, 10, 8, 6, 5, 4, or 3 or within
any two values described above. The base sequence may have one or a
plurality of base sequence deletions, substitutions, insertions or
additions, as long as the sequence has a desired effect. The left
side of each base sequence is denoted as the 5' terminus and the
right side as the 3' terminus.
[0270] The length of the above-described RNAi molecule may be, for
example, 15, 18, 20, 25, 30, 40, 50, 60, 80, 100, 200, or 400 bases
or within a range between any two values described above. The
number is preferably 15 or more or 100 or less from the viewpoint
of improving the therapeutic effect on LSR positive malignant
tumor.
[0271] "RNA strand" in one embodiment of the present invention
includes those constituted in a form in which a plurality of RNAs
or equivalents thereof are bound. "DNA strand" in one embodiment of
the present invention includes those constituted in a form in which
a plurality of DNAs or equivalents thereof are bound. The RNA
strand or DNA strand includes RNA strands or DNA strands in a
single stranded or multi-stranded (e.g., double stranded) form. The
RNA strand or DNA strand may be bound to a substance promoting
incorporation into cells (e.g., PEG or derivative thereof),
labeling tag (e.g., fluorescent labeling tag or the like), a linker
(e.g., nucleotide linker or the like) or the like. The RNA strand
or DNA strand can be synthesized by using a nucleic acid
synthesizer or purchased from a specialist company (e.g.,
Invitrogen or the like). An RNA strand or DNA strand in a living
body may form a salt or a solvate. Further, an RNA strand or DNA
strand in a living body may be chemically modified. The term RNA
strand or DNA strand includes, for example, RNA strands or DNA
strands forming a salt or solvate, RNA strands or DNA strands
subjected to chemical modification, and the like. Further, an RNA
strand or DNA strand may be an analog of the RNA strand or an
analog of the DNA strand.
[0272] Examples of "salt" in one embodiment of the present
invention include anionic salts formed with any acidic (e.g.,
carboxyl) group and cationic salts formed with any basic (e.g.,
amino) group. Salts include inorganic salts and organic salts, as
well as salts described in, for example, Berge et al., J. Pharm.
Sci., 1977, 66, 1-19. Further examples include metal salts,
ammonium salts, salts with organic base, salts with inorganic acid,
salts with organic acid and the like. "Solvent" in one embodiment
of the present invention is a compound formed with a solute or
solvent. For example, J. Honig et al., The Van Nostrand Chemist's
Dictionary P650 (1953) can be referred for solvates. When a solvent
is water, a solvate formed is a hydrate. It is preferable that the
solvent does not obstruct the biological activity of the solute.
Examples of such a preferred solvent include, but not particularly
limited to water and various buffers. Examples of "chemical
modification" in one embodiment of the present invention include
modification with PEG or a derivative thereof, fluorescein
modification, biotin modification and the like.
[0273] The above-described RNAi molecule preferably comprises a
base sequence that is complementary to a portion of a base sequence
of an LSR mRNA from the viewpoint of stably exerting RNAi action.
The above-described "portion" may be, for example, 5, 10, 15, 18,
20, 22, 24, 26, 28, 30, 35, 40 or 50 bases or more or within a
range of any two values described above.
[0274] The siRNA used in Example 3 described below comprises the
base sequence of SEQ ID NO: 9 or 10. These base sequences are
considered to be base sequences complementary to a portion of an
LSR mRNA and responsible for the function as a guide strand. One
embodiment of the present invention comprises an RNAi molecule
comprising such the base sequence of SEQ ID NO: 9 or 10. The RNAi
molecule may further comprise a base sequence complementary to the
base sequence set forth in SEQ ID NO: 9 or 10 (e.g., SEQ ID NO: 11
or 12, respectively). "Complementary base sequence" in one
embodiment of the present invention is abase sequence having a
polynucleotide with high complementarity capable of hybridizing to
another polypeptide. The full length sense strand of the siRNA used
in Example 3 described below is the base sequence of SEQ ID NO: 13
or 14, and the full length antisense strand is the base sequence of
SEQ ID NO: 15 or 16.
[0275] As long as an LSR siRNA has a desired effect, the base
sequences listed above may be (i) an amino acid sequence with one
or several base sequence deletions, substitutions, insertions or
additions in the above-described base acid sequence, or (ii) a base
sequence encoded by a polynucleotide that specifically hybridizes
with a polynucleotide consisting of a base sequence complementary
to the above-described base sequence under stringent
conditions.
[0276] One embodiment of the present invention is a therapeutic
drug for LSR positive malignant tumor, comprising an LSR
antagonist. The LSR antagonist comprises a substance inhibiting the
expression or function of an LSR. The growth of LSR positive
malignant tumor cells can be suppressed by using such an LSR
antagonist. The form of antagonist is not particularly limited as
long as it has an action of inhibiting the expression or function
of an LSR. For example, the antagonist may be in a form of an
antibody, RNA strand, DNA strand, low molecular weight organic
compound, or polypeptide. The above-described RNA strand may be an
RNAi molecule directed to an LSR. A DNA strand encoding an RNAi
molecule directed to an LSR can be used as the above-described DNA
strand. For example, the DNA strand may be in a form of a
vector.
[0277] Examples of "inhibit the expression of a protein" in one
embodiment of the present invention include inhibiting the
transcription mechanism from a gene to an mRNA or inhibiting the
translation mechanism from an mRNA to a protein. Examples further
include inducing degradation of a gene, mRNA or protein to
ultimately decrease the amount of protein. "Inhibit a function of
protein" in one embodiment of the present invention includes
causing a structural change in a protein to reduce the activity of
the protein. Examples thereof further include inhibiting the
expression of a gene, resulting in reduction in the amount of mRNA
or protein production.
[0278] "State where expression is inhibited" in one embodiment of
the present invention includes a state of significantly decreased
amount of expression relative to normal levels. The amount of mRNA
or protein may be used as an indicator for the amount of
expression. "Significantly" in one embodiment of the present
invention may be, for example, a state where there is a
statistically significant difference, when assessed by Student's
t-test (one or two tailed), at p<0.05. Further, a state where a
substantial difference has occurred is also included. "State where
a function is inhibited" in one embodiment of the present invention
includes a state with significantly decreased activity relative to
normal levels.
[0279] One embodiment of the present invention is a novel method of
therapy for malignant tumor. Such a therapeutic method comprises,
for example, a step of administering an anti-LSR antibody to a
patient. LSR positive malignant tumor can be treated by using such
a therapeutic method. Further, such a therapeutic method is
excellent from the viewpoint of safety, as the method uses
antibodies.
[0280] There are LSR positive and LSR non-positive patients among
malignant tumor patients. For this reason, the above-described
therapeutic method is preferably administered to a malignant tumor
patient determined to have malignant tumor that is LSR positive
malignant tumor. In this manner, diagnosis for the presence or
absence of an LSR positive condition in advance enables a more
optimal dosing.
[0281] Thus, the above-described therapeutic method for malignant
tumor preferably comprises a step of diagnosing whether a patient
has an episode of LSR positive malignant tumor from the viewpoint
of administering a more optimal dosing. Further, the therapeutic
method may comprise a step of investigating whether malignant tumor
cells derived from a patient express LSRs. An episode of LSR
positive malignant tumor may be diagnosed, for example, by
diagnosing mRNA expression or protein expression. The diagnosis is
preferably conducted by diagnosis of protein expression from the
viewpoint of accurately diagnosing LSR positive to realize a more
optimal dosing. Protein expression may be diagnosed by using, for
example, an anti-LSR antibody. In diagnosis of an episode, an
episode of LSR positive malignant tumor may be determined to be
present when a protein obtained from malignant tumor cells to be
tested derived from a patient is subjected to Western blot and a
band corresponding to LSRs can be confirmed by visual inspection.
Further, an episode of LSR positive malignant tumor may be
determined to be present when the amount of LSR expression of
malignant tumor cells derived from a patient is significantly
larger relative to normal cells or LSR negative malignant tumor
cells. Further, an episode of LSR positive malignant tumor may be
determined to be present when total protein obtained from malignant
tumor cells derived from a patient and total protein obtained from
normal cells or LSR negative malignant tumor cells are subjected to
Western blot and the malignant tumor cells derived from the patient
have a significantly stronger band intensity corresponding to LSRs
relative to the normal cells or LSR negative malignant tumor cells.
Further, an episode of LSR positive malignant tumor may be
determined to be present when serum or plasma obtained from
malignant tumor patients and serum or plasma obtained form healthy
individuals or LSR negative malignant tumor patients are subjected
to ELISA using anti-LSR antibodies and the amount of LSR expression
is significantly more for the serum or plasma derived from
malignant tumor patients relative to healthy individuals or LSR
negative malignant tumor patients. The serum or plasma sample
itself may be quantified, or exosomes may be isolated from the
serum or plasma to subject LSRs in the exosomes to ELISA for
analysis. RT-PCR may be used instead of Western blot in such
diagnosis for an episode of LSR positive malignant tumor.
[0282] The therapeutic method of malignant tumor according to one
embodiment of the present invention may comprise a step of
administering an LSR antagonist to a patient. Further, the method
may comprise a step of administering an RNAi molecule directed to
an LSR or a polynucleotide encoding the RNAi molecule to the
patient.
[0283] One embodiment of the present invention is a novel
diagnostic drug for malignant tumor, comprising an anti-LSR
antibody. The diagnostic drug may be, for example, a companion
diagnostic drug for malignant tumor therapy targeting LSRs,
comprising an anti-LSR antibody. Since there are LSR positive and
LSR non-positive patients among malignant tumor patients,
therapeutic efficacy of the malignant tumor therapy targeting LSRs
can be diagnosed if the companion diagnostic drug is used to
inspect in advance whether malignant tumor is LSR positive. In such
diagnosis, when the result is LSR positive, malignant tumor therapy
targeting LSRs can be determined to be effective. "Companion
diagnosis" in one embodiment of the present invention comprises
diagnosis implemented in order to assist in the optimal dosing by
predicting individual differences in the effect of agent or side
effects for patients by inspection. For clinical application of an
antibody medicament with anti-LSR antibodies, it is understood that
selective therapy for LSR expressing-malignant tumor patients would
lead to individualized medicine. For this reason, a method of
sorting out an LSR positive patient is needed. An approach that
inspects LSRs in a biopsy tissue of cancer by an
immunohistochemical staining method is considered highly useful as
a method of sorting out an LSR positive patient. However, obtaining
a biopsy tissue is highly invasive. Thus, a method with a low level
of invasiveness is preferred. Furthermore, certain types of
malignant tumor such as ovarian cancer are problematic in that
biopsy tissue is difficult to obtain due to the issues related to
the site of cancer. In contrast, LSRs expressed in cancer or the
extracellular domain thereof may be freely present in blood. In
this regard, the possibility of high level of LSR expression in
ovarian cancer tissue in a patient with a high blood LSR
concentration is suggested when LSRs in the blood of a malignant
tumor patient can be quantified. A blood sample is more
advantageous than biopsy in that the level of invasiveness is low.
It is highly likely that LSR is highly expressed in patient tissue
with elevated blood LSR concentration relative to healthy
individuals after quantifying the blood LSR concentration by ELISA.
Thus, measurement of blood LSR concentration is considered highly
useful as a companion diagnostic drug.
[0284] A diagnostic drug for malignant tumor according to one
embodiment of the present invention may be a diagnostic drug
comprising an anti-LSR antibody for diagnosis of therapeutic
efficacy of the anti-LSR antibody or LSR antagonist on malignant
tumor. Since there are LSR positive and LSR non-positive patients
among malignant tumor patients, it is possible to diagnose the
therapeutic efficacy of an anti-LSR antibody or LSR antagonist to
patients if the diagnostic agent is used in advance to inspect
whether malignant tumor is LSR positive.
[0285] One embodiment of the present invention is a companion
diagnostic method for malignant tumor therapy targeting an LSR,
comprising inspecting whether a malignant tumor sample of a
malignant tumor patient is LSR positive. Since there are LSR
positive and LSR non-positive patients among malignant tumor
patients, it is possible to diagnose the therapeutic efficacy of
malignant tumor therapy targeting an LSR if the companion diagnosis
method is used to inspect in advance whether malignant tumor is LSR
positive. Such a diagnostic method may further comprise a step of
isolating or extracting a malignant tumor sample of a malignant
tumor patient. "Malignant tumor sample" in one embodiment of the
present invention may be malignant tumor tissue or cells obtained
from a malignant tumor patient.
[0286] One embodiment of the present invention is a method of
diagnosing prognosis of malignant tumor using an LSR expression
level as an indicator. High level of LSR expression is demonstrated
to be a poor prognosis marker (FIG. 38). Thus, a high level of LSR
expression can be considered a poor prognosis marker. In one
embodiment, cancer subjected to prognosis is ovarian serous
adenocarcinoma, but the cancer is not limited thereto. It is
understood that the present invention can be applied to ovarian
clear cell adenocarcinoma and the like. It is also understood that
the present invention can be applied to any other LSR positive
malignant tumor. A method of using such a (poor) prognosis marker
may comprise, for example, a step of investigating whether LSRs are
expressed in malignant tumor cells derived from a patient. The
prognosis (diagnosis) of LSR positive malignant tumor may be
conducted, for example, by diagnosis or detection of mRNA
expression or diagnosis or detection of protein expression. Such
diagnosis or detection is preferably conducted by diagnosis of
protein expression from the viewpoint of accurately diagnosing LSR
positive to realize a more optimal dosing. Protein expression may
be diagnosed by using, for example, an anti-LSR antibody. In
diagnosis of an episode, the prognosis of malignant tumor may be
determined to be poor when a protein obtained from malignant tumor
cells to be tested derived from a patient is subjected to Western
blot and enhancement in a band corresponding to LSRs can be
confirmed by visual inspection. Further, the prognosis of malignant
tumor may be determined to be poor when the amount of LSR
expression of malignant tumor cells derived from a patient is
significantly larger relative to normal cells or LSR negative
malignant tumor cells (e.g., LSR negative cell strains such as
OVTOKO). Further, the prognosis of malignant tumor may be
determined to be poor when total protein obtained from malignant
tumor cells derived from a patient and total protein obtained from
normal cells or LSR negative malignant tumor cells (e.g., LSR
negative cell strains such as OVTOKO) are subjected to Western blot
and the malignant tumor cells derived from the patient have a
significantly stronger band intensity corresponding to LSRs
relative to the normal cells or LSR negative malignant tumor cells
(e.g., LSR negative cell strains such as OVTOKO). Further, the
prognosis of malignant tumor may be determined to be poor when
serum or plasma obtained from malignant tumor patients and serum or
plasma obtained form healthy individuals or LSR negative malignant
tumor patients (e.g., "patient whose LSR expression is negative in
ovarian cancer tissue") are subjected to ELISA using anti-LSR
antibodies and the amount of LSR expression is significantly more
for the serum or plasma derived from malignant tumor patients
relative to the healthy individuals or LSR negative malignant tumor
patients. The serum or plasma sample itself may be quantified, or
exosomes may be isolated from the serum or plasma to subject LSRs
in the exosomes to ELISA for analysis. RT-PCR may be used instead
of Western blot in such diagnosis of an episode of LSR positive
malignant tumor.
[0287] One embodiment of the present invention is a method of
inspecting therapeutic efficacy of an anti-LSR antibody or LSR
antagonist on malignant tumor. The inspection method comprises, for
example, inspecting whether a malignant tumor sample of a malignant
tumor patient is LSR positive. The inspection method, which may
comprise a step of detecting the presence of LSRs in a malignant
tumor sample, may comprise a step of detecting that the amount of
LSRs in the malignant tumor sample is significantly larger relative
to normal cells or LSR negative malignant tumor cells. For example,
RT-PCR, Western blot, or immunohistochemical staining method may be
used in detecting LSRs. The standard of assessing the presence or
absence of LSRs may be the same as that in the aforementioned
diagnosis of episode of LSR positive malignant tumor. A method of
inspecting therapeutic efficacy includes a method of inspecting
whether the method is effective for therapy.
[0288] One embodiment of the present invention is a suppressant for
growth of malignant tumor cells, comprising anti-LSR antibodies.
Further, it is a method of suppressing growth of malignant tumor
cells, comprising contacting anti-LSR antibodies with malignant
tumor cells. Further, it is a suppressant for growth of malignant
tumor cells, comprising an LSR antagonist. Further, it is a method
of suppressing growth of malignant tumor cells, comprising
contacting an LSR antagonist with malignant tumor cells. The
therapeutic drug or suppressant for growth of malignant tumor cells
according to the embodiment of the present invention may be an
agent that reduces the growth rate, amount of growth, or volume of
malignant tumor by 10, 20, 30, 40, 50, or 70% or more relative to a
case where a therapeutic drug or growth suppressant is not added.
The percentage may be within the range of two numerical values
listed above.
[0289] One embodiment of the present invention is an agent for
suppressing cell division of malignant tumor cells, comprising an
anti-LSR antibody. Further, it is a method of suppressing cell
division of malignant tumor cells, comprising contacting an
anti-LSR antibody with malignant tumor cells. Further it is an
agent for suppressing cell division of a malignant tumor cell,
comprising an LSR antagonist. Further, it is a method of
suppressing cell division of malignant tumor cells, comprising
contacting an LSR antagonist with malignant tumor cells. The agent
for suppressing cell division of a malignant tumor cell according
to the embodiment of the present invention may be an agent that
reduces the rate of malignant tumor cell division by 10, 20, 30, or
50% or more relative to a case where an agent for suppressing cell
division is not added. The percentage may be within the range of
two numerical values listed above.
[0290] One embodiment of the present invention is a therapeutic
drug for LSR-dependent malignant tumor, comprising an anti-LSR
antibody. LSR-dependent malignant tumor can be treated by using
such a therapeutic drug.
[0291] One embodiment of the present invention is use of an
anti-LSR antibody or LSR antagonist for producing a therapeutic
drug for malignant tumor. In another embodiment, it is a use of an
anti-LSR antibody for manufacturing a companion diagnostic drug for
malignant tumor therapy targeting an LSR.
[0292] One embodiment of the present invention is a method of
producing an anti-LSR antibody, comprising: introducing a
polynucleotide encoding an LSR into a cell; expressing the LSR in
the cell; and immunizing a chicken with an antigen comprising a
cell expressing the LSR. According to the production method, an
anti-LSR antibody that is excellent for the treatment or diagnosis
of LSR positive malignant tumor can be efficiently produced.
[0293] "Bond" in one embodiment of the present invention may be
either a covalent bond or a non-covalent bond. For example, "bond"
may be an ionic bond, hydrogen bond, hydrophobic interaction, or
hydrophilic interaction.
[0294] (General Techniques)
[0295] Molecular biological approach, biochemical approach, and
microbiological approach used herein are well known and
conventional approaches in the art that are described in, for
example, Sambrook J. et al. (1989). Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor and 3.sup.rd Ed. thereof (2001);
Ausubel, F. M. (1987). Current Protocols in Molecular Biology,
Greene Pub. Associates and Wiley-Interscience; Ausubel, F. M.
(1989). Short Protocols in Molecular Biology: A Compendium of
Methods from Current Protocols in Molecular Biology, Greene Pub.
Associates and Wiley-Interscience; Innis, M. A. (1990). PCR
Protocols: A Guide to Methods and Applications, Academic Press;
Ausubel, F. M. (1992). Short Protocols in Molecular Biology: A
Compendium of Methods from Current Protocols in Molecular Biology,
Greene Pub. Associates; Ausubel, F. M. (1995). Short Protocols in
Molecular Biology: A Compendium of Methods from Current Protocols
in Molecular Biology, Greene Pub. Associates; Innis, M. A. et al.
(1995). PCR Strategies, Academic Press; Ausubel, F. M. (1999).
Short Protocols in Molecular Biology: A Compendium of Methods from
Current Protocols in Molecular Biology, Wiley, and annual updates;
Sninsky, J. J. et al. (1999). PCR Applications: Protocols for
Functional Genomics, Academic Press, Bessatsu Jikken Igaku
[Experimental Medicine, Supplemental Volume], Idenshi Donyu Oyobi
Hatsugen Kaiseki Jikken Ho [Experimental Methods for Transgenesis
& Expression Analysis], Yodosha, 1997, and the like, the
relevant portions (which can be the entire document) of which are
incorporated herein by reference.
[0296] DNA synthesis techniques and nucleic acid chemistry for
making an artificially synthesized gene are described in, for
example, Gait, M. J. (1985). Oligonucleotide Synthesis: A Practical
Approach, IRL Press; Gait, M. J. (1990). Oligonucleotide Synthesis:
A Practical Approach, IRL Press; Eckstein, F. (1991).
Oligonucleotides and Analogues: A Practical Approach, IRL Press;
Adams, R. L. et al. (1992). The Biochemistry of the Nucleic Acids,
Chapman & Hall; Shabarova, Z. et al. (1994). Advanced Organic
Chemistry of Nucleic Acids, Weinheim; Blackburn, G. M. et al.
(1996). Nucleic Acids in Chemistry and Biology, Oxford University
Press; Hermanson, G. T. (1996). Bioconjugate Techniques, Academic
Press and the like, the relevant portions of which are incorporated
herein by reference.
[0297] For example, as used herein, the oligonucleotide of the
present invention can also be synthesized by a standard method
known in the art, such as by using an automated DNA synthesizer (a
synthesizer commercially available from Biosearch, Applied
Biosystems or the like). For example, a
phosphorothioate-oligonucleotide can also be synthesized by the
method of Stein et al. (1988, Nucl. Acids Res. 16: 3209), and a
methyl phosphonate-oligonucleotide can also be prepared by using a
control pore glass polymer support (Sarin et al., 1988, Proc. Natl.
Acad. Sci. USA 85: 7448-7451).
[0298] As used herein, "or" is used when "at least one or more" of
the matters listed in the sentence can be employed. When explicitly
described herein as "within the range of two values", the range
also includes the two values themselves.
[0299] Reference literatures such as scientific literatures,
patents, and patent applications cited herein are incorporated
herein by reference to the same extent that the entirety of each
document is specifically described.
[0300] As described above, the present invention has been described
while showing preferred embodiments to facilitate understanding.
The present invention is described below based on Examples. The
aforementioned description and the following Examples are not
provided to limit the present invention, but for the sole purpose
of exemplification. Thus, the scope of the present invention is not
limited to the embodiments and Examples specifically described
herein and is limited only by the scope of claims.
EXAMPLES
[0301] Hereinbelow, the present invention is further described by
examples. However, the present invention is not limited to
these.
<Example 1> LSR Expression Analysis
[0302] 1.1 Quantitative analysis of cell surface membrane protein
according to iTRAQ.TM. method (Creative Proteomics, Shirley,
N.Y.).
[0303] Identification of an ovarian-cancer-specific cancer antigen
protein was tried by searching for a cell surface membrane protein
highly expressed in ovary serous adenocarcinoma cell strains
(OVCAR3, OVSAHO, and JHOS4) in comparison with normal ovarian
epithelial cell strains (HOSE2C and E7/TERT). First, for a cell
strain cultured in a 150 mm Petri dish, the cell surface membrane
proteins were biotinylated with sulfo-NHS-SS-biotin. The extracted
proteins were purified by Neurto-avidin beads. At this time, in
order to correct the error between the samples,
sulfo-NHS-SS-biotin-labeled bovine serum albumin was added to each
in an equal amount as an internal standard, and was used for
correction of quantification results by a mass spectrometer. The
purified proteins were digested by trypsin and labeled with an
iTRAQ.TM. reagent. The samples were mixed into one and it was
roughly fractionated into 24 fractions by ion exchange HPLC. Each
of the fractions was desalinated and then measured by a mass
spectrometer (nano LC-MS/MS) analysis. A data base was searched for
the obtained data using proteome discoverer ver. 1.1 and thereby
the proteins were identified and quantified. It should be noted
that the ovarian cancer surgery tissues used in the examples were
provided from patients whose agreements to informed consents were
obtained in Osaka University Hospital.
[0304] As a result of analysis according to an iTRAQ.TM. method, it
was found that LSR was specifically and highly expressed in the
above-mentioned ovary serous adenocarcinoma cell strains as
below.
TABLE-US-00001 TABLE 1 E7TERT/ Description HOSE2C Criteria OVCAR3
OVSAHO JHOS4 LSR 3.092 HOSE2C 10.939 11.412 9.073 E7/TERT 5.207
5.328 3.301
[0305] 1.2 Rt-PCR
[0306] RNAs of a normal ovarian epithelial cell strain (HOSE2C),
ovary serous adenocarcinoma cell strains (OVCAR3, OVSAHO, and
JHOS4), ovarian clear cell adenocarcinoma cell strains (OVTOKO,
OVMANA, OVISE, and RGMI), normal endometrial cell strains
(E6/E7/TERT) and endometrial cancer (HEC1, HEC1A, HEC6, HEC88nu,
HEC108, HEC116, HEC251, and SNGM) were each purified by the
RNeasymini.RTM. kit (QIAGEN). Further, reverse transcription into
cDNA was carried out using the QuantiTect.RTM. Reverse
Transcription Kit (Qiagen). RT-PCR was carried out using the
TaKaRaEx.RTM. Taq DNA polymerase (Takara Bio, Shiga, Japan).
Primers of the following sequences were used in the RT-PCR.
[0307] LSR:
TABLE-US-00002 forward primer (SEQ ID NO: 17)
5'-GGGAGGACCTCAGGGGTGGC-3' and reverse primer (SEQ ID NO: 18)
5'-TGGTGGGGGTGGGGTCTTGG-3'; and .beta.-actin: forward primer (SEQ
ID NO: 19) 5'-AGCCTCGCCTTTGCCGA-3' and reverse primer (SEQ ID NO:
20) 5'-CTGGTGCCTGGGGCG-3'.
[0308] The results of the above were shown in FIGS. 1 to 3. In the
ovary serous adenocarcinoma cell strains OVCAR3, OVSAHO, and JHOS4,
the ovarian clear cell adenocarcinoma cell strains OVMANA, OVISE,
and RGMI, and the endometrial cancer cell strains HEC1, HEC1A,
HEC6, HEC88nu, HEC108, HEC116, HEC251, and SNGM, a band
corresponding to LSR mRNA was detected. In the normal ovarian
epithelial cell strains, for HOSE2C, it was not detected.
[0309] 1.3 Western Blot
[0310] Ten .mu.g each of proteins obtained from the normal ovarian
epithelial cell strain (HOSE2C), the ovary serous adenocarcinoma
cell strains (OVCAR3, OVSAHO, SKOV3, JHOS2, and JHOS4), the ovarian
clear cell adenocarcinoma cell strains (OVTOKO, OVMANA, OVISE, and
RGMI), the normal endometrial cell strains (E6/E7/TERT) and the
endometrial cancer (HEC1, HEC1A, HEC6, HEC88nu, HEC108, HEC116,
HEC251, and SNGM) were applied to SDS-PAGE (5 to 20% gradient gel
(Wako Pure Chemical Industries, Ltd.)). Then, they were subjected
to migration at 40 mA for 50 minutes and subsequently transferred
to PVDF membranes at 120 mA for 1 hour. After the transfer,
blocking was carried out in 1% BSA/TBST (TBS+0.1% Tween 20) at room
temperature for 1 hour and then incubation with an anti-LSR
antibody (Santa Cruz Biotechnology) was carried out at room
temperature for 1 hour. After washing with TBST for 10 minutes
three times for each, the PVDF membranes were incubated at room
temperature for 1 hour using an HRP-labeled anti-rabbit antibody
(GE healthcare) that had been diluted 5,000 times with TBST. The
PVDF membranes were washed with TBST for 10 minutes three times for
each and then the reacted proteins were detected by a fluorescence
reaction system (Perkin Elmer, Inc.).
[0311] The results of the above are shown in FIGS. 4 to 6. In the
ovary serous adenocarcinoma cell strains OVCAR3, OVSAHO, and JHOS4,
ovarian clear cell adenocarcinoma cell strains OVMANA, OVISE, and
RGMI, and the endometrial cancer cell strains HEC1, HEC1A, HEC6,
HEC88nu, HEC108, HEC116, HEC251, and SNGM, a band corresponding to
LSR was detected. Meanwhile, in the ovarian clear cell
adenocarcinoma cell strain OVTOKO, a band corresponding to LSR was
not detected. In the normal ovarian epithelial cell strain, a band
corresponding to LSR was not detected in any of HOSE2C. From the
above results, it is understood that the LSR protein is
specifically expressed at the above-mentioned cancers.
[0312] Moreover, for proteins obtained from normal ovarian tissues,
ovary serous adenocarcinoma surgery tissues, ovarian clear cell
adenocarcinoma surgery tissues, normal endometrial tissues, and
endometrial cancer surgery tissues, Western blot was carried out
using an anti-LSR antibody (Santa Cruz Biotechnology). An
anti-GAPDH antibody (Santa Cruz Biotechnology) was used as a
loading control. The tissues used for the Western blot were
obtained from healthy humans or patients suffering from respective
cancers.
[0313] The results of the above are shown in FIGS. 7 and 8. The
black circles in the figures mean that the expression of LSR was
confirmed. In the normal ovarian tissue and the normal endometrial
tissue, LSR was not expressed. In the ovary serous adenocarcinoma
tissue, LSR was specifically expressed in 13/16 people (81%). In
the ovarian clear cell adenocarcinoma surgery tissue, LSR was
specifically expressed in 4/11 people (36%). In the endometrial
cancer tissue, LSR was specifically expressed in 19/35 people
(54%). From these results, it was found that while LSR positive
patients were present in ovarian cancer patients and uterine cancer
patients, a certain number of LSR negative patients were also
present.
<Example 2> Making and Evaluation
[0314] 2.1 Making of Human LSR-Expressing Chicken Cell Strain and
Immunization to Chicken
[0315] cDNA (SEQ ID NO: 7) of human LSR was cloned to a mammalian
expression vector (pcDNA3.1-V5/His-TOPO) to make a LSR expression
vector. This LSR expression vector encodes a fused protein in which
a V5/His tag was fused to the C-terminal of the human LSR. Then,
the LSR expression vector was transfected into a chicken
lymphoblast-like cell strain according to an electroporation method
and then 2 mg/ml of G418 was added to select an expression cell.
Chicken was hyperimmunized with the obtained LSR-expressing cell
strain. An antibody titer was measured by flow cytometry (FACS)
analysis. With regard to the FACS analysis, the protocol of
FACSCalibur (BD, USA) was followed.
[0316] 2.2 Making of scFv Phage Antibody Library from Immunized
Chicken Spleen
[0317] The spleen was extracted from the immunized chicken and then
the lymphocytes were separated. The RNA was extracted from the
obtained lymphocytes, a cDNA was synthesized, and a scFv phage
antibody library was made. For the making of a scFv phage antibody
library, a technique described in "Nakamura et al., J Vet Med Sci.
2004 July; 66(7): 807-14" was followed.
[0318] 2.3 Panning Selection
[0319] The scFv phage antibody library was added to a
non-LSR-expressing cell strain to carry out absorption operation of
nonspecific phages, and then was reacted with a LSR-expressing cell
strain. In Lot 1, a mammalian cell strain was used and in Lot 2,
cell panning was carried out using the chicken lymphoblast-like
cell strain used for immunization. After washing with organic
solvent, phages specifically binding to the LSR-expressing cell
strain were recovered and then Escherichia coli were infected with
it. Panning was carried out four times and then the reactivity of
the library was confirmed by FACS analysis using the LSR-expressing
cell strain. Phages from a library of which the reactivity had most
increased were cloned, positive clones were selected, and then the
sequences of six types of clones were determined (SEQ ID NOs: 1 to
6 and FIG. 9). For cell panning, a method described in "Giordano et
al., Nat Med. 2001 November; 7(11): 1249-53" was followed.
[0320] 2.4 Recombination to Recombinant Mouse/Chicken Chimeric
(IgG2a) Antibody
[0321] The VH and VL in a chicken-derived antibody gene were PCR
amplified using a DNA strand encoding a scFv phage antibody as a
template and then were cloned into a mouse/chicken chimeric (IgG2a)
expression vector (H chain: pcDNA3.1 and L chain: pcDNA4
(Invitrogen)). The made construct of the H chain and the L chain
was transfected into mammalian culture cells and then expressed
antibodies (anti-LSR mouse/chicken chimeric monoclonal antibodies)
were purified using Protein G Sepharose (GE). From the above, six
types of clones of anti-LSR antibodies (#9-7, #16-6, No. 26-2, No.
27-6, No. 1-25, and No. 1-43) were obtained. For recombination, a
technique described in "Tateishi et al., J Vet Med Sci. 2008 April;
70(4): 397-400" was followed.
[0322] 2.5 Evaluation of Reactivity to Various Ovary Cancer Cell
Strains
[0323] Using five types (#1-25, #9-7, #16-6, No. 26-2, and No.
27-6) from the anti-LSR antibodies obtained in 2.4 described above,
the reactivity to various ovary cancer cell strains was
investigated by FACS analysis. The results are shown in FIGS. 10 to
14. In ovary serous adenocarcinoma cell strains (OVSAHO and JHOS2)
and ovarian clear cell adenocarcinoma cell strains (RGM-I and
OVISE), a significant shift difference was observed by the presence
or absence of the anti-LSR antibodies.
[0324] Immunohistochemical Staining
[0325] For tissues of ovarian cancer (84) cases, the expression of
LSR was analyzed by immunohistochemical staining. A primary
antibody from Cloud Clone Corp. (PAD744Hu01) was used and the Dako
ChemMate.TM. ENVISION.TM. Kit/HRP (DAB)-universal kit (K5007) was
used to carry out staining.
[0326] Results of the immunohistochemical staining were rated with
scores. The score rating was on a five-point scale: 0+(no staining
cell); 1+(pale staining in any proportion of cells); 2+(darkly
staining cells (<25% of area)); 3+(darkly staining cells (25 to
49% of area); and 4+(dark staining (>50% area)). Scores 0, 1,
and 2 were classified as a LSR low expression group and scores 3
and 4 were classified as a LSR high expression group. They were
classified into the groups of the LSR low expression group and the
LSR high expression group, a survival curve was created using the
Kaplan-Meier method, and a log-rank test was carried out.
[0327] Consequently, in ovary serous adenocarcinoma, it became
clear that prognosis in the LSR high-expression cases was
significantly worse than that in the low-expression cases (median
OS: 73.8 vs 105.5 months) (p=0.0293). Meanwhile, although a
significant difference is not recognized in ovarian clear cell
adenocarcinoma, it was observed that prognosis in the LSR
high-expression cases tended to be worse than that in the
low-expression cases (median OS: 71.4 vs 87.4 months) (p=0.1362).
In each of ovary serous adenocarcinoma and ovarian clear cell
adenocarcinoma, the expression of LSR was examined for surgery
tissues of lymph node metastasis sites and greater omentum
metastasis sites according to an immunohistochemical staining
method and consequently it was confirmed that LSR is expressed at
cancer tissues of the metastasis sites.
[0328] As shown in FIG. 29, previously, there was no effective
therapeutic method for recurrent ovarian cancer. Conventionally,
there was no effective therapeutic method for recurrent ovarian
cancer. The epidemiological characteristic of ovarian cancer is
that ovarian cancer readily infiltrate into the surrounding by the
lymph node and peritoneal metastasis or the like and advances
quickly. For instance, 40% or more of ovarian cancer in Japanese
patients is considered serous, 24% clear cells, 17% endometrioid,
and 13% mucinous adenocarcinoma. As a 1st line of defense,
cisplatin or taxol is used, and Avastin is used for recurrent
ovarian cancer. However, it was considered that improvement in
survival rate was not observed. Antibody pharmaceutical products
approved as a therapeutic drug for cancer include those shown in
the table of FIG. 29 (Carter P J Nat. Rev. Immunol. 006, May
6(5)343-357, Review). Since there is no therapeutic method for the
advanced stage and the time of recurrence, ovarian cancer is
presumed to be poor prognostic tumor and the development of a novel
therapeutic method is presumed urgent. For example, as shown in
FIG. 29, the five year survival rate in Stage IV was 31% (Japan
Society of Obstetrics and Gynecology, Fujinka shuyou iinkai houkoku
[Gynecology tumor committee report], 2012, vol. 64, No. 6).
[0329] In this regard, the inventors confirmed as shown in FIG. 30
whether LSR is expressed at the ovarian cancer primary site. The
protocol of it is as below. It should be noted that a technique
similar to the above-mentioned technique in the present example was
used in immunostaining of LSR. The expression of LSR was analyzed
by immunohistochemical staining. A primary antibody from Cloud
Clone Corp. (PAD744Hu01) was used and the Dako ChemMate.TM.
ENVISION.TM. Kit/HRP (DAB)-universal kit (K5007) was used to carry
out staining.
[0330] In addition, using proteins extracted from ovarian cancer
surgery tissue, the expression of LSR was examined according to the
Western blot method. Consequently, it became clear that LSR is more
highly expressed in ovarian clear cell adenocarcinoma and ovary
serous adenocarcinoma than normal ovarian tissue. GAPDH indicated a
control group.
[0331] The result is shown in FIG. 30. As shown in FIG. 30, it was
confirmed that LSR was expressed at the ovarian cancer primary
site.
[0332] In addition, it was confirmed whether it was expressed at
metastasis sites other than the primary site. The protocol of it is
shown as below. It should be noted that a technique similar to the
above-mentioned technique in the present example was used in
immunostaining of LSR. Specifically, the expression of LSR was
analyzed by immunohistochemical staining. A primary antibody from
Cloud Clone Corp. (PAD744Hu01) was used and the Dako ChemMate.TM.
ENVISION.TM. Kit/HRP (DAB)-universal kit (K5007) was used to carry
out staining.
[0333] The results are shown in FIGS. 31 to 32. As shown in these
figures, they indicate that it is also expressed at metastasis
sites other than the primary site. From these facts, it is
understood for the present invention that a LSR antibody medicine
can be expected to exhibit an antitumor effect on not only primary
ovarian cancer but also metastasis sites.
[0334] Then, for the expression of LSR, it was confirmed whether
LSR is also expressed in other cells (FIGS. 33 to 35). These
include expression at early ovarian clear cell adenocarcinoma, and
gastric cancer and signet-ring cell cancer of gastric cancer, which
are adenocarcinoma other than ovary cancer. Immunohistochemical
staining of LSR was carried out according to a similar technique to
the above-mentioned. Specifically, the expression of LSR was
analyzed by immunohistochemical staining. A primary antibody from
Cloud Clone Corp. (PAD744Hu01) was used and the Dako ChemMate.TM.
ENVISION.TM. Kit/HRP (DAB)-universal kit (K5007) was used to carry
out staining.
[0335] The results are shown in FIGS. 33 to 35. As shown in FIG.
33, it indicates that LSR is also expressed at early ovarian clear
cell adenocarcinoma. As shown in FIG. 34, it indicates that LSR is
also expressed at gastric cancer as adenocarcinoma other than
ovarian cancer. In addition, as shown in FIG. 35, it indicates that
LSR is also expressed at signet-ring cell cancer of gastric cancer.
From these, it is understood that it can be used in the therapy for
ovarian cancer even in the early stage and it has therapeutic
possibility for other adenocarcinoma such as gastric cancer and the
like.
[0336] Then, poor prognosis was investigated. In order to confirm
whether highly-LSR-expressing ovary serous adenocarcinoma has a
poor prognosis in comparison with a low expression group, the
prognosis of ovary serous adenocarcinoma patients and ovarian clear
cell adenocarcinoma patients was investigated based on being high
or low in the expression of LSR. For ovary serous adenocarcinoma,
21 cases of strongly-LSR-expressing patients and 12 cases of
weakly-expressing patients were investigated and for ovarian clear
cell adenocarcinoma, 27 cases of strongly-LSR-expressing patients
and 24 cases of weakly-expressing patients were investigated. The
result is shown in FIG. 38. As shown in FIG. 38, it was found that
the highly-LSR-expressing ovary serous adenocarcinoma has poor
prognosis in comparison with the low expression group.
[0337] (Epitope Analysis)
[0338] PepStar.TM. peptide microarrays were made on glass slides
obtained from JPT Peptide Technologies (GmbH). Fifteen-mer
overlapping peptides that overlap to the extracellular domain
region of LSR by 10 amino acids were synthesized and solid-phased
to glass slides. Binding of a purified recombinant antibody to a
peptide was carried out according to the instructions, however, it
included changes to some parts (www.jpt.com). A primary antibody
was reacted at a concentration of 1.0 .mu.g/mL and the glass slides
were washed with TBST (50 mM TBS-buffer including 0.1% Tween20, pH
7.2). Then, it was reacted using Cy5-labeled goat anti-chicken IgY
(Jackson Immuno Research) and washed with TBST five times and the
glass slides were washed with ddH2O five times. The glass slides
were dried by spraying argon gas mildly. A fluorescence signal was
detected using the GenePix.RTM. 4200AL scanner (Molecular Devices)
at resolution of 10 .mu.m.
[0339] The result is shown in FIG. 39. As shown in FIG. 39, it
became clear that there are two types of epitopes and amino acids
116 to 135 (to which the antibodies #9-7, 1-25, 16-6, 26-2, and
1-43 correspond) and amino acids 216 to 230 (to which the antibody
#27-6 corresponds) are present.
[0340] (Cross Reaction)
[0341] In order to investigate that an anti-LSR antibody
cross-reacts with mouse LSR, a mouse LSR expression vector or a
control vector was transfected into COST cells and the reactivity
with various clones of anti-LSR antibodies prepared in the present
example was analyzed by FACS.RTM.. The result is shown in FIG. 40.
Consequently, it became clear that all the clones exhibit cross
reaction with mouse LSR. The fact that an anti-LSR antibody
cross-reacts with mouse LSR as described above makes it possible to
use mice as an animal for a safety test. Please refer to FIG. 52
and thereafter, where actual acute toxicity tests were carried
out.
[0342] 2.6 Expression Analysis of LSR by Immunohistochemical
Staining Method
[0343] Slices of paraffin-embedded tissues of ovary serous
adenocarcinoma tissue and endometrial cancer tissue were
deparaffinization-treated and dehydrated with alcohol. Then, using
an anti-LSR antibody (#1-25 or #9-7), immunohistochemical staining
for LSR was carried out according to the ABC method. The results
are shown in FIGS. 15 to 17. In the ovary serous adenocarcinoma
tissue and the endometrial cancer tissue, LSR was highly expressed
at the tumor sites.
[0344] Immunohistochemical Staining Using Normal Frozen Tissue
Array
[0345] FDA standard human tissue microarrays (T6234701-2, Biochain)
were immunohistochemically stained using the anti-LSR antibody
#1-25. The expression of LSR was observed at liver and testis of
various normal tissues (FIGS. 36 and 37).
[0346] Calculation of Binding Constant
[0347] Various concentration of various anti-LSR antibodies were
reacted with RMG-I cells and they were stained using goat
anti-mouse IgG-FITC (Southern Biotech, Birmingham, Ala., USA) and
analyzed by a FACSCanto.RTM. II cytometer (Becton Dickinson). With
regard to the fluorescence intensity of FITC, a KD value was
analyzed using GraphPad Prism.RTM. Software Version 6.0 for Windows
(GraphPad Software Inc., San Diego, Calif., USA). The result is
shown in FIG. 37B. When the binding ability of the made LSR
antibodies was analyzed by FACS.RTM., antibodies having a high
binding ability were obtained. The following analysis was carried
out using two kinds of clones having the highest binding ability in
them (FIG. 37B). For #9-7, K.sub.D=2.52 nM; for #1-25, K.sub.D=2.03
nM; for #16-6, K.sub.D=2.33 nM; for #26-2, K.sub.D=4.04 nM; for
#27-6, K.sub.D=4.29 nM; and for #1-43, K.sub.D=24.62 nM.
[0348] Cell Cycle Analysis
[0349] Ovarian clear cell adenocarcinoma (RMG-I) was seeded into a
6-well plate at 15,000 cells/well and incubated in a CO.sub.2
incubator at 37.degree. C. overnight. The culture supernatant was
discarded and 100 .mu.g/ml anti-LSR antibody or mouse IgG2a diluted
with RPMI 1640 medium (containing 1% FBS and 1%
penicillin-streptomycin) was added at 2 mL/well for each. After 96
hours, cell cycle analysis was carried out using the Cycle Test
Plus.RTM. DNA Reagent kits (BD Biosciences).
[0350] Western Blot
[0351] Ovarian clear cell adenocarcinoma (RMG-I) was seeded into a
6-well plate at 15,000 cells/well and incubated in a CO.sub.2
incubator at 37.degree. C. overnight. The culture supernatant was
discarded and 100 .mu.g/ml anti-LSR antibody or mouse IgG2a diluted
with RPMI 1640 medium (containing 1% FBS and 1%
penicillin-streptomycin) was added at 2 mL/well for each. After 96
hours, proteins were extracted using a RIPA buffer (10 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% Nonidet.RTM. P-40, 0.1% sodium
deoxycholate, 0.1% SDS, 1.times. phosphatase inhibitor cocktail
(Nacalai Tesque), and 1.times. protease inhibitor cocktail (Nacalai
Tesque)) and the difference in protein expression was analyzed by
the Western blot method. The following antibodies were used as
primary antibodies: anti-LSR antibody (sc-133765) and anti-GAPDH
antibody (sc-25778) (Santa Cruz Biotechnology (Santa Cruz,
Calif.)); and anti-cyclin D1 antibody (#2926), anti-p27 antibody
(#3686), anti-phospho-Rb (Ser780) antibody (#9307), anti-phospho-Rb
antibody (Ser807/811) (#9308), anti-Rb antibody (#9313),
anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (#4370),
anti-p44/42 MAPK (Erk1/2) antibody (#4695), anti-phospho-MEK1/2
(Ser217/221) antibody (#9154), and anti-MEK1/2 antibody (#9126)
(Cell Signaling Technology).
<Example 3> Growth Suppression of LSR Positive Malignant
Tumor 3.1 Growth Inhibition Assay with Anti-LSR Antibody
[0352] Ovarian clear cell adenocarcinoma (RMG-I) was seeded into a
96-well plate at 1000 cells/well and incubated in a CO.sub.2
incubator at 37.degree. C. overnight. The cell supernatant on the
96-well plate was discarded and diluted solutions (0 .mu.g/ml, 1
.mu.g/ml, 10 .mu.g/ml, and 100 .mu.g/ml) of an anti-LSR antibody
(#9-7 or #1-25) were each added at 100 .mu.L/well. After 72 hours,
cell growth assay was carried out according to the TWT-8 assay
method. In addition, mouse IgG2 (Biolegend, Inc., 400224,
MOPC-173), which is non-anti-LSR antibody, was used as a control.
The results are shown in FIGS. 18 and 19. By contacting an anti-LSR
antibody, the growth of ovarian cancer cells (RMG-I) was
suppressed.
[0353] Ovarian clear cell adenomatous cancer (A2780) was seeded
into a 96-well plate at 1000 cells/well and incubated in a CO.sub.2
incubator at 37.degree. C. overnight. The cell supernatant on the
96-well plate was discarded and diluted solutions (1 .mu.g/ml, 10
.mu.g/ml, and 100 .mu.g/ml) of an anti-LSR antibody (#9-7 or #26-2)
were each added at 100 .mu.L/well. After 72 hours, cell growth
assay was carried out according to the TWT-8 assay method. In
addition, mouse IgG2 (Biolegend, Inc., 400224, MOPC-173), which is
non-anti-LSR antibody, was used as a control. The result is shown
in FIG. 20. By contacting an anti-LSR antibody, the growth of
ovarian cancer cells (A2780) was suppressed.
[0354] Cell Cycle Analysis
[0355] Ovarian clear cell adenomatous cancer (RMG-I) was seeded
into a 6-well plate at 15,000 cells/well and incubated in a
CO.sub.2 incubator at 37.degree. C. overnight. The cell supernatant
on the 6-well plate was removed and an anti-LSR antibody (#1-25)
that had been diluted to a concentration of 100 .mu.g/ml with RPMI
1640 medium (containing 1% FBS and 1% penicillin-streptomycin) was
added at 2 mL/well for each. In addition, mouse IgG2 (Biolegend,
Inc; 400224, MOPC-173), which is a non-anti-LSR antibody, was used
as a control. Ninety six hours after the addition of the antibody,
intracellular DNA was stained using the Cycle Test Plus.RTM. DNA
Reagent kits (BD Biosciences) and cell cycle analysis was carried
out using a FACSCanto.RTM. flow cytometer.
[0356] The result is shown in FIG. 41. It was recognized that by
contacting the anti-LSR antibody, the S phase and the G2/M phase in
the cell cycle of ovarian cancer cells (RMG-I) were significantly
decreased and the G0/G1 phase was significantly increased in
comparison with the control antibody-treatment group.
[0357] Western Blot Analysis
[0358] Ovarian clear cell adenomatous cancer (RMG-I) was seeded
into a 6-well plate at 15,000 cells/well and incubated in a
CO.sub.2 incubator at 37.degree. C. overnight. The cell supernatant
on the 6-well plate was removed and an anti-LSR antibody (#1-25)
that had been diluted to a concentration of 100 .mu.g/ml with RPMI
1640 medium (containing 1% FBS and 1% penicillin-streptomycin) was
added at 2 mL/well for each. In addition, mouse IgG2 (Biolegend,
Inc., 400224, MOPC-173), which is a non-anti-LSR antibody, was used
as a control. Seventy two hours after the addition of the antibody,
proteins were extracted, the expression variation of proteins
related to the cell cycle was analyzed by the Western blot method
using the following various antibodies: anti-cyclin D1 (#2926),
anti-p27 (#3686), anti-phospho-Rb (Ser780) (#9307), anti-phospho-Rb
(Ser807/811) (#9308), anti-Rb (#9313), anti-phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204) (#4370), anti-p44/42 MAPK (Erk1/2)
(#4695), anti-phospho-MEK1/2 (Ser217/221) (#9154), and anti-MEK1/2
(#9126) (Cell Signaling Technology).
[0359] The result is shown in FIG. 42. It was recognized that by
contacting the anti-LSR antibody, the expression of Cyclin D1 was
decreased and the expression of p27 was increased in the ovarian
cancer cells (ovarian cancer cells (RMG-I)) in comparison with the
control antibody. Moreover, it was recognized that the
phosphorylation levels of phospho-Rb (Ser780) (#9307) and
phospho-Rb (Ser807/811) were decreased. It was also recognized that
the phosphorylation levels of phospho-MEK1/2 (Ser217/221) and
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) as kinases related to
cell growth were decreased.
[0360] The above result indicates that the anti-LSR antibody
directly suppressed the growth of malignant tumor cells, and it was
a surprising result. As the mechanism of this, for example, it is
thought that the anti-LSR antibody binds to a malignant tumor cell,
thereby a cell clump of malignant tumor cells was formed, and
consequently the cell division was suppressed.
[0361] 3.2 Epitope Analysis
[0362] For the anti-LSR antibodies obtained in 2.4 described above,
epitopes were analyzed as mentioned above and specifically
identified. In addition, a growth suppressing effect on LSR
positive malignant tumor is investigated for the anti-LSR
antibodies for which the epitopes were identified. Consequently, it
is understood that an anti-LSR antibody recognizing a specific
epitope significantly suppresses the growth of LSR positive
malignant tumor in comparison with anti-LSR antibodies recognizing
other epitopes.
[0363] 3.3 Growth Inhibition Assay with siRNA
[0364] Ovary serous adenocarcinoma cells (OVSAHO) were seeded into
a 96-well plate at 1000 cells/well and incubated in a CO.sub.2
incubator at 37.degree. C. overnight. The cell supernatant on the
96-well plate was discarded and the siRNA was transfected with
LIPOFECTAMINE.RTM. 2000. After 120 hours, cell growth assay was
carried out according to the WST-8 assay method. LSR siRNA and
negative control siRNA were obtained from QIAGEN. The LSR siRNA has
a RNA sequence complementary to LSR mRNA (LSR siRNA 1: SEQ ID NO: 9
and LSR siRNA 2: SEQ ID NO: 10). The result is shown in FIG. 21. By
contacting the LSR siRNA, the growth of ovarian cancer cells
(OVSAHO) was suppressed.
[0365] 3.4 Relation to Lipid Metabolism
[0366] It is confirmed whether the uptake of lipids (cholesterol)
is elevated in stably LSR-expressing cells described in the
Examples. After confirming whether the VLDL metabolism is elevated,
it was confirmed whether the elevation in metabolism due to VLDL is
inhibited by administration of a LSR antibody.
[0367] The protocol is shown as below.
[0368] Lipids were quantified using an empty vector strain of SKOV3
(EMP1) and a LSR-forcibly expressing strain (L45). In a low
concentration, they were seeded at 5.times.10.sup.5 cells per 10 cm
dish and, in a high concentration, at 5.times.10.sup.5 cells per 10
cm dish and were cultured for 48 hours. The mediums were not
exchanged. By adding a methanol+chloroform mixture solution to
cells suspended in PBS and centrifuging it, an organic layer as the
lower layer was recovered to extract lipids. Lipids were quantified
using LabAssay.TM. Triglyceride (GPO/DAOS method, Wako Pure
Chemical Industries, Ltd.), LabAssay.TM. Cholesterol (cholesterol
oxidase/DAOS method, Wako Pure Chemical Industries, Ltd.), and
Phospholipid C-test WAKO.TM. (choline oxidase/DAOS method, Wako
Pure Chemical Industries, Ltd.). The metabolism elevation due to
VLDL was measured using the Extracellular Flux Analyzer XFe24.TM.
(Primetech Corporation). Assay was carried out after glucose in the
buffer was removed, glutamine was added, and the antibody amount
was increased from 10 ug/ml to 100 ug/ml.
[0369] Consequently, on day 1, the high was conf: 100% and the Low
was 50 to 60%. On day 2, the High was 100% and the Low was 70%.
[0370] The results are shown in FIGS. 22 to 24. As shown in FIG.
22, the uptake of lipids (cholesterol) was elevated in the stably
LSR-expressing cells described in the Examples. As shown in FIG.
23, the uptake of lipids (cholesterol) in high-density culture was
elevated in the stably LSR-expressing cells described in the
Examples. As shown in FIG. 24, although the LSR expression
described in the Examples make the VLDL metabolism elevated, the
elevation of metabolism due to VLDL was inhibited by administration
of a LSR antibody (#9-7). In #1-25, although the inhibition of
metabolism elevation was observed in some degree, the degree was
less than #9-7. While not wishing to be bound by theory, this
difference is believed due to the difference in epitope recognition
sites depending on the clones.
<Example 4> Analysis of Antitumor Effect in Mouse by Anti-LSR
Monoclonal Antibody
[0371] An ovarian clear cell adenomatous cancer cell strain RMG-I
was subcutaneously implanted to Scid mice (6-week old, female) at
1.times.10.sup.6 cells/100 .mu.l (PBS:Matrigel.RTM.=1:1). On day 14
after the implantation, the mice were divided into two groups and
an anti-LSR antibody (#1-25) or an isotype control antibody (Mouse
IgG2a, M7769, Sigma) was intraperitoneally administered at 10 mg/kg
at a frequency of twice a week and a total of 6 times (FIG. 25).
The RMG-I-implanted mice were dissected on day 25 after the start
of the antibody administration, and the tumor weight was also
measured. The following was calculated: tumor volume=major
axis.times.minor axis.times.height.
[0372] As a result of measuring a tumor volume, a significantly
inhibitory effect on tumor growth in vivo was exhibited in the
anti-LSR antibody administered group relative to the control IgG
administered group (FIGS. 26 to 28). A significant difference in
tumor weight was also recognized.
<Example 5> Analysis of Antitumor Effect in Mouse by Anti-LSR
Monoclonal Antibody
[0373] An ovarian clear cell adenomatous cancer cell strain RMG-I
was subcutaneously implanted to NOD/Scid mice (6-week old, female)
at 1.times.10.sup.6 cells/100 .mu.l (PBS:Matrigel.RTM.=1:1). On day
14 after the implantation, the mice were divided into two groups
and an anti-LSR antibody (#1-25) or an isotype control antibody
(Mouse IgG2a, M7769, Sigma) was intraperitoneally administered at
10 mg/kg at a frequency of twice a week and a total of 6 times
(FIG. 43). The RMG-I-implanted mice were dissected on day 25 after
the start of the antibody administration, and the tumor weight was
also measured. The following was calculated: tumor volume=major
axis.times.minor axis.times.height.
[0374] As a result of measuring a tumor volume, in the NOD/Scid
mice, a significantly inhibitory effect on tumor growth in vivo was
exhibited in the anti-LSR antibody administered group relative to
the control IgG administered group (FIG. 44). A significant
difference in tumor weight was also recognized. In addition, as a
result of immunohistochemically staining a tumor tissue with an
anti-Ki-67 antibody, a significant decrease in the number of Ki-67
positive cell was recognized in the anti-LSR antibody administered
group in comparison with the control IgG administered group. From
this, it became clear that the anti-LSR antibody exhibits activity
of inducing the arrest of the cell cycle in vivo (FIG. 45).
<Example 6> Analysis of Antitumor Effect in Mouse by Anti-LSR
Monoclonal Antibody
[0375] SKOV3-L45 in which a LSR negative ovary serous
adenocarcinoma cell strain SKOV3 was made stably express LSR, or
SKOV3-E1 into which an empty vector had been gene-transferred was
subcutaneously implanted to Scid mice (6-week old, female) at
5.times.10.sup.5 cells/100 .mu.l (PBS:Matrigel.RTM.=1:1). On day 14
after the implantation, the mice were divided into two groups and
an anti-LSR antibody (#1-25) or an isotype control antibody (Mouse
IgG2a, M7769, Sigma) was intraperitoneally administered at 10 mg/kg
at a frequency of every other day and a total of 8 times (FIG. 46).
The mice were dissected on day 18 after the start of the antibody
administration, and the tumor weight was also measured. The
following was calculated: tumor volume=major axis.times.minor
axis.times.height.
[0376] As a result of measuring a tumor volume, in the
SKOV3-L45-implanted Scid mice, a significantly inhibitory effect on
tumor growth in vivo was exhibited in the anti-LSR antibody
administered group relative to the control IgG administered group
(FIG. 47). Meanwhile, in the tumor volume of the mice into which
the LSR negative SKOV3-E1 had been implanted, a significant
difference was not recognized (FIG. 47). A similar result was also
obtained in tumor weight (FIG. 48). From this, it was suggested
that in order for an anti-LSR antibody to exhibit an antitumor
effect, it is necessary that LSR is expressed at tumor cells.
[0377] Tumors of the SKOV3-L45-implanted Scid mice and the
SKOV3-E1-implanted Scid mice were extracted and fat droplets were
observed by electronmicroscopy. Consequently, in the
SKOV3-L45-implanted tissue, many accumulations of fat droplets were
recognized in comparison with the SKOV3-E1-implanted tumor tissue
(FIG. 49). In the stably LSR-expressing cell strain and the
control-vector-expressing cell strain, when fat droplets after the
VLDL administration were compared, it was recognized that fat
droplets in the LSR-expressing cell strain are larger and the
number thereof is greater.
[0378] In order to investigate that an anti-LSR antibody binds to
LSR and exhibits activity of internalizing in a cell, an antibody
labeling was prepared using CypHer.RTM. 5E mono NHS ester dye (GE
Healthcare) and was used in an assay. A LSR positive cell strain
SKOV3-L45 cell strain and a LSR negative cell strain SKOV3-E1 and a
CypHer.RTM. 5E-labeled antibody were incubated for 3 hours and they
were observed by the In cell analyzer 2000. Consequently, all the
clones of #9-7, #1-25, #16-6, #26-2, and #27-6 exhibited activity
of internalizing (FIGS. 50 and 52). FIG. 50 shows that if an
anticancer agent is conjugated to an antibody, it is applicable as
an antibody-drug conjugate (ADC). FIG. 51 shows that if an
anticancer agent is conjugated to an antibody, it is applicable as
an antibody-drug conjugate (ADC).
[0379] These experiments were carried out as below. Tumor tissues
were extracted from subcutaneously-RMG-I-implanted NOD/SCID mice to
which a control antibody or the anti-LSR antibody #1-25 has been
administered. From the tumor tissues, formalin fixed paraffin
embedded blocks were made and the expression of Ki67 was analyzed
by immunohistochemical staining. A primary antibody from Leica
Biosystems Inc. (NCL-L-Ki67-MM1) was used and staining was carried
out using the Dako ChemMate.TM. ENVISION.TM. Kit.TM./HRP
(DAB)-universal kit (K5007). As a result of calculating the
proportion of Ki-67 positive cells in the respective visual fields,
a significant decrease in the proportion of Ki-67 positive cells
was recognized in the anti-LSR antibody #1-25 administered group in
comparison with the control antibody administered group. From this,
it was suggested that by administering the anti-LSR antibody #1-25,
the cell cycle arrest is also induced in vivo.
Example 7: Safety Test
[0380] Then, a safety test was carried out for an antibody of the
present invention. Since the anti-LSR antibody #1-25 also exhibits
cross reaction with mouse LSR, an acute toxicity test in the case
of administration to a mouse was carried out. One mg of Mouse IgG2a
(Sigma, M7769) or the anti-LSR antibody #1-25 was intraperitoneally
administered to each of male and female C57BL/6J (8w) mice, the
mice were dissected on day 7, the brain, heart, kidney, liver,
lung, and spleen were extracted, and pathological analysis by HE
staining was carried out. In addition, the blood was collected and
analyzed using an automated blood cell counting device
(VetScan.RTM. HMII) and a biochemical blood analyzer for animal
(VetScan.RTM. VS2) (FIG. 52). Consequently, in the data of blood
cell number, any significant change was not recognized in the both
(FIGS. 53 and 54). Similarly, in the blood biochemical data, any
significant change was not recognized in the both (FIGS. 55 and
56). From this, it is understood that the anti-LSR antibody #1-25
has low toxicity and high safety.
[0381] The above Examples 1 to 4 show the following: (i) on
contacting an anti-LSR antibody with malignant tumor cells, the
growth of the malignant tumor cells is suppressed; (ii) on making a
LSR antagonist act on malignant tumor cells, the growth of the
malignant tumor cells is suppressed; (iii) by administering an
anti-LSR antibody to a malignant tumor patient, the therapy for
malignant tumor can be carried out; (vi) while LSR positive
patients were present in malignant tumor patients, a certain number
of LSR negative patients were also present; (v) in malignant tumor
therapy in which LSR is targeted, it is important to diagnose
whether LSR positive is present or absent in a malignant tumor
patient before the therapy; and the like.
[0382] As above, the present invention is described based on the
examples. These examples are only illustrations and those skilled
in the art will understand that various variations are possible and
such variations also fall within the scope of the present
invention.
[0383] As described above, the present invention is illustrated by
preferable embodiments of the present invention. However, it will
be understood that the scope of the present invention should be
interpreted only by the claims. It will be understood that the
contents of patents, patent applications, and literatures cited in
the present specification should be incorporated by reference to
the present specification as if their contents per se are
specifically described in the present specification. The present
application claims priority to Japanese Patent Application No.
2013-272084 (filed on Dec. 27, 2013) and it is understood that with
regard to the contents of them, its contents should be incorporated
by reference to the present specification as if its contents per se
is specifically described in the present specification.
INDUSTRIAL APPLICABILITY
[0384] Malignant tumor markers and malignant tumor control
technologies are provided and technologies applicable in industries
(reagents, medicine manufacture, and the like) involved in
technologies related to diagnosis, therapy, and prophylaxis of
malignant tumor are provided.
[0385] [Sequence Listing Free Text]
[0386] SEQ ID NO: 1: the anti-LSR antibody 9-7 sequence
[0387] SEQ ID NO: 2: the anti-LSR antibody 16-6 sequence
[0388] SEQ ID NO: 3: the anti-LSR antibody 26-2 sequence
[0389] SEQ ID NO: 4: the anti-LSR antibody 27-6 sequence
[0390] SEQ ID NO: 5: the anti-LSR antibody 1-25 sequence
[0391] SEQ ID NO: 6: the anti-LSR antibody 1-43 sequence
[0392] SEQ ID NO: 7: human LSR protein sequence (NP_991403.1)
[0393] SEQ ID NO: 8: human LSR nucleic acid sequence
(NM_205834.3)
[0394] SEQ ID NO: 9: the core sequence (guide sequence) of LSR
siRNA 1
[0395] SEQ ID NO: 10: the core sequence (guide sequence) of LSR
siRNA 2
[0396] SEQ ID NO: 11: the antisense sequence of the core sequence
(guide sequence) of LSR siRNA 1
[0397] SEQ ID NO: 12: the antisense sequence of the core sequence
(guide sequence) of LSR siRNA 2
[0398] SEQ ID NO: 13: the sense full length sequence of LSR siRNA
1
[0399] SEQ ID NO: 14: the sense full length sequence of LSR siRNA
2
[0400] SEQ ID NO: 15: the antisense full length sequence of LSR
siRNA 1
[0401] SEQ ID NO: 16: the antisense full length sequence of LSR
siRNA 2
[0402] SEQ ID NO: 17: LSR forward primer sequence
[0403] SEQ ID NO: 18: LSR reverse primer sequence
[0404] SEQ ID NO: 19: .beta.-actin forward primer sequence
[0405] SEQ ID NO: 20: .beta.-actin reverse primer sequence
Sequence CWU 1
1
221238PRTGallus gallus 1Ala Val Thr Leu Asp Glu Ser Gly Gly Gly Leu
Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala Ser
Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gln Met Asn Trp Val Arg Gln
Ala Pro Ser Lys Gly Leu Glu Trp Val 35 40 45 Ala Gly Ile Asn Gly
Arg Ser Ser Trp Thr Asp Tyr Gly Ala Ala Val 50 55 60 Lys Gly Arg
Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80 Leu
Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90
95 Ala Arg Gly Ser Ser Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile
100 105 110 Val Ser Thr Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 115 120 125 Gly Ser Asp Val Ala Leu Thr Gln Pro Ala Ser Val
Ser Ala Asn Pro 130 135 140 Gly Glu Thr Val Lys Ile Thr Cys Ser Gly
Gly Gly Ser Tyr Tyr Gly 145 150 155 160 Ser Tyr Tyr Tyr Gly Trp Tyr
Gln Gln Lys Ser Pro Gly Ser Ala Pro 165 170 175 Val Thr Met Ile Tyr
Asn Asn Asn Asn Arg Pro Ser Asn Ile Pro Ser 180 185 190 Arg Phe Ser
Gly Ser Leu Ser Gly Ser Thr Asn Thr Leu Thr Ile Thr 195 200 205 Gly
Val Gln Ala Asp Glu Ala Val Tyr Tyr Cys Gly Ser Ile Asp Ser 210 215
220 Asn Ile Ala Gly Val Phe Gly Ala Gly Thr Thr Leu Thr Val 225 230
235 2 239PRTGallus gallus 2Ala Val Thr Leu Asp Glu Ser Gly Gly Gly
Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu Val Cys Lys Ala
Ser Gly Phe Thr Phe Asn Asp Tyr 20 25 30 Gly Met Asn Trp Val Arg
Gln Ala Pro Ser Lys Gly Leu Glu Trp Val 35 40 45 Ala Gly Ile Asn
Gly Arg Ser Thr Trp Thr Asp Tyr Gly Ala Ala Val 50 55 60 Lys Gly
Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65 70 75 80
Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe Cys Ala 85
90 95 Arg Gly Ser Ser Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile
Val 100 105 110 Ser Thr Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly 115 120 125 Ser Asp Val Ala Leu Thr Gln Pro Ala Ser Val
Ser Ala Asn Pro Gly 130 135 140 Glu Thr Val Lys Ile Thr Cys Ser Gly
Gly Gly Ser Tyr Tyr Gly Thr 145 150 155 160 Tyr Tyr Phe Tyr Gly Trp
Tyr Gln Gln Lys Ala Pro Gly Ser Ala Pro 165 170 175 Val Thr Leu Ile
Tyr Asp Asn Thr Asn Arg Pro Ser Asn Ile Pro Ser 180 185 190 Arg Phe
Ser Gly Ser Thr Ser Gly Ser Thr Ser Thr Leu Thr Ile Thr 195 200 205
Gly Val Gln Val Asp Asp Glu Ala Val Tyr Phe Cys Gly Ser Ile Asp 210
215 220 Ser Ser Tyr Ser Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val
225 230 235 3238PRTGallus gallus 3Ala Val Thr Leu Asp Glu Ser Gly
Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Gly Leu Ser Leu Val Cys
Lys Gly Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Glu Met Gln Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gly
Ile Ser Gly Ala Gly Ser Thr Thr Arg Tyr Gly Ser Ala Val 50 55 60
Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val Arg 65
70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr
Tyr Cys 85 90 95 Ala Arg Gly Ser Asn Ile Asp Gly Trp Gly His Gly
Thr Glu Val Ile 100 105 110 Val Ser Thr Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Asp Val Ala Leu Thr Gln
Pro Ser Ser Val Ser Ala Asn Pro 130 135 140 Gly Glu Thr Val Lys Ile
Thr Cys Ser Gly Gly Gly Arg Tyr Ala Glu 145 150 155 160 Ser Tyr Tyr
Tyr Ser Trp Phe Gln Gln Lys Ser Pro Gly Ser Ala Pro 165 170 175 Val
Thr Val Ile Tyr Trp Asn Asp Lys Arg Pro Ser Asn Ile Pro Ser 180 185
190 Arg Phe Ser Gly Ser Leu Ser Gly Ser Thr Asn Thr Leu Thr Ile Thr
195 200 205 Gly Val Arg Ala Glu Asp Glu Ala Val Tyr Tyr Cys Gly Ala
Tyr Glu 210 215 220 Asp Ser Ser Ala Gly Phe Gly Ala Gly Thr Thr Leu
Thr Val 225 230 235 4238PRTGallus gallus 4Ala Val Thr Leu Asp Glu
Ser Gly Gly Gly Leu Gln Met Pro Gly Gly 1 5 10 15 Ala Leu Ser Leu
Val Cys Arg Ala Ser Gly Phe Asp Phe Ser Ser Tyr 20 25 30 Glu Met
Gln Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ala Gly Ile Ser Gly Ala Gly Ser Gly Thr Arg Tyr Gly Ser Ala Val 50
55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr Val
Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile
Tyr Phe Cys 85 90 95 Ala Arg Ser Ser Asn Ile Asp Ala Trp Gly His
Gly Thr Glu Val Thr 100 105 110 Val Ser Thr Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Asp Val Ala Leu Thr
Gln Pro Ala Ser Val Ser Ala Asn Leu 130 135 140 Gly Gly Thr Val Lys
Ile Thr Cys Ser Gly Gly Gly Arg Tyr Ala Glu 145 150 155 160 Ser Tyr
Tyr Tyr Gly Trp Tyr Gln Gln Lys Ser Pro Gly Ser Thr Pro 165 170 175
Val Thr Val Ile Tyr Trp Asn Asp Lys Arg Pro Ser Asn Ile Pro Ser 180
185 190 Arg Phe Ser Gly Ser Leu Ser Gly Ser Thr Asn Thr Leu Thr Ile
Thr 195 200 205 Gly Val Gln Val Glu Asp Glu Ala Val Tyr Phe Cys Gly
Ser Tyr Glu 210 215 220 Asp Ser Arg Ser Ala Phe Gly Ala Gly Thr Thr
Leu Thr Val 225 230 235 5238PRTGallus gallus 5Ala Val Thr Leu Asp
Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu Ser
Leu Val Cys Lys Ala Ser Gly Phe Asp Phe Ser Ser Tyr 20 25 30 Glu
Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45 Thr Gly Ile Ser Gly Ser Gly Ser Ser Thr Arg Tyr Gly Ser Ala Val
50 55 60 Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser Thr
Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr Gly
Thr Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Thr Ile Asp Ala Trp Gly
His Gly Thr Glu Val Thr 100 105 110 Val Ser Thr Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Asp Val Ala Leu
Thr Gln Pro Ala Ser Val Ser Ala Asn Pro 130 135 140 Gly Glu Thr Val
Lys Ile Thr Cys Ser Gly Gly Ser Ser Tyr Ala Gly 145 150 155 160 Ser
Tyr Tyr Tyr Gly Trp Tyr Gln Gln Lys Ser Pro Gly Ser Ala Pro 165 170
175 Val Thr Val Ile Tyr Tyr Asn Asp Gln Arg Pro Ser Asp Ile Pro Ser
180 185 190 Arg Phe Ser Gly Ser Thr Ser Gly Ser Thr Ala Thr Leu Thr
Ile Thr 195 200 205 Gly Val Gln Val Glu Asp Glu Ala Val Tyr Ile Cys
Gly Thr Tyr Glu 210 215 220 Asp Ser Gly Gly Val Phe Gly Ala Gly Thr
Thr Leu Thr Val 225 230 235 6238PRTGallus gallus 6Ala Val Thr Leu
Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly 1 5 10 15 Ala Leu
Ser Leu Val Cys Glu Ala Ser Gly Phe Asp Phe Ser Ser His 20 25 30
Glu Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35
40 45 Ala Gly Ile Ser Gly Ala Gly Ser Ser Thr Arg Tyr Gly Ser Ala
Val 50 55 60 Gln Gly Arg Ala Thr Ile Ser Arg Asp Asn Gly Gln Ser
Thr Val Arg 65 70 75 80 Leu Gln Leu Asn Asn Leu Arg Ala Glu Asp Thr
Gly Thr Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Leu Ile Asp Ala Trp
Gly His Gly Thr Glu Val Ile 100 105 110 Val Ser Thr Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Asp Val Ala
Leu Thr Gln Pro Ala Ser Val Ser Ala Asn Pro 130 135 140 Gly Glu Thr
Val Lys Ile Thr Cys Ser Gly Gly Gly Ser Tyr Tyr Gly 145 150 155 160
Ser Tyr Tyr Tyr Ser Trp His Gln Gln Lys Ser Pro Gly Ser Ala Pro 165
170 175 Val Thr Val Ile Tyr Glu Asn Asn Gln Arg Pro Ser Asp Ile Pro
Ser 180 185 190 Arg Phe Ser Gly Ser Lys Ser Gly Ser Thr Ala Thr Leu
Thr Ile Thr 195 200 205 Gly Val Gln Ala Glu Asp Glu Ala Val Tyr Phe
Cys Gly Ser Tyr Asp 210 215 220 Ser Ser Ala Gly Leu Phe Gly Ala Gly
Thr Thr Leu Thr Val 225 230 235 7649PRTHomo sapiens 7Met Gln Gln
Asp Gly Leu Gly Val Gly Thr Arg Asn Gly Ser Gly Lys 1 5 10 15 Gly
Arg Ser Val His Pro Ser Trp Pro Trp Cys Ala Pro Arg Pro Leu 20 25
30 Arg Tyr Phe Gly Arg Asp Ala Arg Ala Arg Arg Ala Gln Thr Ala Ala
35 40 45 Met Ala Leu Leu Ala Gly Gly Leu Ser Arg Gly Leu Gly Ser
His Pro 50 55 60 Ala Ala Ala Gly Arg Asp Ala Val Val Phe Val Trp
Leu Leu Leu Ser 65 70 75 80 Thr Trp Cys Thr Ala Pro Ala Arg Ala Ile
Gln Val Thr Val Ser Asn 85 90 95 Pro Tyr His Val Val Ile Leu Phe
Gln Pro Val Thr Leu Pro Cys Thr 100 105 110 Tyr Gln Met Thr Ser Thr
Pro Thr Gln Pro Ile Val Ile Trp Lys Tyr 115 120 125 Lys Ser Phe Cys
Arg Asp Arg Ile Ala Asp Ala Phe Ser Pro Ala Ser 130 135 140 Val Asp
Asn Gln Leu Asn Ala Gln Leu Ala Ala Gly Asn Pro Gly Tyr 145 150 155
160 Asn Pro Tyr Val Glu Cys Gln Asp Ser Val Arg Thr Val Arg Val Val
165 170 175 Ala Thr Lys Gln Gly Asn Ala Val Thr Leu Gly Asp Tyr Tyr
Gln Gly 180 185 190 Arg Arg Ile Thr Ile Thr Gly Asn Ala Asp Leu Thr
Phe Asp Gln Thr 195 200 205 Ala Trp Gly Asp Ser Gly Val Tyr Tyr Cys
Ser Val Val Ser Ala Gln 210 215 220 Asp Leu Gln Gly Asn Asn Glu Ala
Tyr Ala Glu Leu Ile Val Leu Gly 225 230 235 240 Arg Thr Ser Gly Val
Ala Glu Leu Leu Pro Gly Phe Gln Ala Gly Pro 245 250 255 Ile Glu Asp
Trp Leu Phe Val Val Val Val Cys Leu Ala Ala Phe Leu 260 265 270 Ile
Phe Leu Leu Leu Gly Ile Cys Trp Cys Gln Cys Cys Pro His Thr 275 280
285 Cys Cys Cys Tyr Val Arg Cys Pro Cys Cys Pro Asp Lys Cys Cys Cys
290 295 300 Pro Glu Ala Leu Tyr Ala Ala Gly Lys Ala Ala Thr Ser Gly
Val Pro 305 310 315 320 Ser Ile Tyr Ala Pro Ser Thr Tyr Ala His Leu
Ser Pro Ala Lys Thr 325 330 335 Pro Pro Pro Pro Ala Met Ile Pro Met
Gly Pro Ala Tyr Asn Gly Tyr 340 345 350 Pro Gly Gly Tyr Pro Gly Asp
Val Asp Arg Ser Ser Ser Ala Gly Gly 355 360 365 Gln Gly Ser Tyr Val
Pro Leu Leu Arg Asp Thr Asp Ser Ser Val Ala 370 375 380 Ser Glu Val
Arg Ser Gly Tyr Arg Ile Gln Ala Ser Gln Gln Asp Asp 385 390 395 400
Ser Met Arg Val Leu Tyr Tyr Met Glu Lys Glu Leu Ala Asn Phe Asp 405
410 415 Pro Ser Arg Pro Gly Pro Pro Ser Gly Arg Val Glu Arg Ala Met
Ser 420 425 430 Glu Val Thr Ser Leu His Glu Asp Asp Trp Arg Ser Arg
Pro Ser Arg 435 440 445 Gly Pro Ala Leu Thr Pro Ile Arg Asp Glu Glu
Trp Gly Gly His Ser 450 455 460 Pro Arg Ser Pro Arg Gly Trp Asp Gln
Glu Pro Ala Arg Glu Gln Ala 465 470 475 480 Gly Gly Gly Trp Arg Ala
Arg Arg Pro Arg Ala Arg Ser Val Asp Ala 485 490 495 Leu Asp Asp Leu
Thr Pro Pro Ser Thr Ala Glu Ser Gly Ser Arg Ser 500 505 510 Pro Thr
Ser Asn Gly Gly Arg Ser Arg Ala Tyr Met Pro Pro Arg Ser 515 520 525
Arg Ser Arg Asp Asp Leu Tyr Asp Gln Asp Asp Ser Arg Asp Phe Pro 530
535 540 Arg Ser Arg Asp Pro His Tyr Asp Asp Phe Arg Ser Arg Glu Arg
Pro 545 550 555 560 Pro Ala Asp Pro Arg Ser His His His Arg Thr Arg
Asp Pro Arg Asp 565 570 575 Asn Gly Ser Arg Ser Gly Asp Leu Pro Tyr
Asp Gly Arg Leu Leu Glu 580 585 590 Glu Ala Val Arg Lys Lys Gly Ser
Glu Glu Arg Arg Arg Pro His Lys 595 600 605 Glu Glu Glu Glu Glu Ala
Tyr Tyr Pro Pro Ala Pro Pro Pro Tyr Ser 610 615 620 Glu Thr Asp Ser
Gln Ala Ser Arg Glu Arg Arg Leu Lys Lys Asn Leu 625 630 635 640 Ala
Leu Ser Arg Glu Ser Leu Val Val 645 82292DNAHomo sapiens
8tcagcccact tccggggagg gaggcagagg aacccctccc cgccgctcac ccctaagccc
60agccctcggc tcccaccctt gtgtacctgg gccgaaccat tcaccggagc gcgcagcggg
120tggagtgtgg ctcggaggac cgcggcgggt caagcacctt tctcccccat
atctgaaagc 180atgccctttg tccacgtcgt ttacgctcat taaaacttcc
agaatgcaac aggacggact 240tggagtaggg acaaggaacg gaagtgggaa
ggggaggagc gtgcacccct cctggccttg 300gtgcgcgccg cgccccctaa
ggtactttgg aagggacgcg cgggccagac gcgcccagac 360ggccgcgatg
gcgctgttgg ccggcgggct ctccagaggg ctgggctccc acccggccgc
420cgcaggccgg gacgcggtcg tcttcgtgtg gcttctgctt agcacctggt
gcacagctcc 480tgccagggcc atccaggtga ccgtgtccaa cccctaccac
gtggtgatcc tcttccagcc 540tgtgaccctg ccctgtacct accagatgac
ctcgaccccc acgcaaccca tcgtcatctg 600gaagtacaag tctttctgcc
gggaccgcat cgccgatgcc ttctccccgg ccagcgtcga 660caaccagctc
aatgcccagc tggcagccgg gaacccaggc tacaacccct acgttgagtg
720ccaggacagc gtgcgcaccg tcagggtcgt ggccaccaag cagggcaacg
ctgtgaccct 780gggagattac taccagggcc ggaggattac catcaccgga
aatgctgacc tgacctttga 840ccagacggcg tggggggaca gtggtgtgta
ttactgctcc gtggtctcag cccaggacct 900ccaggggaac aatgaggcct
acgcagagct catcgtcctt gggaggacct caggggtggc 960tgagctctta
cctggttttc aggcggggcc catagaagac tggctcttcg tggttgtggt
1020atgcctggct gccttcctca tcttcctcct cctgggcatc tgctggtgcc
agtgctgccc 1080gcacacttgc tgctgctacg tcaggtgccc ctgctgccca
gacaagtgct gctgccccga 1140ggccctgtat gccgccggca aagcagccac
ctcaggtgtt cccagcattt atgcccccag 1200cacctatgcc cacctgtctc
ccgccaagac cccaccccca ccagctatga ttcccatggg 1260ccctgcctac
aacgggtacc ctggaggata ccctggagac gttgacagga
gtagctcagc 1320tggtggccaa ggctcctatg tacccctgct tcgggacacg
gacagcagtg tggcctctga 1380agtccgcagt ggctacagga ttcaggccag
ccagcaggac gactccatgc gggtcctgta 1440ctacatggag aaggagctgg
ccaacttcga cccttctcga cctggccccc ccagtggccg 1500tgtggagcgg
gccatgagtg aagtcacctc cctccacgag gacgactggc gatctcggcc
1560ttcccggggc cctgccctca ccccgatccg ggatgaggag tggggtggcc
actccccccg 1620gagtcccagg ggatgggacc aggagcccgc cagggagcag
gcaggcgggg gctggcgggc 1680caggcggccc cgggcccgct ccgtggacgc
cctggacgac ctcaccccgc cgagcaccgc 1740cgagtcaggg agcaggtctc
ccacgagtaa tggtgggaga agccgggcct acatgccccc 1800gcggagccgc
agccgggacg acctctatga ccaagacgac tcgagggact tcccacgctc
1860ccgggacccc cactacgacg acttcaggtc tcgggagcgc cctcctgccg
accccaggtc 1920ccaccaccac cgtacccggg accctcggga caacggctcc
aggtccgggg acctccccta 1980tgatgggcgg ctactggagg aggctgtgag
gaagaagggg tcggaggaga ggaggagacc 2040ccacaaggag gaggaggaag
aggcctacta cccgcccgcg ccgcccccgt actcggagac 2100cgactcgcag
gcgtcccgag agcgcaggct caagaagaac ttggccctga gtcgggaaag
2160tttagtcgtc tgatctgacg ttttctacgt agcttttgta tttttttttt
taatttgaag 2220gaacactgat gaagccctgc catacccctc ccgagtctaa
taaaacgtat aatcacaaaa 2280aaaaaaaaaa aa 2292919DNAArtificial
SequenceSense Strand of LSR siRNA#1 Target Sequence 9cgucguuuac
gcucauuaa 191019DNAArtificial SequenceSense Strand of LSR siRNA#2
Target Sequence 10ggauuaccau caccggaaa 191117DNAArtificial
SequenceAntisense Strand of LSR siRNA#1 Target Sequence
11aaugagcgua aacgacg 171219DNAArtificial SequenceAntisense Strand
of LSR siRNA#2 Target Sequence 12uccggugaug guaaucctc
191321DNAArtificial SequenceLSR siRNA#1 Sense Sequence 13cgucguuuac
gcucauuaat t 211421DNAArtificial SequenceLSR siRNA#2 Sense Sequence
14ggauuaccau caccggaaat t 211519RNAArtificial SequenceLSR siRNA#1
Antisense Sequence 15uuaaugagcg uaaacgacg 191621DNAArtificial
SequenceLSR siRNA#2 Antisense Sequence 16uuuccgguga ugguaaucct c
211720DNAArtificial SequenceLSR Forward Primer 17gggaggacct
caggggtggc 201820DNAArtificial SequenceLSR Reverse Primer
18tggtgggggt ggggtcttgg 201917DNAArtificial SequenceBeta-actin
Forward Primer 19agcctcgcct ttgccga 172015DNAArtificial
SequenceBeta-actin Reverse Primer 20ctggtgcctg gggcg 1521649PRTHomo
sapiens 21Met Gln Gln Asp Gly Leu Gly Val Gly Thr Arg Asn Gly Ser
Gly Lys1 5 10 15Gly Arg Ser Val His Pro Ser Trp Pro Trp Cys Ala Pro
Arg Pro Leu 20 25 30Arg Tyr Phe Gly Arg Asp Ala Arg Ala Arg Arg Ala
Gln Thr Ala Ala 35 40 45Met Ala Leu Leu Ala Gly Gly Leu Ser Arg Gly
Leu Gly Ser His Pro 50 55 60Ala Ala Ala Gly Arg Asp Ala Val Val Phe
Val Trp Leu Leu Leu Ser65 70 75 80Thr Trp Cys Thr Ala Pro Ala Arg
Ala Ile Gln Val Thr Val Ser Asn 85 90 95Pro Tyr His Val Val Ile Leu
Phe Gln Pro Val Thr Leu Pro Cys Thr 100 105 110 Tyr Gln Met Thr Ser
Thr Pro Thr Gln Pro Ile Val Ile Trp Lys Tyr 115 120 125Lys Ser Phe
Cys Arg Asp Arg Ile Ala Asp Ala Phe Ser Pro Ala Ser 130 135 140Val
Asp Asn Gln Leu Asn Ala Gln Leu Ala Ala Gly Asn Pro Gly Tyr145 150
155 160Asn Pro Tyr Val Glu Cys Gln Asp Ser Val Arg Thr Val Arg Val
Val 165 170 175Ala Thr Lys Gln Gly Asn Ala Val Thr Leu Gly Asp Tyr
Tyr Gln Gly 180 185 190Arg Arg Ile Thr Ile Thr Gly Asn Ala Asp Leu
Thr Phe Asp Gln Thr 195 200 205Ala Trp Gly Asp Ser Gly Val Tyr Tyr
Cys Ser Val Val Ser Ala Gln 210 215 220Asp Leu Gln Gly Asn Asn Glu
Ala Tyr Ala Glu Leu Ile Val Leu Gly225 230 235 240Arg Thr Ser Gly
Val Ala Glu Leu Leu Pro Gly Phe Gln Ala Gly Pro 245 250 255Ile Glu
Asp Trp Leu Phe Val Val Val Val Cys Leu Ala Ala Phe Leu 260 265
270Ile Phe Leu Leu Leu Gly Ile Cys Trp Cys Gln Cys Cys Pro His Thr
275 280 285Cys Cys Cys Tyr Val Arg Cys Pro Cys Cys Pro Asp Lys Cys
Cys Cys 290 295 300Pro Glu Ala Leu Tyr Ala Ala Gly Lys Ala Ala Thr
Ser Gly Val Pro305 310 315 320Ser Ile Tyr Ala Pro Ser Thr Tyr Ala
His Leu Ser Pro Ala Lys Thr 325 330 335 Pro Pro Pro Pro Ala Met Ile
Pro Met Gly Pro Ala Tyr Asn Gly Tyr 340 345 350 Pro Gly Gly Tyr Pro
Gly Asp Val Asp Arg Ser Ser Ser Ala Gly Gly 355 360 365Gln Gly Ser
Tyr Val Pro Leu Leu Arg Asp Thr Asp Ser Ser Val Ala 370 375 380Ser
Glu Val Arg Ser Gly Tyr Arg Ile Gln Ala Ser Gln Gln Asp Asp385 390
395 400Ser Met Arg Val Leu Tyr Tyr Met Glu Lys Glu Leu Ala Asn Phe
Asp 405 410 415Pro Ser Arg Pro Gly Pro Pro Ser Gly Arg Val Glu Arg
Ala Met Ser 420 425 430Glu Val Thr Ser Leu His Glu Asp Asp Trp Arg
Ser Arg Pro Ser Arg 435 440 445Gly Pro Ala Leu Thr Pro Ile Arg Asp
Glu Glu Trp Gly Gly His Ser 450 455 460Pro Arg Ser Pro Arg Gly Trp
Asp Gln Glu Pro Ala Arg Glu Gln Ala465 470 475 480Gly Gly Gly Trp
Arg Ala Arg Arg Pro Arg Ala Arg Ser Val Asp Ala 485 490 495Leu Asp
Asp Leu Thr Pro Pro Ser Thr Ala Glu Ser Gly Ser Arg Ser 500 505
510Pro Thr Ser Asn Gly Gly Arg Ser Arg Ala Tyr Met Pro Pro Arg Ser
515 520 525Arg Ser Arg Asp Asp Leu Tyr Asp Gln Asp Asp Ser Arg Asp
Phe Pro 530 535 540Arg Ser Arg Asp Pro His Tyr Asp Asp Phe Arg Ser
Arg Glu Arg Pro545 550 555 560Pro Ala Asp Pro Arg Ser His His His
Arg Thr Arg Asp Pro Arg Asp 565 570 575Asn Gly Ser Arg Ser Gly Asp
Leu Pro Tyr Asp Gly Arg Leu Leu Glu 580 585 590Glu Ala Val Arg Lys
Lys Gly Ser Glu Glu Arg Arg Arg Pro His Lys 595 600 605Glu Glu Glu
Glu Glu Ala Tyr Tyr Pro Pro Ala Pro Pro Pro Tyr Ser 610 615 620Glu
Thr Asp Ser Gln Ala Ser Arg Glu Arg Arg Leu Lys Lys Asn Leu625 630
635 640Ala Leu Ser Arg Glu Ser Leu Val Val 64522594PRTMus musculus
22Met Ala Pro Ala Ala Ser Ala Cys Ala Gly Ala Pro Gly Ser His Pro1
5 10 15Ala Thr Thr Ile Phe Val Cys Leu Phe Leu Ile Ile Tyr Cys Pro
Asp 20 25 30Arg Ala Ser Ala Ile Gln Val Thr Val Pro Asp Pro Tyr His
Val Val 35 40 45Ile Leu Phe Gln Pro Val Thr Leu His Cys Thr Tyr Gln
Met Ser Asn 50 55 60Thr Leu Thr Ala Pro Ile Val Ile Trp Lys Tyr Lys
Ser Phe Cys Arg65 70 75 80Asp Arg Val Ala Asp Ala Phe Ser Pro Ala
Ser Val Asp Asn Gln Leu 85 90 95Asn Ala Gln Leu Ala Ala Gly Asn Pro
Gly Tyr Asn Pro Tyr Val Glu 100 105 110Cys Gln Asp Ser Val Arg Thr
Val Arg Val Val Ala Thr Lys Gln Gly 115 120 125Asn Ala Val Thr Leu
Gly Asp Tyr Tyr Gln Gly Arg Arg Ile Thr Ile 130 135 140Thr Gly Asn
Ala Asp Leu Thr Phe Glu Gln Thr Ala Trp Gly Asp Ser145 150 155
160Gly Val Tyr Tyr Cys Ser Val Val Ser Ala Gln Asp Leu Asp Gly Asn
165 170 175Asn Glu Ala Tyr Ala Glu Leu Ile Val Leu Gly Arg Thr Ser
Glu Ala 180 185 190Pro Glu Leu Leu Pro Gly Phe Arg Ala Gly Pro Leu
Glu Asp Trp Leu 195 200 205Phe Val Val Val Val Cys Leu Ala Ser Leu
Leu Phe Phe Leu Leu Leu 210 215 220Gly Ile Cys Trp Cys Gln Cys Cys
Pro His Thr Cys Cys Cys Tyr Val225 230 235 240Arg Cys Pro Cys Cys
Pro Asp Lys Cys Cys Cys Pro Glu Ala Leu Tyr 245 250 255Ala Ala Gly
Lys Ala Ala Thr Ser Gly Val Pro Ser Ile Tyr Ala Pro 260 265 270Ser
Ile Tyr Thr His Leu Ser Pro Ala Lys Thr Pro Pro Pro Pro Pro 275 280
285Ala Met Ile Pro Met Arg Pro Pro Tyr Gly Tyr Pro Gly Asp Phe Asp
290 295 300Arg Thr Ser Ser Val Gly Gly His Ser Ser Gln Val Pro Leu
Leu Arg305 310 315 320Glu Val Asp Gly Ser Val Ser Ser Glu Val Arg
Ser Gly Tyr Arg Ile 325 330 335Gln Ala Asn Gln Gln Asp Asp Ser Met
Arg Val Leu Tyr Tyr Met Glu 340 345 350Lys Glu Leu Ala Asn Phe Asp
Pro Ser Arg Pro Gly Pro Pro Asn Gly 355 360 365Arg Val Glu Arg Ala
Met Ser Glu Val Thr Ser Leu His Glu Asp Asp 370 375 380Trp Arg Ser
Arg Pro Ser Arg Ala Pro Ala Leu Thr Pro Ile Arg Asp385 390 395
400Glu Glu Trp Asn Arg His Ser Pro Arg Ser Pro Arg Thr Trp Glu Gln
405 410 415Glu Pro Leu Gln Glu Gln Pro Arg Gly Gly Trp Gly Ser Gly
Arg Pro 420 425 430Arg Ala Arg Ser Val Asp Ala Leu Asp Asp Ile Asn
Arg Pro Gly Ser 435 440 445Thr Glu Ser Gly Arg Ser Ser Pro Pro Ser
Ser Gly Arg Arg Gly Arg 450 455 460Ala Tyr Ala Pro Pro Arg Ser Arg
Ser Arg Asp Asp Leu Tyr Asp Pro465 470 475 480Asp Asp Pro Arg Asp
Leu Pro His Ser Arg Asp Pro His Tyr Tyr Asp 485 490 495Asp Leu Arg
Ser Arg Asp Pro Arg Ala Asp Pro Arg Ser Arg Gln Arg 500 505 510Ser
His Asp Pro Arg Asp Ala Gly Phe Arg Ser Arg Asp Pro Gln Tyr 515 520
525Asp Gly Arg Leu Leu Glu Glu Ala Leu Lys Lys Lys Gly Ala Gly Glu
530 535 540Arg Arg Arg Val Tyr Arg Glu Glu Glu Glu Glu Glu Glu Glu
Gly His545 550 555 560Tyr Pro Pro Ala Pro Pro Pro Tyr Ser Glu Thr
Asp Ser Gln Ala Ser 565 570 575Arg Glu Arg Arg Met Lys Lys Asn Leu
Ala Leu Ser Arg Glu Ser Leu 580 585 590 Val Val
* * * * *